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Abstract
There is renewed interest in the use of induced hyperthermia in
the treatment of malignant disease. It has been proposed that the
anti-tumour effects of hyperthermia are mediated by the immune system.
The aim of this investigation was to determine whether whole-body
hyperthermia (41.8°C) affected the immune status of patients with
advanced cancer. General immunocompetence has been monitored before,
during, and after therapy, using several tests in vitro.
During treatment there was a stress-mediated leucocytosis,
characterised by an increase in the concentration of phagocytically-
active immature neutrophils, a T-lymphopenia, and a B-lymphocytosis,
but no change in the total lymphocyte concentration. Lymphoid antibody-
dependent cellular cytotoxicity, and phytohaemagglutinin-induced
lymphocyte transformation, were slightly depressed by heating.
The day following treatment, the T lymphocyte concentration
remained depressed, and there was a fall in the level of serum
complement. Within 3-5 days of treatment, most parameters had
returned to their pre-treatment values, and there was a marked
increase in the T lymphocyte response to PHA, to 2-3 times the pre-
hyperthermia level. This was no longer evident within a week of
treatment. Hyperthermia therapy had no significant long-term effect
on any of the indices of cellular, or humoral, immunocompetence that
were monitored.
Heating lymphocyte suspensions in vitro, for 2|h at 42°C,
abolished PHA-induced RNA and DMA synthesis, and severely depressed
their capacity to form spontaneous, normal and 'rapid' rosettes with
unsensitised sheep erythrocytes. The ability of lymphoid cells to
lyse antibody-coated tumour cells was also reduced by heating the
effector population in vitro. Granulocytes heated at 42°C were less
efficient at phagocytosing low concentrations of latex particles.
The depression of lymphocyte immune function occurred, to a lesser
extent, when whole blood was heated in vitro before separation of
the lymphocytes.
These results indicate that heat treatment, both in vivo and
in vitro, depresses general inimunocompetence. In the clinical
situation the depression lasts for 24-48h following treatment,
during which, thermoresistant, viable tumour cells may be seeded
into the peripheral circulation, and become established as metastases.
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Due to the diverse nature of the assays used in this work, the
results are presented in the form of several papers, each of which
deals with a different test. These are supplemented by general
sections, containing information relevant to all of the assays.
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PREFACE AND GENERAL INTRODUCTION
Hyperthermia and the Immune Response
Preface
In recent years there has been an upsurge of interest in the
treatment of cancer by raising the body temperature to 41-43°C -
whole-body hyperthermia. This form of therapy appears to damage
tumour cells selectively, but it is likely to affect other organs
and systems in the cancer patient.
Virtually nothing is known about the effects of systemic
hyperthermia on the components of the immune system, although it
is generally accepted that the immune response can modulate the
course of malignant disease in both animals and man. An improvement
in general immunocompetence of cancer patients correlates with a
more favourable prognosis, and this has lead to the introduction of
therapies specifically designed to potentiate immunity.
Conventional treatments, such as radiotherapy and chemotherapy,
rely upon selective direct damage to the tumour cell, but also
produce immunodepression as a side effect.' As a result, the patient
is deprived of what may be a highly-selective tumour destroying
reaction.
The aim of this work was to determine whether whole-body
hyperthermia treatment, for advanced malignant disease, affected the
immunocompetence of the cancer patient, thereby either potentiating
any tumour-di rected immune response, or, producing the immuno¬




Therapeutic hyperthermia may be defined as the treatment of
disease by the induction of fever (normally in the 40-43°C range).
Elevation of body temperature has been used as a form of therapy
for a wide range of conditions, including gonorrhoea (Report, 1934),
arthritis (Markson & Osborne, 1933), neurological diseases
(Nelson, Jeffreys and McDowell, 1958) and advanced cancer (Pettigrew
et al, 1974). Although many of these applications have been
superseded by the introduction of simpler, and more effective,
drug treatments, there is still considerable interest in the use of
hyperthermia in the therapy of malignant disease (Symposia, 1975 &
1977). This interest has, as its basis, the evidence that cancer
cells are selectively sensitive to temperatures between 40 and
45°C (Lambert, 1912 -, Cavaliere et al, 1967).
The Clinical Development of Hyperthermia Therapy for Cancer
Evidence that hyperthermia has a beneficial effect on the
status of the cancer patient stems from two main sources:-
i) The correlation observed between spontaneous tumour
regressions and concomitant febrile infections.
ii) The clinical improvements that have been observed
following systemic, regional, or localised heat
treatments.
These observations are supported by studies using animals, and
in vitro.
Spontaneous regressions and the introduction of toxin therapy
For more than a century there have been reports of spontaneous
tumour regressions in patients who have had intercurrent pyrogenic
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infections.
In 1866 Busch described the disappearance of a histologically-
confirmed sarcoma of the face, in a patient who had suffered two
attacks of erysipelas. Some years later, Bruns (1888) reported the
complete regression of a number of melanomas in a terminal patient,
following an attack of erysipelas, in which the body temperature
exceeded 40°C for several days. In 1893 Coley reviewed 26 cases of
erysipelas in cancer patients, and found that, following pyrexia,
the tumour size decreased in the majority of cases, and nine
patients were finally cured. Remissions of between 5 and 44 years
were reported by Fowler (Unpublished observations) in a series of
33 patients with a variety of histologically-confirmed cancers, who
had had concomitant, pyrogenic, infections.
In 1918 Rohdenberg reviewed the literature on spontaneous
regressions of tumours, and concluded that 72 of the 166 carcinoma
patients, and 19 of the 26 sarcoma patients, had had high fevers,
heat applications, or severe infections. Everson and Cole (1966)
accepted only one of these as a genuinely 'spontaneous' regression,
however, they excluded all the pre-1900 cases. Nevertheless, in
their own review of more than 1,000 claimed regressions, they
mention fever, or infection, in some of the 176 cases which they
consider to be adequately documented.
Towards the end of the nineteenth century, the link between
fever and tumour regression was so well established that fevers
started to be used as a form of therapy. The earliest treatments
simply involved placing the cancer patient in close proximity to
a case of erysipelas (Busch, 1869), but these soon "progressed'to
to the direct inoculation of bacteria (Fehleison, 1883), often with
lethal results (Janicke & Neisser, 1884). One of the pioneers of
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this form of treatment was the American physician Coley. He produced
the complete disappearance of tumours by the injection of live
erysipelas cultures, obtained from Koch in Berlin (Coley, 1893).
He soon realised the dangers and difficulties in the use of these
vaccines, and tried heat-sterilised or filtered cultures, but
without great success. Coley was to spend many years of his life
trying to discover and standardise a more effective product. This
work formed the foundation of the dubious toxin therapies that are
still in use today (Miller & Nicholson, 1971 ; Issels, 1971).
Although Coley originally believed that he was injecting a toxin
that killed the 1 cancer-producing microbe1, it is now believed that
his success was, in some measure, due to the hyperpyrexia that the
toxins produced. Nauts (1976) has extensively reviewed the
literature on toxin and bacterial therapies, and has concluded that
they were of greatest benefit when they produced marked febrile
reactions. It is unlikely however that toxins cause large-scale
tumour necrosis solely by the low level of hyperthermia that they
produce (39-41°C). Their action is probably multifactorial,
involving both nyperpyrexia, and possibly, stimulation of the
immune system. Potentiation of the host's immunity would give
Coley's toxins a similar role to that of Bacillus Calmette Guerin
(BCG) and Corynebacteriurn parvum.
Externally-applied heat
The elevation of body temperature, for therapeutic purposes,
by the production of systemic pyrogenic infections, is fraught with
difficulties. Any such treatment runs the risk of killing the patient
directly by the infection, or toxin, employed, and is virtually
impossible to control or standardise. It was therefore inevitable
-4-
that an externally-applied heat source would gradually replace
natural, or induced, fever as a form of therapy.
Methods for direct heating can be conveniently divided into
two categories: localised or regional, and whole-body. Both are
increasingly being used in combination with a second, more
conventional, form of treatment, such as radiotherapy or chemotherapy.
Regional and localised heating Localised hyperthermia is of greatest
use in cases where the tumour is either external, or directly-
accessible to the heat source e.g. melanomas and bladder cancers,
although it has been used on tumours exposed by surgery (Crile,
1962).
In 1898 Westermark treated an inoperable, ulcerated, carcinoma
of the cervix by passing hot water through a spiral metal tube
inserted into the vagina, thus achieving a temperature of 42.5°C,
which resulted in complete healing. Good results were also achieved
by Goetze (1932) who treated carcinoma of the penis by immersion in
a hot bath.
Chemotherapy has been used in combination with local hyperthermia
in the treatment of malignant gliomas of the brain, by Sutcon (1971),
who suggested that the procedure showed particular promise for early,
localised, tumours. Combinations involving heat and radiation, or
drugs, have been used since 1909 (De Keating-Hart) and are of
greatest value where the hyperthermia is produced by heated perfusion,
or irrigation, of the affected area. Often the drugs are administered
in the heated perfusates, but heat alone has been used in a few
instances. Cavaliere et al (1967) have used pre-warmed, heparinised,
blood to perfuse limb tumours. In a survey of their first 22 patients
they reported major complications, including burns, kidney failure and
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shock; however, there was massive histological necrosis of the tumour
in 8 patients, 6 of whom were still alive and well in 1975 (Cavaliere,
Moricca & Caputo, 1976). Subsequently, the procedure was refined, and
between October and December 1974, a further 111 patients were treated
either by heat alone, or in combination with chemotherapy or surgery.
They concluded that hyperthermia could be very effective, especially
in cases of recurrent melanoma (Cavaliere et al, 1976). This view
is also held by Stehlin et al (1975), who showed that the heating
of perfusions, containing the drug Melphalan, may produce a 300
percent increase in survival rates, and eliminate the necessity for
amputation. They have also treated soft-tissue sarcomas by the
combination of heated perfusions, irradiation and excision, and
report that this regime greatly reduced the need for radical amputation.
Promising results have been obtained by Cummins et al (1976)
who have used local perfusions of the cerebral hemisphere to treat
inoperable malignant gliomas of the brain.
Heated (42-45°C) irrigations produced tumour necrosis in 60
percent of non-invasive transitional cell carcinomas of the urinary
bladder, and superficial damage to more deeply-invasive tumours
(Hall, Schade & Swinney, 1974). Heated bladder irrigations have
been combined with radiotherapy (Cockett et al, 1967) and chemo¬
therapy (Lunglmayr, 1973). Two complete regressions were reported
by Woodhall et al (1960) who used hyperthermic, cytotoxic perfusions
in the treatment of 20 head and neck cancers. Abdominal tumours have
been treated by perfusions of alkylating agents at 38°C, whilst
cooling the surrounding area to 31°C, but without remarkable results
(Shingleton et al, 1962).
In spite of considerable technical difficulties (See p. 8 ),
microwaves are now being used to produce localised heating, and are
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currently being evaluated, in combination with radiotherapy, in
the treatment of melanomas (Hahn, 1977 ; Johnson, 1977, Personal
communications).
Local heating can only be of value in the treatment of large,
recurrent, or single metastatic cancers, which are loralised to an
extremity or perfusable organ. In cases where the tumour is
advanced, and has metastasised to other organs, whole-body hyper¬
thermia may be of greater benefit.
Whole-body hyperthermia Whole-body heating has long been used in
the treatment of non-malignant conditions, e.g. general paralysis
of the insane, and resistant gonorrhoea. A variety of techniques
has been employed to induce hyperthermia, but most fall into one
of two groups:-
i) Direct heating by short-wave radiations.
ii) Immersion in a warmed medium e.g. water, wax, or air.
Infra-Red and Short-Wave Radiations. At its simplest, this technique
uses high power lights as a heat source. Warren (1935) treated 32
advanced cases of cancer using five, 200 watt, carbon filament lamps
to produce and maintain rectal temperatures of 41.5°C. He reported
an immediate improvement in the general condition of most of the
patients, which lasted for up to 6 months, and indicated that there
may be some synergism between whole-body hyperthermia and radiotherapy.
More recently, Heckel (1975) has used infra-red lamps to produce
temperatures up to 40°C for several hours in un-narcotised patients,
however, he has not yet published the clinical results.
Recently there has been increasing interest in the production of
localised, or whole-body hyperthermia by microwaves and ultrasound
(Symposium, 1975). Although the techniques for achieving controllable,
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uniform heating are still under development, there have been some
clinical applications 'Brenner & Yerushalmi, 1975). The Tronado
microwave machine, which basically consists of banks of encircling
diathermy antennae, has been used to treat more than 300 patients in
Australia. The controversial results have been disputed, and the
machine was phased out in 1975 (Report, 1976).
Both ultrasound (Lele, 1976 ; Baker, 1976) and radio-frequency
fields (Doss, 1976 ; Dickson and Shah, 1977) are under experimental
evaluation for use in heat generation, however, there are problems to
be surmounted (e.g. non-thermal damage to normal tissues, differential
absorption and reflection, and difficulties of temperature monitoring
due to interactions between the microwave field and metallic thermo¬
couples) before these methods can find wide clinical application.
Immersion Techniques. The earliest method of elevating the body
temperature was the hot bath, whose beneficial effects have been
known since the time of Hippocrates. Therapeutic hot water immersions
have been used in the treatment of malignant disease by Von Ardenne,
as part of his Selective Multiphase Cancer Therapy (Krebs-Mehrschritt-
Therapie-Forschung) (Von Ardenne, 1972). Unanaesthetised patients
were immersed in water at 40°C (while the head region was kept
cooled to 20°C), for periods of 150 minutes, without complications.
It is not clear from the literature, however, what clinical results
have been obtained using this method. A similar technique has been
documented by Suryanarayan (1966), who has produced oral temperatures
of 44°C (whilst cooling the carotid arteries and head) in
unanaesthetised patients, who were give infusions of cytotoxic drugs
when they reached peak temperature. He reported rapid palliation of
symptoms, but the cases were only followed-up for 60 days. Kirsch
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and Schmidt (1966) have used immersions and local diathermy to
treat 48 cancer patients, and produced only 5 cases of insignificant
clinical improvement. Domisch and Koeppen (1968) have also used
immersions to treat neoplastic disease, but have not detailed the
clinical response to therapy.
Circulating hot air has been used by Edwards (1976) to produce
and maintain temperatures of 41.8°C for up to 5 hours in
unanaesthetised patients. At present it is used to try to eradicate
residual viable tumour, following surgery for lung cancer, and although
still at an early stage, the results seem promising.
Each of these methods has its own particular advantages and
disadvantages. Hot water baths can produce unpleasant side-effects
such as skin damage (Giles, 1938), and Von Ardenne has reported
pre-collapse, or collapse, states in elderly patients after only
120 minutes of 40°C treatment. Hot air techniques seem to produce
fewer complications, and the use of general anaesthesia has been
found to increase both the patient's tolerance and reduce the
incidence of jaundice (Edwards, 1976).
It is possible that a combination of methods may result in a
safer, more controllable, procedure. It is known that retention of
metabolic heat by insulation can raise the body temperature to over
40°C within 6 hours (Giles, 1938). Therefore, by insulating the
patient against the normal methods of heat loss, and, applying an
additional external heat source, it should be possible to produce
temperatures in excess of 40°C fairly quickly,without the risk of
burning or scalding. This was the approach adopted by Henderson
and Petti grew (1971), and subsequently modified by Petti grew (1976).
They produced temperatures greater than 41 °C by:-
i) Insulating the body against the loss of metabolic heat
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by covering the patient with a layer of solidifying paraffin
wax.
ii) Heating theinspired gases to prevent heat loss via the
respiratory surfaces, and to provide a small additional
heat source.
iii) Immersing the patient in molten paraffin wax. This acts as
the primary heat source, and although it is initially at
50°C, the wax in contact with the patient cools to form
the insulating layer. The surrounding molten wax gradually
solidifies, at between 40 and 43°C, and as it does so, it
releases its latent heat of solidification to the patient,
thereby acting as a form of thermostat, keeping the
temperature elevated, but still tolerable.
The clinical results from this form of hyperthermia therapy have
been encouraging (Pettigrew et al, 1974 ; Pettigrew, 1976). More than
100 patients, ranging in age from 3 to 80, have been treated, either
by heat alone or in combination with radiotherapy or chemotherapy
(Pettigrew et al, 1977). Most patients received 2-4 treatments (each
lasting 2-4 hours), however in one case, a patient was given 24
heating sessions. The results from 49 patients treated by hyper¬
thermia alone are summarised in Table 1. In general, sarcomas of
soft tissue origin showed the best response. Gastro-intestinal
tumours also responded well, whereas breast cancers were less respon¬
sive to heat alone, but reacted better to a combination of
hyperthermia and cytotoxic drugs. Pettigrew has concluded that
the initial results from whole-body hyperthermia treatment of gastro¬
intestinal tumours justify further study, in the form of a controlled
clinical trial.
This method for inducing hyperthermia has also been used by
-10-



























































































* NECROPSYEVIDENCEOFRECENTTUM URN CROSIS.
TABLE1
CLINICALRESULTSFROMWHOLE-BODYHYPERTHERMIAT ATMENTFADVANCEDCANCER From:Pettigrew(1976)
Levin (Levin, 1977 ; Blair & Levin, 1977), who has combined heat
treatment with radiotherapy. Six patients with various advanced
tumours experienced immediate pain relief and tumour shrinkage,
within 4-5 days of treatment. The cancers grew again in all cases,
however, it should be remembered that, at present, all the cases
being treated by hyperthermia are in the terminal stages of their
disease. Levin is currently conducting a controlled clinical trial
of hyperthermia in the treatment of Stage IV carcinoma of the cervix.
In conclusion:-
i) Safe and effective methods for achieving hyperthermia by
whole-body, or localised methods exist, and are being
developed.
ii) Clinical results are still sketchy and anecdotal, but,
taken in combination with experimental studies, indicate
that this method may be of value in the treatment of
human cancer, especially when used in conjunction
with other forms of therapy.
Further investigation of the potential of hyperthermia is
clearly warranted.
The Effects of Hyperthermia on the Cell
Introduction
Clinical applications of hyperthermia in the treatment of
malignant disease have been parallelled by laboratory investigations
into its mode of action. There have been reports on the inhibitory
effects of heating in vivo, on both the growth and metastasis of
animal tumours, as assessed by direct tumour measurement or autopsy
evidence (Westermark, 1927 ; Crile, 1962 ; Overgaard & Overgaard,
1972 ; Thrall, Gillette & Bauman, 1973 ; Yerushalmi, 1976).
However, since there are, at present, few good animal systems which
can be used to investigate hyperthermia in vivo, studies have focused
on the effects of heat on malignant and normal cell lines in vitro.
The first of these experiments, more than 70 years ago, demonstrated
the thermosensitivity of tumour cells by the decreased number of
'takes' resulting from the injection of heated cancer cells into
animals (Loeb, 1903 ; Jensen, 1903). Inhibition of growth in vitro
was reported, at about the same time, by Lambert (1912), in possibly
the first experiment in which tumour cells were tissue cultured.
Since then a large number of workers have confirmed this inhibitory
effect using both cultured tumour cells (Levine & Robbins, 1969 ;
Giovanella et al, 1973 ; Harisiadis et al, 1975), and on cells
explanted from human tumours (Schrek, 1966 ; Giovanella, Stehlin &
Morgan, 1976 ; Dickson & Suzangar, 1976).
It is important to emphasise that the sensitivity of tumour
tissue to hyperthermia is relative. Cancer cells appear to be
damaged selectively at temperatures above 41.5°C, and there is a
definite relationship between the temperature and the exposure time
(Stevenson, 1919 ; Overgaard & Overgaard, 1972 ). At temperatures
-12-
above a critical level (usually about 40.S°C - depending upon the
tumour) an increase of one Centigrade degree halves the time
required to produce the same biological effect (Gerweck & Dewey, 197c),
but also tends to reduce the selectivity of the heat damage.
Therefore, at any temperature above the threshold value, there is
likely to be a fine balance between tumour destruction and normal
tissue damage. Clinical treatments, whilst aiming to optimise the
former, are likely to produce varying degrees of the latter, especially
during whole-body hyperthermia, in which normal cells and organs, with
a range of thermal sensitivities, will be subjected to elevated
temperatures.
A brief summary of the effects of heat on tumour cell structure
and metabolism is given below. This is included because the nature
of the selectivity of heat damage is not fully understood, and it is
likely that the changes produced in tumour cells occur ( but presumably
to a lesser extent, or at higher temperatures) in other cell types,
including those which mediate immune responses.
Mechanisms by which Heat Damages Tumour Cells
Effects on Cell Structure and U1trastructure Characteristic changes
in tumour cell structure, following hyperthermia in vivo, have been
described by the Overgaards (Overgaard & Overgaard, 1972 & 1976).
In general the cytoplasm and nuclei shrank and vacuoles appeared in
the cytoplasm, which stained more intensely. Cells in culture may
also show deformation after heating (Levine & Robbins, 1969 ;
Selawry et al, 1957) and the surface topology may change (Overgaard,
1976).
At the ultrastructural level the changes are often more profound.
Overgaard and Overgaard (1976) have observed an increase in the numbers
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of lysosome-like bodies in the cytoplasm, following hyperthermia
in vivo. The mitochondria were also affected, initially showing
dilatation, and subsequently, inflation, and membrane rupture. In
tissue cultured cells the effect on mitochondria seems to be less
severe (Simard & Bernhard, 1967), but there have beer reports of
increased lysosome numbers (Heine et al, 1971). The most sensitive
cytoplasmic structure appears to be the polyribosome, which shows
reversible disaggregation in response to heat (McCormick & Penman,
1969), both in vitro (Love, Soriano & Walsh, 1970), and in vivo
(Overgaard, 1976).
Changes also occur in nuclear ultrastructure. The number of
peri chromatin granules increases (Heine et al, 1971) and chromosome
aberrations may occur, but at low frequency (Dewey et al, 1971);
the most sensitive structure seems to be the nucleolus. Changes
in nucleolar structure following hyperthermia are striking.
Chromatin and granular ribonucleoprotein are lost, and the nucleolar
reticulum disappears (Simard & Bernhard, 1967). The whole nucleolus
becomes morphologically and histologically amorphous (Love et al,
1970), consisting largely of fibrils (Heine et al, 1971). These
changes are reversible if the cells are returned to normal
temperatures, providing that the exposure time has not passed a
critical limit.
Effects on Cell Metabolism
Respiration and glycolysis Temperatures above 40°C, applied both
in vivo (Muckle & Dickson, 1973) and in vitro (Cavaliere et al,
1967) have been found to inhibit selectively the respiration of
tumour cells (Muckle & Dickson, 1971). This inhibition becomes
irreversible if the duration of heating passes a critical time
(Mondovi et al, 1969a), and can be correlated with irreversible cell
damage (Mondovi, 1976). This correlation has formed the basis of
an assay in vitro for predicting the sensitivity of human solid
tumours to hyperthermia (Dickson & Suzangar, 1976).
The effect of heat on glycolysis is less predictable. Inhibition
has been reported for some tumours, e.g. the Yoshida rat tumour
(Dickson & Ellis, 1974) and the Sprague Dawley breast tumour (Dickson
& Shah, 1972); but not in a number of others (Cavaliere et al, 1967 ;
Mondovi et al, 1969a). A reduction in anaerobic glycolysis has
been described for human tumours heated in vitro (Dickson & Suzangar,
1976).
The time scales for the inhibition of both respiration and
glycolysis of tumours suggest that these factors are not the primary
target of hyperthermia (Dickson & Shah, 1972 ; Mondovi, 1976).
Nucleic acid and protein synthesis Nucleic acid and protein synthesis
have been studied by measuring the uptake of specific, radiolabeled,
precursors. Heating in vitro to 41°C has been found to inhibit
the uptake of these precursors by both tumour cells and rapidly-
proliferating tissues (Wust et al, 1973). In contrast, Mondovi
et al (1969b) have shown that uptake was only inhibited in tumour
cells, in comparison to cells from regenerating liver. Other
workers have also reported selective inhibition of synthesis, but
are divided as to which pathway is the most sensitive. Mondovi
et al (1969b) have found that DNA production was the most inhibited,
whereas Dickson and Shah (1972) reported that RNA synthesis was
the more severely affected. Mondovi (1976) has since stated that
these discrepancies may be due to differences in experimental
conditions, and in the rates of ribosomal RNA synthesis (See p.16).
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In an attempt to discover which process is the primary target
for heat damage, drugs have been used to block the individual
synthetic pathways during heating. Drugs inhibiting nNA synthesis
were found to increase the thermoresistance of a tumour cell line
(Giovanella & Heidelberger, 1969 ; Palzer & Heidelberger, 1973a),
indicating that the depression of DNA synthesis, which itself
occurs as a response to heat, may possibly be thermoprotective.
Dewey et al (1971) found that there was an additive, rather than
synergistic, reaction between the drug BUdR and heat, indicating that
the same structures were damaged by both. They concluded that
this structure was chromatin - the DNA of which was damaged by
the BUdR, and the associated protein, by the heat. In contrast,
radiation acted synergist!"cally with BUdR, and was of least effect
during the heat-sensitive late S phase of the cell cycle.
Respiration is also much less sensitive to radiation than glycolysis
(Caputo & Giovanella, 1960). These differences between the effects
of heat and radiation would argue against a common primary target of
damage, and as radiation is believed to act directly upon DNA, it is
unlikely that this is also the centre for heat killing. It is possible
however, that DNA is indirectly affected by heat inactivation of some
enzyme, or protein, associated with it (Loshek, Orr & Solominidis,
1976).
Compounds which inhibit RNA production have been shown to
increase hyperthermic cell killing e.g. MPB and Cordycepin (Palzer
& Heidelberger, 1973b) and Actinomycin D (Giovanella et al, 1970),
indicating that RNA may be the primary target for heat damage.
However, increasing the extracellular concentration of RNA
precursor (uridine) can reduce the inhibition of uptake (Strom
et al, 1973), which suggests that the damage might be occurring at
the cell membrane level. This is supported by experiments showing
that membrane passive permeability (Strom et al, 1973) and trans-
cellular migration (Strom et al, 1969) are both increased by
elevated temperatures. Such changes could be responsible for
the heat-induced inhibition of RNA synthesis, but, in contrast to
drugs which increase membrane permeability, or inhibit nucleoside
permeation, heat did not affect the ability of labelled uridine to
be incorporated into RNA (Strom et al, 1973). It has now been shown
that, although drugs which alter membrane permeability may have
superficially the same effect as heat upon RNA synthesis, their mode
of action is not identical; and the membrane changes that occur after
hyperthermia are, in fact, secondary (Mondovi, 1976), and are
therefore not responsible for the inhibition of RNA synthesis (Strom
et al, 1975). This implies that RNA production may indeed be the
primary target for heat damage. High-resolution autoradiography
(Simard & Bernhard, 1967), cytochemistry (Love et al, 1970), and
extraction techniques (Heine et al, 1971 ; Strom et al, 1975)
have shown that there is a selective inhibition of nucleolar RNA by
heat. The marked morphological changes that occur in the nucleolus
of the heated cell would tend to support the theory that it is the
centre of heat damage.
In the normal nucleolus, DNA is transcribed into nucleolar RNA,
which eventually matures and becomes ribosomal RNA. As a step in
this maturation process, a high molecular weight (45S) RNA is formed -
pre-ribosomal RNA. This cleaves to form first 35S, and then 28S RNA.
Morphologically the maturation of pre-ribosomal RNA can be correlated
with a change from a fibrillar to a granular structure (Simard &
Bernhard, 1967), the fibrillar component being the 45S molecule
(Love et al, 1970).
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Following hyperthermia, the granular component of the nucleolus
disappears and the stricture develops an homogenous appearance,
consisting mainly of fibrils (Heine et al, 1971). Love et al (1970)
have suggested that hyperthermia alters the configuration of the RNA,
and the reduced synthesis may depress the production of the pre-
ribosomal particles, or ribosomes, by the nucleolus. They state that
the more mature, granular RNA is probably eliminated from the
nucleolus, via the nuclear pores, to the cytoplasm, where it is seen
as inclusions, and that this process is accentuated by heat.
Simard and Bernhard (1967) have, however, shown that the granular
material is not lost from the nucleolus, but is converted back into
the fibrillar form, by unravelling. They believe that heating affects
the hydrogen bonds of the nucleolar DNA (which may be more sensitive
to heat than nuclear DNA), and maturing, pre-ribosomal RNA. This
results in a severe depression of RNA synthesis and configurational
changes in the already-synthesised RNA.
Normal RNA production is essential for the synthesis of late-
replicating DNA (Mueller & Kajawara, 1965), and the progression into
mitosis. It is possible that, by disrupting RNA production,
hyperthermia dissociates this relationship, and thereby affects tumour
cell replication, as suggested by Dickson and Shah (1972). This is
probably an over-simplification, and it is more likely that there
are a number of mechanisms involved in the process of thermal cell
damage and killing.
Factors Affecting Selectivity of Heat Damage
As has been stated, many of the changes produced in tumour cells
by elevated temperatures probably occur to a lesser extent in other
types of cells. The extent to which this happens may be governed by
an inherent thermal sensitivity of the cell, but it is likely to be
greatly influenced by the following factors
i) pH Several workers have reported that the thermosensitivity
of tumour cells can be increased by reducing the intra¬
cellular, or extracellular pH (Overgaard, 1976 ; Kim,
1977 & Gerweck, 1977 Personal communications). Other
groups have not found a pH effect (Dickson & Oswald, 1976).
ii) Oxygen Status Hypoxic cells are reported to be more
thermosensitive than fully-oxygenated equivalents (Gerweck,
Gillette & Dewey, 1974 ; Schulman & Hall, 1974 ; Thrall et
al, 1975 ; Harisiadis et al, 1975). This is in marked
contrast to the effect of oxygen status on radiation killing.
iii) Nutritional Status (probably related to (i) and (ii) above).
Cells deprived of nutrients are more sensitive to hyperthermic
killing (Hahn, 1974).
iv) Phase of the Cell Cycle There are two peaks of thermo¬
sensi tivity during the cell cycle. The first occurs during
mitosis (Rao & Engelberg, 1965 ; Gerweck & Dewey, 1976),
and, in particular during metaphase (Sisken, Morasca & Kibby,
1965 ; Selawry, Goldstein & McCormick, 1957); and the second
during S phase (Dewey et al, 1971), especially during late S
and early (Palzer & Heidelberger 1973b ; Kase & Hahn, 1975).
Rapidly-proliferating cells may also be more sensitive
(Wust et al, 1973 ; Wust, 1976).
During whole-body hyperthermia treatment every system and organ in the
body will be exposed to increased temperatures, and differences in
the parameters listed above, which are insignificant at 37°C, may have
a critical role in determining the degree of thermal damage sustained
by a particular cell or organ.
Hyperthermia is known to produce changes in, for example, the
liver (Wills, Findlay & McManus, 1976) and alterations in serum protein
and vitamin levels (Mendez et al, 1959), and pituitary/adrenal responses
(Few & Worsley, 1975) are suggestive of effects on other normal tissue.
Little is known about the action of hyperthermia on the
components of the immune system (See p. 38 ), in spite of the fact
that it may have an important role in mediating hyperthermia therapy
(Symposia, 1975 & 1977). In addition, if one accepts that tumours
may be inhibited by an immune reponse, then it is of primary importance
to ascertain whether whole-body hyperthermia therapy affects the
immunocompetence of the patient.
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Cancer and the Immune Response
Introduction
It is believed that the purpose of the immune system is to
recognise, and eliminate, that which is 'not self'. This role may
be described as one of surveillance (Thomas, 1959 ; 3urnet, 1971),
and, as such, can be used to explain defence against bacterial,
fungal, and parasitic infections, and phenomena such as the rejection
of foreign grafts. Whilst the process of antigen recognition is not
fully understood, the nature of some of the immune responses to
antigenicity have been elucidated.
The Immune Response to Antigens - A Brief Summary
The response to an antigen may involve many different facets of
the immune system, however, it can be visualised as taking two forms,
namely the humoral and the cell-mediated response. Although this
division is now regarded as somewhat artificial, it is still a useful
concept for the classification of immune responses.
Humoral Immunity The humoral response to antigens is mediated by
immunoglobulins produced by 3 cells. These cells are lymphocytes
which have originated in the bone marrow and have become immuno¬
competent, following processing by the Bursa of Fabricius in birds,
or its equivalent in mammals (possibly gut-associated lymphoid
tissues, and/or the haemapoietic tissues e.g. the cortex of the
lymphoid follicles, foetal liver and spleen). It is believed that
each B cell can make one (or a very limited number) particular
antibody, which it bears at its surface as a receptor. When the cell
contacts an antigen which complements this receptor, it divides
and proliferates (clonal selection theory of antibody production).
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The original receptors are shed and replaced. The lymphocyte then
undergoes repeated mitoses, resulting, after several days, in the
production of a mature clone of specific-antibody secreting plasma
cells, and a number of memory cells. The latter respond more
sensitively and rapidly to any re-appearance of that particular
antigen.
The released antibody can act by precipitating antigen which is
in solution, by binding with it to form insoluble complexes. If the
antigen is bound to cells then these may be:-
i) Agglutinated - by the antibody cross-linking antigen on
adjacent cells.
ii) Phagocytosed - after coating with antibody (opsonisation)
and, in the case of immune adherence, complement, cells
show an affinity for the receptors on polymorphs and
macrophages.
iii) Lysed - antibodies on the cell surface may fix complement,
thus activating the sequence leading to damage of the cell
membrane and lysis. Alternatively, antibody-coated cells
can be killed by K cells (See p.25)
In addition, both B lymphocytes and humoral antibody have an important
role in the modulation of eel 1-mediated responses (Moller, 1972).
Cel1-Mediated Immunity Cellular immunity may be mediated by a
variety of cell types, but most is known about T cell responses.
The T cell is a lymphocyte which derives from stem cells in the
bone marrow, and is processed by the thymus gland, before becoming
immunocompetent (Davies, 1969). Mature T cells are usually long-
lived and mobile, being found in the peripheral blood, paracortical
areas of the lymph nodes and the white pulp of the spleen. They
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are thought to carry surface receptors (IgT) for the antigen to
which they have become sensitised by previous contact. The nature
of these receptors is still in doubt, but it is possible that they aie
immunoglobulin M monomers, derived either from B lymphocytes, or
possibly synthesised by the T cell itself (Burnet, 1976).
Alternatively, they may be complexes of antibody and antigen (Roitt,
1974).
Once the antigen combines with the receptors, the cell is
transformed from a small lymphocyte into a large lymphoblast, which
proliferates to produce large numbers of specifically-sensitised cells
which are able to kill any cells which bear that antigen. The killing
process is independent of added complement and is believed to involve
initial cell-to-cell contact (Perlmann & Holm, 1969), producing
membrane damage, resulting in final osmotic lysis (Ferluga & Allison,
1974), although this mechanism is disputed (Sanderson, Hall & Thomas
1977).
Blastogenesis is usually accompanied by the synthesis, and release
of soluble factors - lymphokines. It. is possible that lymphokine
production may occur independently of blast transformation (Spittler
et al, 1970). These factors are identified by their action, and up
to date more than 20 have been described (Pekarek and Krejci, 1974).
Their functions, in the mediation of delayed hypersensitivity reactions,
are diverse, ranging from inhibiting cell growth - lymphotoxins
(Ruddle & Waksman, 1967) and virus multiplication - interferon
(Wheelock, 1965), to the induction of blastogenesis in non-sensitised
lymphoid cells - mitogenic factor (Kasakura and Lowenstein, 1965) and
the inhibition of macrophage migration - MIF (Bloom & Bennet, 1966).
T cells also have a vital role in controlling immune responses.
They act synergist!"cally in the production of some antibodies, both
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in vivo (Claman, Chaperon & Seiner, 1568) and in vitro (Feldmann et al,
1974).
In complete contrast, T cells can have a suppressor effect on
the immune response (Moller, 1975). In this role they have been
found to abrogate, or diminish, both humoral (Droege, 1971 ;
Herzenberg et al, 1973), and eel 1-mediated immunity (Hardin, Chused
& Steinberg, 1973 ; Zembala & Asherson, 1973). The T cell
population is therefore not as homogenous as was once thought, but
is probably composed of various subpopulations of suppressor and
helper cells, which may exert a stimulatory, or an inhibitory
influence, depending upon the circumstances.
Macrophages Macrophages can show both specific and non-specific
cytotoxicity. Specific killing is shown in vitro by cells which have
been armed (Evans & Alexander, 1972) by:-
i) Incubating the macrophages in the supernatant from a
culture of immune lymphoid cells and specific antigen -
this supernatant contains a specific arming factor
produced by the sensitised T cells (Ziegler, Lohmann-
Matthes & Fischer, 1975).
ii) Incubating normal macrophages with immune lymphoid cells.
If these armed macrophages are now incubated with the specific
antigen, they become activated (Evans & Alexander, 1972) and are then
non-specifically cytotoxic. Activation is believed to occur in vivo
(Hibbs, Lambert & Remington, 1972) where it appears that the activated
macrophages are selectively cytotoxic for malignant cells (Droller &
Remington, 1975)
Macrophages are also involved in the generation of helper T cells
(Erb & Feldmann, 1975), potentiation of T cell responses (Gery &
Waksman, 1972), and the presentation of antigen to lymphoid cells
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(Unanue, 1972). Monocytes, which may be the precursors of peripheral
blood macrophages in the human (Krikorian et al, 1975), have also
been found to display cytotoxicity in vitro (Holtermann et al, 1974).
Similar effects have been claimed for other cell classes (Pickaver
et al, 1972).
Antibody-Dependent Cellular Cytotoxicty - ADCC Leucocytes can
kill target cells in the presence of sub-lytic concentrations of
antibody to the target cell. This effect was first described by
Moller (1965), and is distinguished by the following
i) Mediation by non-immune effector cells.
ii) Lack of species barrier between target cell, antibody
and effector cell.
iii) Requirement for sub-lytic concentrations of target cell-
specific antibody (Perlmann, Perlmann & VJigzell, 1972).
iv) Lack of requirement for complement (Van Boxel et al, 1974).
The fact: that ADCC can be demonstrated in syngeneic, allo¬
geneic and xenogeneic systems has made it difficult to compare results
from different laboratories, with the result that the nature of the
effector cell is still in doubt. The cell preparations that have been
shown to have lytic activity differ widely in source and purity, so
that lysis may have been due to small numbers of contaminating cells.
In fact, it has been found that virtually every type of leucocyte,
including perhaps the T lymphocyte (Saal et al, 1977a ; Greenberg &
Wolosin, 1977), which was originally excluded by Van Boxel et al
(1972) and Perlmann et al (1972), amongst others, can display ADCC
under the right conditions. This rather confusing situation has
been clarified recently by the demonstration that the nature of the
effector cell is largely determined by the type of target cell used
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in the assay (MacDonald et al, 1975). The two most commonly used
target are the erythrocyte and the continuous cell line.
Cytotoxicity against cell lines is usually shown by non-
phagocytic mononuclear cells - K cells (MacDonald et al, 1975 ;
Trinchieri et al, 1975 : Peter et al, 1975). These cells may be
lymphocytes (Zeijlemaker et al, 1975), as judged by their morphology
(Kovithavongs et al, 1975), radiosensitivity and low density.
Neutrophils and macrophages have also been found to show K cell
activity by a number of workers (Gale & Zighelboim, 1974 ; Wardley,
Rouse & Babuik, 1976 ; Ormerod & Jolley, 1976).
Human erythrocytes are lysed by both adherent, phagocytic,
mononuclear cells and polymorphonuclear cells (MacDonald et al,
1975 ; Zeijlemaker et al, 1975 ; Trinchieri et al, 1975). However,
Urbaniak (1976) has found that the adherent cells could be removed
from a lymphoid effector cell population, without greatly affecting
its cytotoxic activity. Sheep and chicken erythrocytes can be lysed
by virtually any leucocyte population. The adherent cells are
probably monocytes, macrophages and polymorphs (Inglis et al, 1975),
whereas the non-adherent cells are of lymphoid origin, but probably
not T or B cells (Calder et al, 1974).
The nature of the effector cell therefore seems to depend on the
type of target cell used. The reason for this is not clear, although
there have been several explanations
i) The size of the target cell is the critical factor
(Papamichail & Temple, 1975).
ii) The distribution and fluidity of the antigen on the target
cell surface, and the receptors on the K cell, determine
the type of effector cell activated (Trinchieri et al, 1975).
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iii) There is a difference between the Fc receptors on
lymphocytic and monocytic effector cells (' arsson et al,
1975).
Whatever the mechanism involved, it is now apparent that antibody-
dependent cellular cytotoxicity can be displayed by a number of cell
types, making it one of the most interesting cell-mediated immune
responses.
The Antigenicity of Tumour Cells
For a cell to elicit an immune response it must be antigenic
to the host which bears it. Furthermore, any proposal that the
immune response may play a role in the prevention, or control, of
cancer depends on the existence of antigens which, although not
absolutely specific to tumour cells, will initiate a selective,
anti-tumour immune response. These antigens were first demonstrated
at the turn of the century, when it was shown that animals in which
tumours had spontaneously regressed, were resistant to challenge by
tumour cells from the same line (Clowes & Baeslack,1905); however
the animals used in these experiments were not syngeneic, and there¬
fore the resistance observed may have been directed towards histo¬
compatibility antigens, which are present on all tissues. When
homozygous, inbred, strains became available this possibility could
be eliminated. Using these strains, Gross (1943) was able to show
that animals, in which transplanted, methylcholanthrene-induced
tumours had regressed, were resistant to subsequent challenges with
the same tumour. This work was confirmed by Foley (1953), who found
that the destruction of a growing tumour, by ligation, conferred
resistance to future challenges, by the same tumour growing in a
syngeneic animal.
It was still possible to attribute these findings to some
residual heterozygosity in the animals, but this question was finally
resolved by Prehn and Main (1957). They extended Foley's work by
showing that their animals were truly homozygous, since they were
able to accept skin grafts from donors of the same inbred line.
In addition, they demonstrated that the immunity they observed was
tumour-specific, since normal tissue, obtained from the animal used
to provide the immunising tumour implant, could not confer immunity
against the tumour, conversely, tumour implants from an isologous
animal failed to immunise against skin grafts from the implant donor.
All these experiments involved challenges with tumour grown
in an isologous host, but Klein et al (1960) showed that an animal
may be immunised against its own tumour. They amputated the tumour-
bearing limbs of mice and immunised the animals with irradiated cells
from the cancer. They then reinjected the original host with its
autochthonous tumour, and were able to show resistance.
These tumour-specific transplantation antigens - TSTAs - have
been detected in a variety of experimental animal tumours, but have
different characteristics, depending upon how the tumours were
induced, for example, all chemically-induced tumours seem to be
antigenically distinct (Old et al, 1962), whereas all the tumours
produced by one virus, share a common antigen (Sjogren, 1965).
This is undoubtedly an over-simplification, as chemically-produced
tumours may share common, weaker, antigens (Prehn and Main, 1957 ;
Reiner and Southam, 1967), and viral tumours may display individual
antigens (Heppner & Pierce, 1969 ; Vaage, 1968). So-called
spontaneous tumours are thought to contain relatively weak TSTAs
(Symes, 1974 ; Cuarie, 1974), however Hewitt, Blake and Walder
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(1976) have failed to demonstrate an immune response to 27 different
spontaneous tumours, during the course of more than 20,000 transplants.
In addition, they have noted that immunisation with irradiated tumour
cells often increased susceptibility to challenge by the tumour.
This work may be of considerable importance to the future of tumour
immunology, as spontaneous animal tumours are thought to provide a
good model for human cancers. However, in general, present evidence
indicates that many animal tumours bear specific antigens that are
capable of eliciting an immune response in the host.
The Immune Response to Human Tumours
The transplantation of malignant tumours between human subjects,
besides being highly unethical, does not provide evidence for TSTAs,
since humans are outbred, and will therefore reject almost any implant
because of histocompatibility differences. This has resulted in the
development of assays for detecting the immune response to human
tumour tissue in vitro. The antigens which these tests detect may
be shown to be tumour-specific by the inclusion of the appropriate
normal controls in the test system; since these antigens may not be
identical to those demonstrated by transplant techniques, they are
known as Tumour-Associated Antigens - TAAs.
Humoral Immunity Anti-tumour antibodies have been discovered in the
serum of cancer patients, using a variety of techniques. Indirect
fluorescent antibody tests have shown that patients with Burkitt's
lymphoma (Klein et al, 1967), malignant melanoma (Morton et al, 1968),
osteogenic sarcoma (Mortom & Malmgren, 1968) and leukaemia (Dore et al,
1967) possess humoral antibody to their tumours. Their role in the
cancer patient is not clear, although it has been shown that they
may be cytotoxic in melanoma (Canevari et al, 1975) and breast cancer
(Baldwin et al, 1973), and their presence may correlate with delay in
the recurrence of disease, following surgical procedures (Hudson et al,
1974).
It is generally accepted, however, that the immune response to
tumours is largely cell mediated (Baldwin & Price, 19"76 ; Report,
1975). The evidence for this has been extensively reviewed by the
Hellstroms (1974) and Herberman (1974), but basically it centres
around the demonstration that tumour-specific immunity could be
transferred adoptively to a normal animal by the injection of cells,
rather than serum, from an immune animal (01d et al, 1962).
Cellular Immunity Cell mediated immune responses to human tumours
have been detected using a wide range of test systems (Monograph 1973)
Measurements in vivo have been made, using neutralisation tests and
skin testing. The former involve assessing the patient's hyper¬
sensitivity response to a sub-cutaneous injection of a mixture of
autochthonous, viable tumour cells and blood leucocytes (Southam,
1967). Apart from being very doubtful ethically, it is virtually
impossible to determine whether the absence of a tumour nodule is
due to an immune response to the cells, or some secondary event.
Delayed cutaneous hypersensitivity reactions to a variety
of non-vable tumour preparations have been described in various
cancers. In these tests an extract of autochthonous, or
allogeneic tumour of the same histological type, is injected intra¬
dermal^, and the response compared to that obtained by the injection
of various control extracts. Positive reactions have been noted
in leukaemia (Oren & Herberman, 1971), Burkitt's lymphoma (Bluming
et al, 1975), malignant melanoma (Holmes, Roth & Morton, 1975),
breast cancer (Alford, Hollinshead & Herberman, 1973) and carcinoma
of the colon (Hollinshead et al, 1972). These tests can produce
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many problems, arising mainly from the lack of purity and sterility
of the extracts, and the incidence of false positive reactions to
the control tests (Burdick, Wells & Herberman, 1975). As a result,
emphasis has been placed on the measurement in vitro of eel1-mediated
immunity.
The most commonly used of these assays is the microcytotoxicity
test, in which lymphocytes from patients with tumours have been shown
to kill, or inhibit the growth, or metabolism of, tumour cells of the
same histological type (Pekarek & Krejci, 1974). Positive results
have been reported in meningioma (Pees & Seidel, 1975), bladder
carcinoma (O'Toole et al, 1973), lung tumours (Vose, Moore & Jack,
1975), melanomas (DeVries & Rumke, 1975) and renal cell carcinomas
(Cole et al, 1975), amongst others. This test is particularly
prone to problems (Herberman & Oldham, 19/5 ; Baldwin, 1975 ;
Devries, 1975). These range from those involving questions of
technique and quantitation of results (ReDort, 1975), to very serious
doubts about the nature and specificity of the response. Hellstrom
et al (1971) suggested that human tumours of the same histological
type, share common antigens, since lymphocytes from patients with a
particular tumour were more reactive against tumours of that type
than were lymphocytes from normals, or patients with other cancers.
On this basis, allogeneic tumours and tumour cell lines of the same
histological type, have been used in microcytotoxicity tests, however
it now appears that lymphocytes from both normals, and cancer patients,
can display activity against a range of tumour cell targets (Takasugi,
Mickey & Terasaki, 1973 & 1974 ; 01dham et al, 1975). Recently,
Brooks, Rees and Baldwin (1975) have suggested that the killing by
normal lymphoid cells may be an artefact, due to modifications of the
tissue culture medium by the effector cells. In general, there is
evidence that the cancer patient does show a positive reaction against
his own tumour type (Hakala et al, i9"74).
Another commonly used assay for cellular immunity is the leucocyte
or macrophage migration inhibition test. If the patient's lymphocytes
are sensitised to his tumour, then upon contact with tumour antigen,
they will release a lymphokine that inhibits the otherwise normal
migration of human leucocytes, or guinea pig macrophages, in vitro
(Sinkovics, 1973). Inhibition has been shown in a variety of tumours
(Elias & Elias, 1975a), however, the test is often difficult to
interpret, since the results can be affected by the nature of the
tumour extract (Jones & Turnbull, 1975 : Elias & Elias, 1975b), and
the type of indicator cell (Armitstead & Gowland, 1975). Migration
may also be inhibited by serum (Bice, Gruwell & Salvaggio, 1976),
and tumour factors (Wolberg, 1974). Nevertheless, positive results
have been obtained, and although the technique can show histogenic
cross-reactions (Segal et al, 1972), it may correlate with clinical
findings (Kjaer, 1976). A modification of this system, known as the
monocyte spreading test, has been used to demonstrate tumour antigen
in melanoma patients (Mazuran et al, 1976).
Lymphocyte blastogenesis assays, using either autochthonous
or allogeneic tumour cells, or extracts, have been developed,
(Stjernsward, 1974 ; Mavligit, Hersh & McBride, 1974). However, they
show considerable cross-reactivity if tumour extracts are used (Dean
et al, 1975), and it is almost impossible to determine whether a
blastogenic response to whole cells is really a secondary reaction,
rather than a primary, recognition, response.
An immune response to human tumours has also been detected by
the leucocyte adherence inhibition test (Halliday, Maluish & Isbister,
1974 ; Grosser et al 1976). This test was thought to resemble the
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leucocyte migration inhibition assay, in that a lymphokine was released
by sensitised lymphocytes, in the presence of specific tumour antigen
(Holt et al, 1975). It now seems that the test may depend upon
circulating anti-tumour antibody, rather than lymphokines, and is
therefore not strictly a eel 1-mediated response (Marti, Grosser &
Thomson, 1976).
In summary, assays in vitro and in vivo, using human cells and
humoral factors, taken together with comparable animal experiments,
tend to indicate that the tumour-bearing host can mount an immune
response to his tumour.
These experimental results are reinforced by clinical observations.
The incidence of cancer in patients with primary immunodeficiency
is about 10,000 times that in the general, age-matched, population
(Gatti & Good, 1971); however, these figures should be treated with
caution, since the majority of the tumours in these patients are
lymphoreticular, and may be the result of the immune system failing
to modulate the response to antigen (Prehn, 1976). It has also been
found that tumours transplanted accidently into immunosuppressed
kidney transplant patients, have regressed when the immunosuppression
was discontinued (Gatti & Good, 1971). It is important to realise
that the transplanted tumour was an allograft, and therefore the
rejection is not really tumour-specific. The immune system may have
a role in the many cases of spontaneous regression that have been
reported (Everson & Cole, 1966), and also in the remissions
occurring in Burkitt's lymphoma patients on minimal chemotherapy
(Burkitt, 1967). It may be implicated in the regression of
metastases, following the removal of the primary tumour, and in the
waxing and waning of tumour deposits (Currie, 1974). Although there
is no conclusive proof that there is a tumour-directed immune response
in the cancer patient, the body of evidence is now so large that it
cannot be ignored.
How Tumours Evade the Immune Response
There are numerous theories as to how a tumour evades the
destructive mechanisms of the immune system:-
i) 'Sneaking through'. Very small numbers of tumour cell
may not activate an immune response, and can therefore
become established (Bonmassar et al, 1974).
ii) Immunodepression prior to tumour development. There is
very little evidence to confirm, or reject, this theory.
Recent investigations tend to disprove the concept of
immune surveillance against tumours (Moller, 1976) and
this would argue against any immunodepression theory.
iii) Shedding of Tumour Antigen. Some tumours have been
found to shed their TAAs under certain conditions
(Currie and Alexander, 1974).
iv) Antigenic Modulation. Antigens which are subjected
to a continuous immune response may disappear by a
process that is known as modulation (Boyse and Old,
1969).
v) Inhibition and Blocking. Virtually all tests in vitro
for cell-mediated immunity can be inhibited by the
addition of serum from a tumour-bearing animal. It is
believed that two mechanisms may be involved (Baldwin
and Pri ce, 1976)
Blocking occurs at the level of the tumour cell and involves
masking of tumour antigen, probably by antibodies, in the
early stages of tumour growth, and later, by immune
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complexes.
Inhibition irvolves the receptors of the sensitised
lymphocytes being blocked by immune complexes from the
tumour cell surface, and by free tumour antigen, which
may be shed late in tumour development,
v) Stimulation of the Tumour by the Immune System. (Prehn,
1976)
At present, although it is generally accepted that there is an immune
response to cancer, there is no convincing explanation of how tumours
become established in the face of this response.
The Relationship between Tumour-Specific and Non-Specific Immunity
In many cases it is not possible to measure tumour directed
responses, due to lack of either biopsy material, or suitable cell
lines, or both. In this situation, tests of general immunocompetence
are substituted, since there is evidence that these bear some
relevance to tumour directed responses. This evidence stems from
two main sources
i) Therapies which stimulate general immunocompetence have
been shown to have an anti-tumour effect e.g. Bacillus
Calmette Guerin (BCG), Corynebacteriurn parvum and
Levamisole (Morales & Eidinger, 1976a; Lieberman, Epstein
& Fudenberg, 1974 ; Mathe et al, 1973 ; Israel, 1973).
Israel and Edelstein (1975) have used C. parvum to treat
more than 400 patients with advanced cancer. They found
that it produced a significant increase in survival in cases
of bronchogenic carcinoma and advanced breast cancer.
Although C. parvum is known to be a potent immunological
stimulant, resembling BCG (Stiffel et al, 1970), its use
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in cancer immunotherapy depends upon both inhibitory and
stimulatory responses. Carter (1976) has indicated that
most immunopotentiating agents are more effective when they
come into direct contact with the tumour, suggesting thai
their mode of action is complex and multifactorial.
Nevertheless their use is based upon the stimulation of
general, and thereby, tumour-directed, immunity,
ii) A correlation has been shown between the course of
malignant disease and various assays of general immuno¬
competence in vivo (Eilber & Morton, 1970) and in vitro
(Silverman et al, 1976). The nature of these tests, and
their value as monitors of tumour-directed immunity, and
clinical prognosis, are discussed in greater detail
later. The assays cannot discriminate between cause
and effect when used to monitor the response to therapy
e.g. does an increase in immunocompetence during treatment
reflect direct potentiation of tumour-directed responses,
by the therapy, or is it a result of changes in the
tumour itself, which secondarily stimulate the immune
response?
However, the fact that the results from these tests can be related
to the course of malignant disease, validates their use in charting
the effects of therapy on both general, and possibly, tumour-
directed immune responses.
Principle behind Tests of General Immunocompetence
Tests of general immunocompetence are based on three procedures:
i) Determining the concentration of immunologically-competent
cells in the peripheral blood.
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ii) Determining the ease of in vivo sensitisation to, and
subsequent rechallenge with, a previously unencountered
antigen.
iii) Monitoring changes in pre-existing sensitivity to commonly
occurring antigens (including histocompatibility antigens)
in vivo and in vitro.
The methodology of, and results from, the various individual
tests are reviewed in later sections.
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Hyperthermia and Immunity
All forms of cancer therapy exploit a sensitivity which is
peculiar to the tumour cell. Whole-body hyperthermia treatment
depends mainly upon selective heat sensitivity. However, this
sensitivity is relative, and other organs and systems in the body,
including the immune system, will be affected by generalised heating.
If one accepts that the immune system has a role in cancer
control, it is of primary importance to determine the effects of
hyperthermia therapy on the lymphoreticular system. In the absence
of empirical evidence, it has been suggested that hyperthermia may
either stimulate, or depress, tumour-directed immunity. Much of
this speculation is based upon the disappearance of metastases,
or immunity to tumour rechallenge, in animals whose primary tumour
has been destroyed by localised heating, or electro-coagulation
(for reviews of early literature see:- Nauts, 1970 & 1976 ; Dickson,
1976 ; Dietzel, 1976).
Dickson and Muckle (1972) have proposed a role for the immune
response in the destruction of metastases, observed following local
hyperthermia treatment of the VX-2 carcinoma in the rabbit. Similar
animals, treated by local radio-frequency heating, showed increased
delayed hypersensitivity skin responses to Bovine Serum Albumin (BSA),
Dinitrochlorobenzene (DNCB) and tumour extracts; and lymphocytes
from these rabbits caused greater inhibition of tumour cells, than
those from untreated animals. Local heating of normal rabbits had no
effect on the response to DNCB, but reduced the anamnestic response
to BSA (Dickson & Shah, 1977).
Immunopotentiation by local heating has also been reported by
Szmigielski et al (1977a). They subjected rats bearing Guerin
epitheliomas in the logarithmic phase of growth, to local microwave
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heating (intra-tumour temperature - 43°C ; maximum body temperature -
38°C), in three 45 minute fractions, during the third and/or fifth
week after tumour implantation. In some cases, heating was
supplemented by the administration of immunopotentiators - intra¬
peritoneal Streptolysin-S, or intra-tumoral C. parvum, during the
period of treatment. Heat alone, whilst producing no cures, caused
inhibition of tumour growth; however, combination with potentiators
resulted in the disappearance of 75% of the tumours, and the
regression of the remainder. Following hyperthermia alone, there
was a significant increase in non-specific immunocompetence, as
measured by:-
i) Serum titre of BSA antibodies (BSA antibody synthesis
is T cell dependent).
ii) Incorporation of radio-labelleu uridine or leucine by
non-adherent spleen cells, in short-term culture with
phytohaemagglutinin (PHA) (Response to PHA is a T cell
phenomenon).
iii) Serum lysozyme. activity.
Tumour-directed immunity, as assessed by:-
i) Blastogenic response of non-adherent spleen cells to
Mitomycin-C treated Guerin cells.
ii) Microcytotoxicity tests, using non-adherent spleen cells,
51
or peritoneal macrophages, against Cr-labelled Guerin
cells.
was also elevated. The largest increases were evident after two,
three-fraction treatments, which was the regime that produced the
best anti-tumour response. Combination with immunopotentiators
produced increases in all of the immunological parameters, but only
the addition of Streptolysin-S resulted in any significant
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improvement over hyperthermia alone. Szmigielski has suggested that
the increases in both general, and ti.nour-directed, responses,
following local hyperthermia, may be due to activation of the immune
system, either by necrotic tumour, or, by a change in the antigenicity
of heat-suppressed, but still-viable, cancer cells.
There is some experimental evidence to support the hypothesis
that heat may alter the antigenicity of cells. Mondovi et al (1972)
found that immunisation of mice with Ehrlich ascites cells that
had been heated in vitro for 3 hours at 42.5°C, conferred greater
resistance to challenge, than injection with radiation-inactivated
cells. They concluded that heating resulted in increased immuno-
genicity of the tumour, possibly by unmasking, or modification, of
antigens on the cell surface. Similar results have been reported
by Bourdon and Halpern (1976), who found that immunisation with
tumour cells heated at temperatures ranging from 46-52°C, resulted
in subsequent resistance to tumour challenge, and that this resistance
could be adoptively transferred by the injection of immune peritoneal
or spleen cells, into syngeneic hosts.
As an explanation for these phenomena, Rosen (1976) has proposed
that hyperthermia reverses the binding of a repressor molecule to
the cancer cell genome. This results in the cell losing the ability
to produce antigens randomly, and thereby escape elimination by the
immune system. However, the alteration in immunogenicity, following
heating, is not restricted to intact cells. Bhatti, Ablin and Guinan,
(1976) found that leucocytes from patients with genito-urinary tumours
were more reactive to heated (40°C for 1 hour), rather than unheated,
allogeneic, specific and non-specific tumour antigen extracts, in a
leucocyte adherence inhibition assay.
In the only study on tumour directed immunity in vitro, in humans
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being treated by local hyperthermia, Stehlin et al (1975) found that
the cytotoxicity of melanoma patients' serum and lymphocytes, towards
autochthonous, cultured, tumour cells, increased following heated
perfusions of their cancer. This increase was seen after each
treatment, and seemed to correlate with the amount of tumour destroyed.
Modification of tumour immunogenicity by local heating, and
stimulation of the immune system by tumour debris, may explain some
of the responses to hyperthermia that have been reported in vivo,
when the heat is restricted to the region of the tumour. If whole-
body hyperthermia is used the differential effect is lost, in that
cells of the immune system are also subjected to increased temperatures.
Preliminary results indicate that this complicates the situation.
Dickson and Muckle (1972) have reported an increased incidence
of metastases in rabbits with VX-2 tumours treated by whole-body
heating. They attribute this to a combination of immune depression
and more favourable metabolic conditions for the seeding of viable
tumour cells. Advancement of the appearance of metastases, in mice
bearing the Lewis lung carcinoma, following generalised hyperthermia,
has also been described by Yerushalmi (1976), who cites immune
depression as one of the possible causes.
Recent work by Dickson and Shah (1977) supports this idea. They
have shown that VX-2-bearing rabbits treated by local radio-
frequency heating, followed 8 days later by total-body hyperthermia,
displayed poorer responses to BSA, DNCB, and tumour-extract skin
testing, and a lower cure rate, than animals treated by local heating
alone. A combination of local heating and simultaneous, unintentional
systemic heating (to approximately 40°C), in rats with Yoshida
sarcomas implanted in the leg, resulted in enhanced tumour
dissemination, if the tumour had passed a critical size (Dickson &
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Ellis, 1974). Dickson believes that this indicated that the immune
system was still functional at 40°C, but may not be able to cope
once the tumour burden has reached a certain level, and become
'activated' by inadequate heating (Dickson, 1976).
In contrast, Luczak et al (1977) and Szmigielski et al (1977b)
have found that general microwave hyperthermia of mice, following
infection by Herpes or Vaccinia virus, inhibits the establishment
of the virus, and can prevent it completely in 80% of the cases of
Herpes virus infections. This may indicate direct stimulation of
the immune system, however, heat administered before virus infection,
was ineffective, suggesting that hyperthermia may be affecting the
multiplication, or immunogenicity, of the virus particles. Work
on tissue culture cells favours the former explanation.
Whole-body heating, in the absence of introduced antigen, in
the form of tumour cells or viruses, has been reported to decrease
the delayed hypersensitivity skin response to BSA, but not to
DNCB (Dickson and Shah, 1977). Degenerative changes in the lymphoid
tissue have been described, following whole-body heating of normal
rats to 41°C (Williams & Gait, 1977), and are associated with a
depression of general immunocompetenee (Gait & Williams, 1976).
The results of heating animals in vivo correlate with several
observations in vitro. Harris (1976) has found that mouse splenic T
cells, heated for 45min at 43°C, virtually lost their capacity to
lyse allogeneic mastocytoma cells, although still 70% viable by dye
exclusion. Mendes, Saraiva and Santos (1975) have reported that
human T lymphocytes no longer rosetted with sheep erythrocytes (an
accepted marker for T cells) after heating in vitro for 1 hour at 45°C.
Little work has been done on the effects of heat in vivo on
human immunocompetence. Temperatures of 38.8°C have recently been
reported to result in increased B cell, decreased T cell, and
unchanged total lymphocyte levels in healthy volunteers (Bork-Wolwer,
Buhring & Krippner, 1977). Only slight changes in these parameters
were observed in healthy adults heated for 1 hour at 40°C, although
a significant increase in the lymphocyte response to PHA was observed
(Fabricius et al, 1977).
While studies on normal subjects are of fundamental importance
to our understanding of the mode of action of hyperthermia therapy,
they cannot be applied directly to the clinical situation. Patients
undergoing heat therapy are likely to have impaired immunocompetence
due to their advanced disease, in addition, they will be subjected
to higher temperatures for longer times, and will receive varioas
medications during their treatment. These procedures are all likely
to affect the immune system, but , at present, they are inherent in
nearly all forms of whole-body hyperthermia therapy, and must be
considered as an integral part of the treatment.
There is only one study of the immunocompetence of whole-body
hyperthermia patients, and this mentions several of these factors.
DeHoratius et al (1977) have monitored various indices of
general immunocompetence in patients with disseminated malignancy,
treated by whole-body heating to 42°C for 2 hours. Results from three
patients have been reported, two of whom received concomitant
chemotherapy.
They found an increase in leucocyte count, 15 hours after
treatment, but no significant changes in the percentage, or total
lymphocyte count. There was no significant change in the percentage
or total number of T or B cells, although rapid-rosetting T cells
rose significantly in numbers after treatment. Lymphocyte response
to mitogens (PHA, Concanavalin A and Pokeweed Mitogen) showed no
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general trends, although there were changes in individual patients.
Antibodv-dependent cellular cytotoxicity, mediated by lymphocytes
against ^hicken erythrocytes, was unaffected by hyperthermia, whereas
polymorph-mediated cytotoxicity was depressed in all three patients.
There was a marked fall in the concentration of complement, as C'3,
after the first treatment, and C'4, C3PA and CH50 components were
also depleted. Levels of IgG, IgA and IgM were not persistantly
affected by treatment.
They believe that whole-body heating may have a beneficial
effect upon the immune balance between the patient and his tumour,
however the study is only preliminary, and they emphasise the need
for more work on this aspect of hyperthermia tretment.
The aim of this research was to try to determine whether the whole-
body hyperthermia treatment, used by Petti grew to treat cases of
advanced malignant disease, produced any changes in the general
immunocompetence of the patients; and, if so, whether these changes
could be related to the clinical response to therapy.
PREFACE TO THE PAPERS ON IMMUNOCOMPETENCE
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Preface to the Papers on Immunocompetence
Introduction
The studies on the immunocopetence of hyperthermia patients,
and the parallel experimental work on the effects of heat in vitro,
are presented in separate papers, each of which describes a particular
assay. The factors governing both the choice of these assays, and
the selection of hyperthermia patients, are detailed in this preface.
Selection of Patients for Immunocompetence Studies
Every patient given whole-body hyperthermia treatment during
the period of this research project, was considered for inclusion
in the immunocompetence studies. Patients were excluded from the
study if:-
g
i) they were grossly leucopenic (fewer than 2x10 leucocytes
per ml peripheral blood) or anaemic.
ii) they were difficult to bleed.
iii) they proved to be very immunosuppressed.
A record was kept of all previous forms of therapy, together
with procedures likely to have a marked effect on the patient's
immune status.
Selection of Normal Control Subjects
Normal control subjects were obtained from healthy volunteers
amongst hospital staff, and donors at two sessions organised by the
South East Regional Blood Transfusion Service. All were informed
of the nature of the experiments for which their blood was required.
None was taking medications, or was Australia Antigen positive.
All the samples were taken by a physician, or qualified haematology
technician, using venepuncture of the median cubital vein.
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Non-Hyperthermia Patients
A few blood samples were taken from hospital patients with non-
malignant conditions. These were obtained with the permission of
the patient, and the consultant in charge of the case.
Immunity Studies
Since the patients treated by hyperthermia were suffering from
a variety of tumours (See Table 2 ), it was not feasible to study
their tumour-directed immunity, as this would have entailed, either
establishing a large number of human tumour cell lines (a notoriously
difficult procedure), or extracting a range of soluble tumour antigens.
Although the latter was technically possible, it had to be ruled out,
since the majority of tumours were not biopsied during treatment,
and consequently, any changes in their antigenicity could not have
been followed. As a result, a range of tests was used to monitor
the effects of hyperthermia therapy on the patients' general
immunocompetence.
Selection of Assays for Monitoring General Immunocompetence
The tests which were selected had to fulfil several criteria:-
i) As well as indicating general immune status, they should,
where possible, reflect tumour-directed immunity.
ii) They should involve the minimum of discomfort to the
patient.
iii) Micro-modifications of the tests should be available, to
avoid the repeated withdrawal of large volumes of blood.












A.S. d» 77 CARCINOMA OF
THE STOMACH
1 NR
H. A. $ 54 HYPERNEPHROMA >/ N/ 3 ?
P.N. <J» 49 PILONIDAL SINUS NON-TUMOUR PATIENT 3 ?
M.D. $ 36 HYPERNEPHROMA V B.C.G. 4 ?




D.G. <f 63 FIBROSARCOMA IN
LUMBAR SPINE AREA
s/ 3 R




M.M. £ 56 CARCINOMA OF
THE COLON
s/ 2 ?
M.P. d* 60 HYPERNEPHROMA 2 ?
T.M. 66 CARCINOMA OF
THE BRONCHUS
5 ?
J.C. <f 64 ADENOCARCINOMA
OF THE PROSTATE
sj 2 ?
L.T. $ 73 PSEUDOMYXOMA 2 ?









R.M. cf 65 CARCINOMA OF
THE STOMACH >/
2 NR
W.M. d* 39 LEIOMYOSARCOMA
OF SMALL BOWEL v/ s/
1 NR
A.B. o» 51 ADENOCARCINOMA
OF THE RECTUM sj
1 ?
E.C. $ 51 LEIOMYOSARCOMA s/ s/ 2 R
TABLE 2
CLINICAL DETAILS OF HYPERTHERMIA PATIENTS STUDIED BY IMMUNOCOMPETENCE TESTING
R = Responsive NR = Non responsive ? = Unclassified
v) The test should not take longer than 4|h to set up.
Hyperthermia treatments rarely last longer than 5h, and
therefore a time limit has to be imposed or. the
establishment of any test, since it is noc feasible to
deal with pre-, end- and in-treatment blood samples
simultaneously.
A number of assays were examined to determine their suitability
(Table 3 ). On the basis of this assessment it was decided to use
the following tests:-
i) Peripheral blood leucocyte and lymphocyte concentration.
ii) Peripheral blood T and B lymphocyte concentration.
iii) Blastogenic response of lymphocytes to Phytohaemagglutinin.
iv) Antibody-dependent cellular cytotoxicity testing.
v) Serum immunoglobulin and complement concentrations.
as these satisfied virtually all of the criteria. A more detailed
analysis of the value of each of the selected tests is given in the
introductory section to the paper on its use.
The remaining tests were rejected on the following, more
detailed grounds:-
DNCB Sensitisation and Skin Testing This test involves topically
sensitising the patient in vivo to a measured dose of a hapten -
2,4-dinitrochlorobenzene (DNCB). After 14 days, during which
delayed hypersensitivity will have been developed, the subject is
challenged with much smaller doses, and the ability to respond to
these challenges is graded to give an overall hypersensitivity rating
(Lee et al, 1975). This test has many advantages:-
i) Circulating antibodies do not develop with contact






















1. LEUCOCYTE / LYMPHOCYTE
COUNTS
sj V N/ v/ v/
2. T AND B LYMPHOCYTE
COUNTS
v/ y/ s/ V >/
3. BLASTOGENIC RESPONSE
TO PHYTOHAEMAGGLUTININ
V y/ V V V
4. K CELL ACTIVITY ? N/ V V N/
5. SERUM IMMUNOGLOBULIN &
COMPLEMENT CONCENTRATIONS
X ? V V yf V
6. DNCB SENSITISATION &
SKIN-TESTING y/ X v/ >/ >/
7. RECALL ANTIGEN SKIN-TESTING V ? y/ X v/
8. LYMPHOCYTE TRANSFER TEST ? y/ X v/ X
9. LEUCOCYTE MIGRATION /
ADHERENCE INHIBITION TEST
? V >/ X v/
10. MIXED LYMPHOCYTE
CULTURES
? N/ >/ V X?
TABLE 3
ASSESSMENT OF THE SUITABILITY OF TESTS OF GENERAL IMMUNOCOMPETENCE FOR USE ON HYPERTHERMIA PATIENTS
See text for details
immunity (Waksman, 1960).
ii) Both the sensitising and challenging procedures are
controlled by the investigator.
iii) 95% of normal subjects can be sensitised, thereby reducing
the number of false negatives (Kligmar, & Epstein, 1959).
iv) It detects defects in both the afferent and efferent limbs
of the immune system.
v) Changes in immunocompetence, detected by this test, have
been shown to correlate with the patient's clinical course
(Eilber, Nizze & Morton, 1975 ; Pinsky et al, 1974) and
in certain tumours, with the stage of the disease (Huus
et al , 1975 ; Eilber & Morton, 1970 ; Schellhammer et al
1976).
Although permission for its use was obtained from the Hospital Ethical
Committee, this test was not used because
i) Patients were not always available to allow pre-treatment
sensitization and challenge.
ii) In a trial run, it produced a painful, irritant, reaction,
soon after the application of the sensitising dose
(Hartman, Hoedemaeker & Nater, 1976).
iii) It has been found not to correlate with prognosis, or
response to therapy, in some cases (Mandel, 1976).
iv) It was not possible to obtain sufficient age-matched
controls.
Skin Testing with Recall Antigens This technique tests the functional
integrity of the efferent branch of the immune system, by exposing
the patient to a battery of antigens (by intradermal injection) with
which he should have had previous contact e.g. Candida, Tuberculin
-49-
P.P.D., Mumps etc.. Assumed prior scnsitisation allows the test
to be performed at short notice, however this assumption also leads
to a number of false negative responses. Results tend to be very
variable,for example, Eilber and Morton (1970) found that 45% of
patients found to be free of cancer we.^e still negative to all of
the seven antigens which they tested. Although the assays have been
found to correlate with some measures of eel 1-mediated immunity
in vitro (Brugarolas et al, 1973), their use was ruled out because
of the lack of control over the sensitisation procedure.
The Human-to-Mouse Lymphocyte Transfer Test This test, originally
developed by Rees and Symes (1973), involves measuring the induration
produced by the graft-versus-host reaction resulting from the
injection of human lymphocytes into a mouse. Lymphocytes from
patients with a variety of tumours have been found to produce a
diminished reaction. The test was rejected because it requires
large numbers of lymphocytes (up to IxlO7) from both controls and
patients. Furthermore, the relationship between the induration
produced, and indices of tumour-directed immunity, remains to be
established.
Leucocyte Adherence/Migration Inhibition Both of these assays have
produced interesting results when used with antigen extracted from
autochthonous or allogeneic tumours (See p. 32 ). Much less
information is available on their use in conjunction with other types
of antigen. Migration inhibition by P.P.D. has been studied in
patients with trophoblastic tumours (Walden et al, 1976), but with
disappointing results. Again, lack of control over prior sensitisation
to the antigen, makes these tests unsuitable for routine use.
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Mixed Lymphocyte Cultures Mixed lymphocyte cultures are widely
used in work on tissue typing for transplantation surgery. Test
lymphocyi.es undergo blastogenesis in response to histocompatibility
antigens on the surface of stimulator lymphocytes (pre-treated with
irradiation or Mitomycin-C, to prevent blast transformation). This
test represents a graft-versus-host reaction in vitro, and as such,
is a more 'natural' assay of lymphocyte activity, than response to
a powerful mitogen. In addition, lymphocytes from patients with
advanced cancer have been reported to show depressed responding and
stimulating capacity in an MLC assay, in comparison to cells from
a healthy control and disease-free patients (Blomgren et al, 1977).
Similarly, an increased incidence of negative responses, by patients
with untreated Hodgkin's disease, has been described, but the results
did not correlate with the patients' clinical stage or symptoms
(Lang et. al, 1974). It was proposed to include this test, using
a lymphoblastoid cell line (ODY-1, kindly supplied by Dr. C.M. Steel,
M.R.C. Clinical and Population Cytogenetics Unit, Edinburgh) as a
source of stimulator lymphocytes; however, the relevance of the
results to tumour-directed immunity, and the time factor involved
in setting up the test, made it unsuitable for inclusion.
Experimental Design
Since patients were not accepted for hyperthermia treatment on
a regular basis, it was important to obtain the maximum amount of
information from each patient. This meant that the assays had to
be used on material from patients, before their worth could be fully
evaluated. As a result, the normal evaluation experiments were
carried out during the periods when no patients were being treated.
Although this situation is not ideal, it was adaptable to a clinically-
oriented research project, the activity of which was dependent on
the availability of th"? clinical material.
The selected assay" were developed on an initial group of
eight patients, the results from these tests were then analysed.
The tests were subsequently extended, modified, or discarded, on the
basis of this analysis, taken together with the results from normal
individuals, and experiments in vitro.
-52-
GENERAL MATERIALS AND METHODS
-53-
Index of Materials
This index applies only to materials used in immunocompetence
assays, and not to those used in tests performed by hospital service
departments.
Reagents and Glass/Piasticware
Agglutination Tubes, Dreyer, Neutral Glass, Townson & Mercer Ltd.,
Edinburgh.
Air/CO^ Mixture, 95%/5%, British Oxygen Co. Ltd., Edinburgh.
Araldite 'Rapid', CIBA/GEIGY (UK) Ltd., Duxford.
B^lood Agar Base Number 2, Oxoid Ltd., London.
Blood Smearing Slides, Asschem, Falkirk.
Buffer Powder, for staining procedures, pH 6.8, Difco Labs.,
West Molesey.
Crystal Violet, BDH Chemicals Ltd., Poole.
Crystamycin, Glaxo Labs., Greenford.
Decon 75 Concentrate, Decon Labs. Ltd., Brighton.
Dextran T.500, Pharmacia (Great Britain) Ltd., London.
Di ami noethanetetra-aceti c acid, di-sodium salt, EDTA, BDH Chemicals
Ltd., Poole.
Dimethyl Sulphoxide, DMSO, Grade 1, Sigma London Chemical Co. Ltd.,
Kingston-upon-Thames.
Eagles Basal Medium, Powdered, Wellcome Reagents Ltd., Beckenham.
EDTA Blood Collection Tubes, 1ml, Pediatric, Teklab Medical Labs.,
Durham.
Eosin, Water soluble, Yellow Shade, BDH Chemicals Ltd., Poole.
Euparal Essence, GBI Labs. Ltd., Manchester.
Euparal 'Vert' Mountant, GBI Labs. Ltd., Manchester.
Ficol 1 400, Pharmacia (Great Britain) Ltd., London.
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Ficol 1-Paque, Pharmacia (Great Britain) Ltd., London.
Foetal Calf Serum, Heat Inactivated, Gibco Bio-Cult Ltd., Glasgow.
Freund's Adjuvant, Complete, Difco Labs., West Molesey.
Fungizone, (Amphotericin B), 250pg/ml, Gibco Bio-Cult Ltd.,
Glasgow.
Giemsa Stain, Exogen Modified, Exogen Ltd., Glasgow.
Glutaraldehyde EM, 25% Aqueous solution, Taab Labs., Reading.
Glutamine, L-Glutamine powder, Flow Labs. Ltd., Irvine.
Haemacytometer, Improved-Neubauer, Cristalite, Gelman Hawksley Ltd.,
Lancing.
Ham's F10 Medium, Powdered, with L-Glutamine, without Sodium
Bicarbonate, Flow Labs. Ltd., Irvine.
HEPES (N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid),
Buffer powder, Flow Labs. Ltd., Irvine.
Human Serum, Pooled, Normal, Heat Inactivated, South East Regional
Blood Transfusion Service, Edinburgh.
Hydrometer, Range 40.0 to Proof, Peter Stevenson Ltd., Edinburgh.
Hypaque, Sodium Powder, (Sodium Diatrizoate), Winthrop Labs.,
Surbiton-upon-Thames.
Lasso Adhesive Tape, T.J. Smith & Nephew Ltd., Welwyn Garden City.
Latex, Bacto, 0.81, Difco Labs., West Molesey.
Lunch Boxes, Plastic, A. & J. Beveridge Ltd., Edinburgh.
May-Grunwald Stain, (Gurr), Searle Diagnostic, High Wycombe.
Membrane Filters, 0.22pm pore size, Mi 1 lipore (UK) Ltd., London.
Microtest Plates, Tissue Culture Grade, Sterile,
Flat Bottom, Sterilin Ltd., Teddington.
V-Bottom, Sterilin Ltd., Teddington.
U-Bottom, (Linbro), Flow Labs. Ltd., Irvine.
Nitrogen Bank Ampoules, Polypropylene, Sterile, Nunc UK Ltd.,Stafford.
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Nitrogen Bank Ampoule Canes, Jencons Scientific Ltd., Heme!
Hempstead.
Phenol Red, BDH Chemicals Ltd., Poole.
Phosphate Buffered Saline Tablets, Dulbecco 'A', Oxoid Ltd., London.
Phytohaemugglutinin, Reagent Grade, Wellcome Reagents Ltd.,
Beckenham.
POPOP, (Phenyl-oxazolyl-phenyl-oxazolyl-phenyl), Sigma London
Chemical Co. Ltd., Kingston-upon-Thames.
PPO, (2,5-Diphenyloxazole), Koch-Light Labs.Ltd., Colnbrook.
Pyroneg, Diversey Ltd., Barnet
Rabbit Anti-Sheep Red Cell Serum, Wellcome Reagents Ltd., Beckenham.
Roux-Pattern Tissue Culture Flasks, Pyrex, Central Neck, Townson &
Mercer Ltd., Edinburgh.
Saponin, White, Suitable for Haemolysis, BDH Chemicals Ltd., Poole.
Scintillation Vials, Low-Potassium Glass, Pathlab Supplies Ltd.,
Gillingham.
Serum Storage Tubes, 5ml Crystal Polystyrene + Screw Cap, Label-
Printed, Sterile, Raven Scientific Ltd., Haverhill.
Silicon Rubber Bungs:-
For Roux Flasks - Size E23,
For Dreyer Agglutination Tubes - Size E5,
Esco (Rubber) Ltd., London.
Sodium Bicarbonate, 4.4% Sterile Aqueous Solution, with Phenol Red,
Wellcome Reagents Ltd., Beckenham.
Sodium Cacodylate EM, Taab Labs., Reading.
51
Sodium Chromate Cr, solution, B.P., ImCi/ml, Radiochemical Centre,
Amersham.
Specimen Stubs, Aluminium, Agar Aids, Bishop's Stortford.
14
Thymidine (2- C), 50mCi/mmol, Radiochemical Centre, Amersham.
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Toluene, Scintillation Grade, BDH Chemicals Ltd., Poole.
Tris, Tris(Hydroxymethy 1)-Aminomethanp, Hopkin & Williams Ltd.,
Romford.
Tubes, Flat-Bottom + Lid, 2ml, Product Number: NA2, Sterile,
Sterilin Ltd., Teddington.
Trypsin Solution, (xlO), 2.5%, Gibco Bio-Cult Ltd., Glasgow.
Tylocine, 5,000pig/ml, Gibco Bio-Cult Ltd., Glasgow.
Universal Containers, Plastic, Sterile, Sterilin Ltd., Teddington.
14
Uridine, (2- C), 50mCi/mmol, Radiochemical Centre, Amersham.
Visking Dialysis Tubing, Size 1, (8/32"), Medicell International
Ltd., London.
All other reagents were 'Analar' grade, and were obtained from
BDH Chemicals Ltd., Poole.
Cells and Continuous Cell Lines
H.Ep.2 Human epidermoid carcinoma of the larynx was supplied as a
monolayer culture by the Department of Bacteriology, University
of Edinburgh.
KB Human epidermoid carcinoma of the mouth was purchased, as a
monolayer culture, from Gibco Bio-Cult Ltd., Glasgow.
Sheep Erythrocytes were supplied by courtesy of Dr. C.M. Steel,
M.R.C. Clinical & Population Cytogenetics Unit, Edinburgh.
Rhesus Monkey Erythrocytes were supplied by courtesy of Inveresk
Research International, Musselburgh.
Apparatus and Equipment
Automatic Cell Harvesters (with accessories):-
Titertek Multiple Cell Culture Harvester*, Flow Labs. Ltd., Irvine.
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Mash II Multiple Automatic Sample Harvester, Dynatech Labs.
Ltd., Billingshurst.
AutoMash Multiple Automatic Sample Harvester, Dyratech Labs.
Ltd., Bi11ingshurst.
Titertek Supernatant Harvester, Flow Labs. Ltd., Irvine.
Automatic Pipettes:-
Fixed Volume - Eppendorf, V.A. Howe & Co. Ltd., London.
Variable Volume - Pipetman, Anachem Ltd., Hale.
Finnpipette, Buckley Membranes Ltd.,
Great Missenden.
Centrifuges:-
Refrigerated - MSE 'Mistral' 4L, MSE Scientific Instruments,
Crawley.
Bench - MSE 'Minor', MSE Scientific Instruments, Crawley'.
Cytocentrifuge** - Shandon Elliot Cytospin, Shandon Southern
Instruments Ltd., Camberley.
Critical Point Drier, Model: E3000, Polaron Equipment Ltd., Watford.
Differential Cell Counter, Manual, Clay-Adams Inc., U.S.A.
Dispensor, for Scintillator, Model: Oxford Pipetter, Boehringer
Corp. (London) Ltd., Lewes.
Electric Digital Thermometers, Model: Ivac 841, Loxley Medical
Supplies Ltd., London.
Gamma Sample Counter***, Model: 80000, LKB Wallac, U.S.A.
Photomicroscopy:-
Microscope - Orthoplan Wide Field, Leitz Wetzlar, F.R.G.
Camera - Orthomat-W Automatic Microscope Camera, Leitz Wetzlar,
F.R.G.
Films - Black and White - Panatomic X, Eastman Kodak Ltd., London.
Colour - Photomicrography Film 2483, Eastman Kodak Ltd.
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Scanning Electron Microscope*, Model: Stereoscan 180, Cambridge
Instrument Co. Ltd., Cambridge.
Scintillation Spectrometer***, Model: TriCarb 2425, Packard, U.S.A.
Sterile Cabinet, Model: Laminar Flow Work Station, Microflow Ltd.,
A1dershot.
Water Baths:-
37 C Unstirred, Thermostatic Bath, Model: JB3, Grant Instruments
(Cambridge) Ltd., Cambridge.
Variable:-
Static Bath, Model: 020, Griffin & George Ltd., Glasgow.
Tempunit Constant Temperature Bath Controller, Model: TU-8
Techne (Cambridge) Ltd., Duxford.
Constant Level Device, Techne (Cambridge) Ltd., Duxford.
Key
* Facilities provided by courtesy of the M.R.C. Clinical and
Population Cytogenetics Unit, Edinburgh.
** Facilities provided by courtesy of Dr. Anne Ferguson, Gastro¬
intestinal Unit, Department of Medicine, Western General Hospital,
University of Edinburgh. '
*** Facilities provided by courtesy of the Department of Medical
Physics, Western General Hospital, University of Edinburgh.
Animals
Mature New Zealand White Rabbits (Age 8-10 months) were used for the
production of antisera (See p.174 ). These animals were fed (SGI





This section describes procedures which are common to more than
one of the assays. Methods peculiar to any particular test are
described in the section relating to chat test.
Washing Procedure
Unless stated otherwise, plasticware was of tissue culture grade
and was discarded after use.
All glassware was discarded into a 10% v/v dilution of Chloros
in tap water, and then tissue culture washed, according to the
following procedure:-
i) Rinse thoroughly in running tap water.
ii) Soak overnight in a solution of Pyroneg (2.4g/l) in tap
water.
iii) Rinse thoroughly in running tap water.
iv) Soak overnight in tap water.
v) Rinse in deionised water.
vi) Soak overnight in glass distilled water.
vii) Dry in hot air oven.
Pipette-Tip Washing Procedure
New disposable pipette tips were soaked overnight in distilled
water, and hot air dried. They were then packed into glass beakers,
which were sealed with steam-permeable paper, and autoclaved (See
p.61)
Scintillation Vial Washing Procedure
Waste scintillator and glass fibre filter pads were discarded.
The vials were rinsed 6 times in methanol (Reagent grade) and left
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to soak overnight in a 20% v/v solution of Decon Concentrate in
distilled water. After rinsing in tap water the vials were washed
in accordance with the schedule given on p. 60.
Steri lisation
Glassware and apparatus was either heat sterilised, at a
temperature of 160°C for 2h, or autoclaved, at a pressure of
2
151 b/in for 15min. Solutions were autoclaved or membrane filtered
through a filter of 0.22pm pore size (Millipore (UK) Ltd.).
Water
All aqueous solutions were prepared in glass-distilled,
deionised water, which had been autoclaved and stored at 4°C
until required.
Storage
Solutions were stored at 4°C for the stated period, unless
indicated otherwise.
Tissue Culture Media
All media contained 0.06mg benzylpenicillin (sodium) and
O.lmg streptomycin sulphate per litre. These antibiotics were
added together, in the form of a solution of Crystamycin.
Bicarbonate-Buffered Ham's F10 Medium - F10B
Ham's F10 Medium, powdered 9.90g
L-Glutamine powder 0.15g
NaHC03 1.20g
Water To 1 1
The pH of the medium was adjusted to 6.90 with 1M Hydrochloric
acid. The solution was membrane filtered and stored for up to
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1 month.
HEPES-Buffered Ham's F10 Medium - F10H




Water To 1 1
The pH of the medium was adjusted to 7.15 with 1M Sodium
Hydroxide. The solution was membrane filtered, and stored for up
to 1 month.
Eagles Basal Medium
Eagles Basal Medium, powdered 9.50g
Fungizone, (250 g/ml) 1ml
Water 950ml
The solution was membrane filtered and stored for up to 1 month.
Growth Medium
Eagles Basal Medium, as above, 150ml
4.4% NaHCO^ solution 8.0ml
Foetal Calf Serum, heat inactivated 17.5ml
This medium was prepared immediately before use.
Sterility
The sterility of tissue culture medium was routinely tested by
plating out samples onto Blood Agar Base 2 plates. These were




Phosphate-Buffered Saline - Dulbecco 'A' - PBS'A' One buffer tabVt
was dissolved in 100ml water and the solution autoclaved, and stored
for up to 3 months.
Tris-Buffered Ammonium Chloride Solution 100ml Tris buffer solution
(24.3g/l) was added to 900ml 0.83% w/v Ammonium Chloride solution.
The pH was adjusted to 7.20 with 1M Hydrochloric acid. The solution




Sodium Citrate (Dihydrate) 8.00g
Citric Acid (Monohydrate) 0.55g
NaCl 4.20g
Water To 1 1
The ingredients were dissolved successively in the water, and the
final solution autoclaved (pH 6.1). The solution was stored until
required.
Density Gradient Solutions for Cell Separations
Solution A
Hypaque sodium 33.9% w/v in water, allowing for
the water content of the powder. Membrane filtered and stored,
in the dark, for up to 6 months.
Solution B
Ficol 1 400 9% w/v in water. Membrane filtered
and stored for up to 6 months.
Before sterilisation, 3.75ml Solution A was mixed with 9ml Solution B
and the specific gravity checked, using a mini-hydrometer. If it
-63-
was between 1.0076 and 1.0078 the solutions were membrane filtered,
and mixed in this proportion immediately before use.
Trypsinisng Solution for Cell Subculture
Trypsin solution, 2.5% w/v 0.4ml
EDTA solution, 2% w/v 0.2ml
Phenol Red solution, 0.1% w/v 0.1ml
PBS1 A' 9.3ml
The mixture was prepared immediately before use.
Reagent Solutions
The following solutions were prepared and stored as indicated:-
Acetic Acid (glacial) 2% v/v in water, tinged with Crystal
Violet. Used non-sterile. Stored at room temperature.
Dextran T500 6% w/v in physiological saline (see below).
Membrane filtered or autoclaved. Stored for up to 3 months.
Eosin 0.1% w/v in physiological saline (see below).
Autoclaved. Stored in the dark, at room temperature, until
required.
EDTA 2% w/v in water. Membrane filtered. Stored until
required.
G1 utamine 3% w/v L-Glutamine in water. Membrane filtered.
Stored at -20°C for up to 3 months.
HEPES 500mM solution in water (119.5g/l). Membrane
filtered. Stored at room temperature until required.
Phenol Red 0.1% w/v in water. Membrane filtered. Stored
until required.
Physiological Saline Single strength (0.9% w/v) and double
strength (1.8% w/v). Autoclaved. Stored at room temperature.
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until required.





The toluene used was scintillation grade. The solution was
left stirring, on a magnetic stirrer, for at least 6 hours
before use. Scintillator was dispensed from an automatic
dispensor. It was reused after being filtered through Whatman's
No.l qualitative paper, and checked for background radioactivity.
Exhausted scintillator was disposed of by the Department of




Blood was obtained by venepuncture of the median cubital vein,
using a siliconised 21 -G needle. In some cases a Butterfly-21
intermittent infusion set (Abbott Laboratories Ltd., Queenborough.)
was used when more than 20ml blood was required.
Separation of Lymphocytes from Peripheral Blood
The method used was that of Boyum (1968) with several
modi fi cations.
The needle was removed from the collecting syringe, and the
blood gently expelled into a sterile plastic universal container,
or glass tube (in the case of volumes greater than 25ml). It was
slowly stirred with sterile wooden orange sticks, until the clot
had formed, and retracted onto the sticks, which were then removed
and discarded. The defibrinated blood was transferred to another
universal container and centrifuged at 1 ,000g for 15min. The serum
was removed to a sterile container (for storage at -25°C), and
replaced by an equal, or greater, volume of F10B. The cell pellet
was gently resuspended by inverting the bottle several times.
4-9ml of the blood mixture was carefully layered onto 7ml Ficoll-
Hypaque, or Pharmacia Ficoll-Paque solution, in a glass universal
container. This was done by letting the blood flow slowly down the
walls of the container and onto the surface of the Ficoll mixture.
The bottle was then centrifuged at 400g, at the blood/Ficoll inter¬
face, for 30min at 18°C.
The supernatant medium and the white lymphocyte band were
removed to a sterile centrifuge tube, using:aPasteur pipette. The
cells were pelleted by centrifugation at 800g for 15min. The pellet
was washed in 10ml F10B and recentrifuged for lOmin.
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Contaminating erythrocytes were removed by incubating the cells
in 1ml Tris-buffered Ammonium Chloride solution, for 5min at 37°C.
9ml F10B was then added to the tube and the cells mixed by gentle
pipetting before centrifugation at 800g for 7min. The cell pellet
was resuspended in 10ml F10B, and recentrifuged for a further 7min.
The cells were finally resuspended in the appropriate medium for
the particular test, and the concentration of viable cells
assessed by Eosin exclusion.
g
This method routinely produced approximately 1x10 viable cells
per ml. of normal blood. Viability was usually in excess of 95%.
The yield of cells from cancer patients' blood was often lower, as
reported by Greaves (1977) for various disease states.
The purity of the cell separation was determined by making
4
cytocentrifuge preparations of 2-7x10 cells in a total volume of
200-400^.1 medium. This suspension was centri fuged onto a very
clean glass slide, at a speed of 1,500 rpm for lOmin. This separation
technique usually produced greater than 95% mononuclear cells,
mainly small lymphocytes (Fig.l), when used on normal blood. The
main contaminants were neutrophils and eosinophils.
Separation of Granulocytes from Peripheral Blood
The method used was that of Boyum (1974).
Granulocytes were isolated from the cell pellet remaining
after the separation of lymphocytes from whole blood. Each cell
pellet was resuspended in 10ml PBS'A' and transferred to a plastic
universal container. The glass bottle was rinsed witha further
5ml PBS'A1, which was added to the cell suspension. The cells were
pelleted by centrifugation at 1 ,000g for 15min, and then
resuspended in F10H supplemented with 10% v/v autochthonous serum,
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FIGURE 1
CYTOCENTRIFUGE PREPARATION OF FICOLL/HYPAQUE-SEPARATED
HUMAN MONONUCLEAR LEUCOCYTES
May-Grunwald/Giemsa stained (Magnification x445)
FIGURE 2
CYTOCENTRIFUGE PREPARATION OF GRANULOCYTES SEPARATED
FROM HUMAN PERIPHERAL BLOOD
May-Grunwald/Giemsa stained (Magnification x445)
and the appropriate volume of 6% w/v Dextran T500 in saline, added,
e.g. for 9ml whole blood, the cell pellet was resusp^nded in 4.5ml
F10H + serum, and 1.35ml 6% Dextran added.
After vortex mixing, the suspension was transferred to a clean
plastic universal container, care being taken to avoid trapping air
bubbles in the mixture. The erythrocytes were then allowed to
sediment for approximately 20min, when the granulocyte-rich
supernatant was transferred to another plastic universal bottle.
The cells were spun down at 800g for 7min, and the contaminating
erythrocytes removed, either by Tris-buffered Ammonium Chloride
treatment (See p. 67 ), or by resuspending the cell pellet in
sterile water for 5sec, and then adding an equal volume of 1.8%
w/v saline. The cells were recentrifuged for 7min, washed once
in 15ml F10H + 10% v/v foetal calf, or autochthonous, serum,
and resuspended in the appropriate medium for the assay.
The concentration was assessed by counting a dilution of the
suspension in 2% acetic acid, this prevented the cells attaching
to the haemacytometer during counting, as this hinders focusing.
Viability of a second dilution, in medium, was determined by eosir.
exclusion.
This technique produced variable results, with regard to
£
yields (up to 4x10 granulocytes/ml whole blood), and purities
(45-99% See Fig. 2), depending on the blood sample. Viability
was routinely in excess of 98%.
Determination of Cell Concentrations and Viability
The concentration and viability of cell suspensions was
determined in a haemacytometer, using the eosin exclusion method
(Schrek, 1936).
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Culture of Continuous Call Lines
H.Ep.2 and KB human tun.our cell lines (fuller details of which are
give on p.174 ) were grown in monolayer culture in Roux flasks.
Both cell lines were cultured in Growth Medium. This was
supplemented, in the case of the KB cell line, by a final 1% v/v
concentration of Minimum Essential Medium Non-Essential Amino Acids.
The media were gas buffered using an humidified 95%/5% Air/CO^
mixture.
Tylocine solution was occasionally added to the medium to a final
concentration of 1% v/v, to combat any suspected mycoplasma infection.
Subculturing and Passaging
Confluent cell monolayers were washed twice in 100ml PBS'A'
and then incubated, at room temperature, with 10ml Trypsin solution
(See p. 64 ), until the cells became detached from the glass.
10ml growth medium was added to each flask to inactivate the trypsin.
The suspension of cells was transferred to a plastic universal
container, and centrifuged at 800g for 5min. The cell pellet
was resuspended in 2m! growth medium and gassed. A viable count
was made of a 1/10 dilution of this suspension, and from this,
0
3x10 cells were seeded into a Roux flask containing 100ml
growth medium. The flask was gassed and incubated at 37°C.
Fully-confluent monolayers could be maintained in a viable
condition, for several days, by replacing the growth medium with
bicarbonate-buffered Basal medium containing a 2% v/v concentration
of serum - Maintenance Medium.
Preparation of Cell for Storage in Liquid Nitrogen
The possible loss of a continuous cell line was prevented by
long-term storage of samples in liquid nitrogen. The cells were
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harvested in the usual way, and adjusted to a concentration of
g
3.4x10 /ml in growth medium. Dimethy1 Sulphoxide was then slowly
added to this suspension, with thorough mixing, to give a final
6
concentration of 10% v/v. 3x10 cells, i.e. 1ml of the cell
suspension, were seeded into Nitrogen bank ampoules, which were
sealed and placed in an expanded-polystyrene rack, wedged in the
neck of a vacuum flask, half-full of liquid nitrogen. The flask
was kept closed for at least 3h, when the vials were rapidly
transferred to the nitrogen bank, for long-term storage.
Recovery of Cells from the Nitrogen Bank
Vials were removed from the bank, and rapidly thawed in water
at 37°C (taking precautions against the possible explosion of the
vial). The contents of the ampoule were transferred to a universal
bottle containing 20ml growth medium, and the cells pelleted by
centrifugation at 800g for 5min. The cell pellet was resuspended
in 10ml growth medium and recentrifuged. The cells were finally
dispersed in 2-5ml medium and transferred to a plastic tissue
culture flask, containing about 50ml growth medium, which was gassed,
sealed, and incubated at 37°C.
Viability of cryopreserved cells was routinely greater than
90%, by eosin exclusion.
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The Petti grew Technique of Whole-Body Hyperthermia Therapy
This safe, controllable, technique has been used by Pettigrew
to treat more than 100 patients in Edinburgh (Pettigrew, 1976),
and is also in use in other centres (Mackenzie et al, 1976 ; Levin,
1977). The method is described in some detail since it was used by
Pettigrew to treat all the patients studied as part of this research.
Selection of Patients All the patients treated by whole-body
hyperthermia had previously received conventional forms of therapy
e.g. surgery, radiotherapy or chemotherapy, with little or no success,
and had reached the terminal stages of their disease. Although these
patients were largely unselected as to tumour type, the majority
had gastro-intestinal malignancies (Table 2).
Every patient gave informed consent to the nature and use of
hyperthermia, and fully understood that the treatment offered no
guarantee of success.
Hyperthermia Treatment The patient, who had been fasted overnight,
was first narcotised (Thiopentone) and curarised (Curare). He was
then intubated with a thermally-insulated endotracheal tube, and
maintained on an oxygen/nitrous oxide mixture. An epidural catheter
was inserted, and the patient transferred to a specially-constructed
bath. A long-line intravenous catheter was inserted into the median
cubital vein, and threaded into the superior vena cava. This was
connected, via a three-way tap, to allow both the intravenous
infusion of pre-warmed (43°C) fluids, and the withdrawal of blood
samples, including those used in the immunity studies.
A naso-gastric tube and urinary catheter were passed, and left




Patient immersed in molten paraffin
wax (50°C) at the start of heating
FIGURE 4
WHOLE-BODY HYPERTHERMIA TREATMENT
Patient at peak temperature (41.8°C)
Molten wax has been removed, leaving
the patient enclosed in a thermally-
insulating carapace of solidifying wax
means of ECG chest electrodes, a thumb pulsometer and a blood-
pressure cuff. The temperature was recorded using 5 thermometers :-
2 rectal, 2 oesophageal (at different levels), and one tympanic
probe; the readout was both graphic and visual. The eyes and all
possible pressure areas were padded, and an intravenous diuretic
(Lasix) given. Ventilation was then maintained via a heat exchanger,
which warmed the inspired gases to about 80°C, and so counteracted
the heat losses via the respiratory surfaces. The plastic bag,
containing the patient, was then heat sealed, and molten paraffin
wax, at 50°C, was pumped into the bath, until the body was almost
completely immersed (Fig. 3). During treatment anaesthesia was
maintained by topping-up the epidural line with Lignocaine
(Xylocaine), and by intravenous Operidine, as required. Further
injections of diuretic were given if the urinary output was low.
The rectal temperature rose at between 3 and 6°C per hour,
depending on body weight, until it reached 41.8°C, when the wax
was siphoned off, leaving the patient in an insulating carapace
of solidifying wax (Fig. 4). The rectal temperature continued to
rise slowly, and at 41.9 - 42°C the bag was opened and the skin
was exposed, to allow cooling by the evaporation of sweat. By
varying the area of exposed skin, and the thickness of the
insulating layer of wax, the temperature could be controlled to -
within 0.1°C of 41.8°C (Fig. 5).
At the end of the hyperthermia period - usually 2-5h - the
patient was removed from the bath, and cooling was rapid (2-3°C/h).
Patients were returned to the recovery room overnight, and were
discharged to the ward, or home, the following day.
Treatments were given in fractions, which were standardised
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FIGURE 5
IN BODY TEMPERATURE AND CARDIOVASCULAR PARAMETERS DURING
WHOLE-BODY HYPERTHERMIA TREATMENT
From: Petti grew (1976)
Degree Minute (C°M). This is defined as the number of Centigrade
degrees by which the rectal temperature exceeds 40°C, multiplied
by the time over 40°C, in minutes. Most patients were treated in
serially-increasing, weekly, fractions, starting at 300C°M
(Ludgate et al, 1976).
Assessment of the Clinical Response to Hyperthermia Therapy
The response to treatment was judged to be favourable if there
was either pain relief, or weight gain, in addition to one of the
foil owing:-
i) Regression of tumour size on measurement.
ii) Radiological evidence of regression.
iii) Pathological evidence of necrosis in serial biopsy sections.
Safety and Complications of the Technique
The safety of this technique for inducing hyperthermia is
demonstrated by the fact that over 300 sessions have produced
remarkably few complications, especially since the introduction of
epidural anaesthesia (Petti grew, 1976). This has reduced the
requirement for intravenous barbiturates and narcotics, and hence
problems of liver detoxication. Approximately one third of the
patients develop circum-oral Herpes simplex, but this only occurs
after the first treatment. Pressure sores can be a problem if
padding is insufficient. Lack of fractionation can result in
consumption coagulopathy of the blood elements (Ludgate et al, 1976),
and this may be a limiting factor in this form of therapy. The
method is labour-intensive, requiring the constant attendance of a
physician and nurse.
In conclusion, this technique still provides the safest, most
controllable method for inducing whole-body hyperthermia.
PAPER A
THE EFFECTS OF WHOLE-BODY HYPERTHERMIA THERAPY ON THE TOTAL AND
DIFFERENTIAL LEUCOCYTE COUNT
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Leucocytes are the carriers of cell-mediated immune mechanisms.
Meyer (1970) has stated that the lymphocyte level is an index of
immune competence. This statement has been borne out by numerous
experimental studies.
Zacharski and Linman (1971), in a survey of 7,850 patients,
found that the most common factor associated with lymphopenia, was
malignancy. Krant et al (1968) also noted a significantly lower
lymphocyte count in the peripheral blood of patients with broncho¬
genic cancer, in comparison with age-matched normal controls.
Lymphocyte concentrations within the normal range, were found
by King et al (1976), in lymphoma patients who had been success¬
fully treated by chemotherapy, or radiotherapy, in spite of the
fact that various other immune functions were impaired. In
contrast, Cochran et. al (1976) could find no significant difference
between the total lymphocyte count, or percentage of lymphocytes,
in the blood of cancer patients and controls. They concluded that
these parameters 'had little or no place' in the purely
immunological assessment of their patients. In the same study,
they found no correlation between the lymphocyte count and the
extent of the disease, whereas Morales and Eidinger (1976) found
significantly lower counts in patients with metastases. They also
noted that the number of lymphocytes declined with advancing
disease. This observation had been made earlier by Krant et al
(1968), who found that a smooth regression curve could be obtained
by plotting the lymphocyte concentration against the time until
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death. However they emphasised that there was nothing to indicate
a causal relationship between the lymphopenia and clinical
deterioration. Nonetheless, their results suggest that the total
lymphocyte count could be used as an indicator of prognosis.
This has been confirmed by various workers. Papatestas and
Kark (1974) showed that patients who had been free of metastases
for 5 years, following mastectomy, had significantly higher
lymphocyte concentrations than those who had subsequently developed
metastases. A larger retrospective study was published in 1976
(Papatestas et al), which consolidated these observations, and
suggested that low lymphocyte counts may be due to the presence
of suppressor substances, possibly produced by the thymus.
Similar relationships between lymphocyte concentrations and
clinical prognosis, have been described for a variety of tumours,
e.g. breast (Fodor, 1976), bladder (Amin & Lich, 1974), colon
(Kim & Papatestas, 1974) and advanced lung cancer (Wanebo et al,
1976). In a survey of nearly 600 patients, with different types
of cancer, Riesco (1970) found a significant, positive, correlation
between cancer curability and the total numbers of peripheral
lymphocytes. This would suggest that the lymphocyte concentration
could be used as an indication of the probable response to therapy,
however, this is rarely the case.
Two of the most common forms of cancer treatment, namely
radiotherapy and chemotherapy, are immunosuppressive, producing
leucopenia and lymphopenia. As such, they can be likened to a
double-edged sword, which attacks the tumour directly, but, by
simultaneously depressing immunocompetence, leaves the patient
vulnerable to both the re-establishment of his tumour, and to
infectious diseases.
Induction of lymphopenia by radiotherapy has been reported in
breast cancer (Jenkins et al, 1975 ; Glas et al, 1976 ; Blomgren
et al, 1976), seminoma testis (Heier et al, 1975) and various other
tumours (Byfield, Stratton & Cole, 1976 ; Raben et al, 1976 ;
Strattor, et al, 1975). However, one group (Braeman & Deeley, 1972),
found that fractionated, radical radiotherapy for carcinoma of the
bronchus, did not produce the fall in leucocyte numbers reported
by other workers. In general, though, leucopenia usually results
from both wide-field, and local radiotherapy (Stutz & Slawson,
1976), including, or excluding the thymus gland (Stratton et al,
1975).
Many of the chemotherapeutic drugs in use in cancer therapy
are known to produce leucopenia as a side effect. This results
mainly from their toxic effects on the rapidly-proliferating
stem cells in the bone marrow. As a result, leucopenia is often
a limiting factor in the effective treatment of cancer by either
radiotherapy or chemotherapy. Immunotherapy with B.C.G. is still
in its early stages, but reports indicate that it has relatively
little effect on lymphocyte numbers (B1 uming et al, 1972 ;
Gutterman et al, 1973 ; Lui et al, 1975), and this may indicate
that this is an effective cancer therapy without an associated
vulnerable period of immunosuppression.
The purpose of this study was to determine whether the Petti grew
method for whole-body hyperthermia, produced changes in the total
and differential concentration of peripheral blood leucocytes
characteristic of other forms of cancer therapy, and whether these
changes could be related to the patients' clinical status.
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Methods
Total Leucocyte Count 1ml samples of peripheral blood from
subjects under study, were collected in commercially-available
plastic tubes containing EDTA. These were agitated for up to Ih
on a blood cell suspension mixer. A 0.1ml sample was then
transferred to a plastic tube containing 1.9ml 2% aqueous acetic
acid. The pipette tip was rinsed several times in the acid
solution to remove any residual blood. The tube was capped and
mixed by inversion, before duplicate samples were counted in an
improved-Neubauer haemacytometer.
The reproducibility of the counting and sampling techniques
is shown in Table A1.
Differential Leucocyte Counts One drop of well-mixed, anti-
coagulated (EDTA) peripheral blood was placed on a clean glass
microscope slide, and smeared using a commercially-available
blood-spreader slide. Smears were air-dried and stained using the
following protocol:-
i) 'Ar.alar' Methanol lOmin
ii) May-Grunwald Stain .5min
iii) Giemsa Stain, diluted 1/10
in staining buffer pH6.8 7min
Two changes
iv) Staining buffer pH6.8 Rinse
Stained slides were air-dried and scanned under a x40
objective to assess the general appearance and quality of the
smear. Differential counts were made using an oil-immersion xlOO
objective. Smears were longitudinally scanned, using the method
described by Dacie and Lewis (1975). At least 200 leucocytes were




































COUNTS + 1 S.D. 4 01 + 0.09
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MEAN 4.02 4.22 3.88 4.40 4.26 4.16 + 0.23 4.14 + 0.21
TABLE A1
REPRODUCIBILITY OF TOTAL LEUCOCYTE COUNTS
A and B are two samples of anticoagulated blood obtained from the same
donor at the same time. For both samples replicate counts (1-5) were
made on a 1/20 dilution of the blood in 2% acetic acid. Both chambers
of the haemacytometer were used for each count, and a mean calculated.
In addition, similar counts were made on five separate dilutions of
Sample A (a-e) and means calculated. _fi











A 59.0 34.0 4.5 2.0 0.5
57.0 33.5 4.0 4.0 1.5
59.5 33.5 5.5 1.0 0.5
56.5 37.0 5.5 0.0 1.0
61.0 33.0 4.0 1.5 0.5
MEAN + 1 S.D. 58.6 + 1.8 34.2+1.6 4.7 + 0.8 1.7 + 1.5 0.8 + 0.4
B 57.0 37.0 4.0 1.5 0.5
TABLE A2
REPRODUCIBILITY OF DIFFERENTIAL LEUCOCYTE COUNTS OF 200 CELLS
Slides A and B were prepared from the same sample of normal
human blood. Slide A was counted 5 times to determine the
reproducibility of cell classification. Slide B was counted
once to indicate the reproducibility of the blood smearing
technique.
the number was occasionally reduced to 100. The criteria used
for classification were those of Diggs, Sturm and Bell (19 73).
The reproducibility of the technique is shown in Table A2.
Phagocytosis Assay
Materi als
Bacto Latex 0.81p. - dialysed in Visking tubing, for 4 days
against four changes of glass-distilled water, and stored at
4°C, until required.
Tubes - 2ml capacity, flat bottomed tubes, code NA2, with cap.
Supplied sterile. Sterilin Ltd., Teddington.
Method
Isolated polymorphonuclear leucocytes were resuspended in a
few ml of F10H, and the concentration determined by counting a
dilution of the suspension in 2% v/v acetic acid (to prevent cells
attaching to the haemacytometer during counting and thereby
hindering focusing). The viability of a second dilution of cells
in medium, was determined by dye exclusion.
Tubes for phagocytosis assays were prepared as follows:-
C
i) Viable polymorphs 2.5x10 cells
ii) Autochthonous serum 0.1ml
iii) Dialysed latex diluted n , ,
1/25 or 1/50 in F10H u*imi
iv) F10H to 1ml
The tubes were capped, briefly vortex mixed, and incubated
for 30min in a 37°C water bath. Each tube was gently shaken and
replaced for a further 30min. The cells were centrifuged at 800g
for 5min, and the cell pellet carefully resuspended in 1ml F10H
supplemented with 20% v/v foetal calf serum. 10-20|_il of the
cell suspension was transferred to a tube containing 0.4ml medium
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and this suspension was cytocentrifuged at 1,500-1 ,700rpm for
lOmin. The preparation was air-dried, and May-GrunwaTd/Giemsa
stained. Stained preparations were mounted in Euparal 'Vert'
and examined using an oil immersion xlOO objective. Cells were
classified into three groups, namely, those containing:-
i) no latex, ii) 1-5 particles, iii) 6+ particles (Fig. Al).
Classification was sometimes facilitated by the use of phase
contrast, or dark-field illumination.
Serum Corti sol Measurernerits
The concentration of Cortisol in serum samples obtained from
hyperthermia patients during and after treatment, was measured by
the Department of Clinical Chemistry, Western General Hospital,





CYTOCENTRIFUGE PREPARATION OF PERIPHERAL BLOOD GRANULOCYTES SHOWING
PHAGOCYTOSED LATEX PARTICLES
A =Cell containing numerous particles
B =Cell apparently containing no latex
May-Grunwald/Giemsa stained (Magnification xl,490)









CYTOCENTRIFUGE PREPARATION OF PERIPHERAL BLOOD GRANULOCYTES SHOWING
PHAGOCYTOSED LATEX PARTICLES
Same field as in Figure Ala under dark field illumination
Cell B is shown to contain phagocytosed latex particles
Results
Total and Differential Leucocyte Concentration prior to Hyperthermia
Prior to hyperthermia the total and differential leucocyte
concentration of 18 patients (12cP, mean age 53.8 years, range 23-
77 years) were compated with those of a group of 35 normal controls
(19 O1, mean age 32.1 years, range 17-55 years), and with two
published series of normal values (Wintrobe, 1961 ; Dacie & Lewis,
1975) (Table A3). Statistical analysis was performed using the
Student's t test, and p values of less than 0.05 were considered
significant.
The patients had significantly higher (p<0„001) total leucocyte
concentrations than the control group, but were still within the
published normal ranges. This elevation was primarily due to a
significant (p-=0.001) increase in the proportion of neutrophils,
the concentration of which was approximately double that of the
controls, and at the upper limit of the published normal ranges0
This was accompanied by a significant (p«=0.01) reduction of
lymphocyte concentration in the patients, to a level at the lower
end of the normal range. Eosinophil and basophil counts also
tended to be lower in the hyperthermia patients (p«=0.1).
Total and Differential Leucocyte Concentration during and after
Hyperthermia The effect of hyperthermia treatment on total and
differential leucocyte counts was studied by taking blood samples
at regular intervals during, and following, treatment. Results
from some typical patients are shown in Table A4 and Figures A 2
and A3. Statistical analysis was performed on the concentrations
(before and after logarithmic transformation to correct for any





























































































TOTALANDDIFFERENTIALLEUCOCY ECONCENT ATIONSITHPERIPHER LB O DON RM LCO TR LSA DDVANCECA CP TI SR TOWHOLE-BODYHYPERTHERMIATREA MENT Twopublishedrangesofnormalv luesash wn.*Statistical ysignifica tbyStudent'te t
for paired samples, p values of less than 0.05 were considered
significant.
The following response occurred in most of the patients studied.
Following pre-medication, but prior to heating, there was a fall
in the leucocyte count, characterised by a decrease in the neutro¬
phil concentration, but little change in lymphocyte numbers. This
fall continued during active heating, the minimum leucocyte count
occurring when the oesophageal temperature was 41.4-41.9°C (i.e.
the temperature at which the wax was removed). This leucopenia
was then followed by a substantial leucocytosis, the magnitude of
which varied from patient to patient. The rise in leucocyte
numbers usually started during the maximum temperature phase of
treatment, but continued after the patients had been removed from
the bath, and allowed to cool. At this stage, during the first
treatment, the mean leucocyte count reached 125% of the pre¬
heating value; by the following morning it had dropped to 116%,
and, in most cases, had returned to the pre-treatment value within
a further 2 days. This pattern was repeated during subsequent
treatments (Figures A 2 and A 4), although the magnitude of the
leucocytosis generally increased during each treatment. This may
be due either directly, or indirectly, to the increasing fraction
of hyperthermia given on each occasion, or to the increased
likelihood of registering the peak of leucocytosis during the
longer second and third treatments.
The changes in leucocyte count during hyperthermia can be
largely explained by variations in the neutrophil concentration.
During the period of leucopenia, and neutropenia, there was in
some cases, a slight lymphocytosis. This was foil owed by the
leucocytosis and neutrophilia, which was initially accompanied by
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FIRST TREATMENT





TOTAL LEUCOCYTES 100 125.5 116.5 116.1
NEUTROPHILS 100 142.0 151.3* 129.1
LYMPHOCYTES 100 101.6 75.5 86.5
SECOND TREATMENT





TOTAL LEUCOCYTES 100 158.9 125.5 102.4
NEUTROPHILS 100 182.3 145.8* 113.9
LYMPHOCYTES 100 123.2 92.3 81.6
THIRD TREATMENT
1 DAY 3 DAYS
( 4 PATIENTS) PRE END POST POST
TOTAL LEUCOCYTES 100 185.0 147.5 95.3
NEUTROPHILS 100 213.1* 191.8 102.9
LYMPHOCYTES 100 145.2 69.6 89.6
TABLE A4
EFFECT OF HYPERTHERMIA TREATMENTS ON THE TOTAL AND DIFFERENTIAL
CONCENTRATION OF PERIPHERAL BLOOD LEUCOCYTES
Pretreatment concentration = 100
* Statistically significant by Student's t test on logarithm-
transformed data
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TOTAL AND DIFFERENTIAL PERIPHERAL BLOOD LEUCOCYTE COUNTS IN SIX
PATIENTS DURING WHOLE-BODY HYPERTHERMIA TREATMENT
a lymphopenia, and subsequently, by a return to the pre-hyperthermia
lymphocyte concentration. During subsequent treatments, in which
there was a substantial neutrophilia, there was often a slight
lymphocytosis towards the end of treatment. The peak in neutrophil
concentration usually occurred within 48h of treatment, with a
return to the pre-hyperthermia concentration within 3 days. There
was a tendency for the lymphocyte count to be slightly depressed
following treatment, although this was only statistically
significant (p<0.01 ) after the first session.
Over a complete course of hyperthermia treatments, there was
no significant difference between the initial and final total
and differential leucocyte count.(Figure A4)
Serum Cortisol Concentrations during and after Hyperthermia The
concentration of serum Cortisol was measured in 5 patients, during
and after their first treatment.
At the end of hyperthermia the concentration had risen to
169.0% of the pre-heating level (Range 100.0-328.2%).. The following
day it had fallen to 118.2%, and 2-3 days later stood at 103.4%.
None of these changes was statistically significant, by the Student's
t test for paired samples.
Piscussion
In this study, the total and differential leucocyte concentration
in hyperthermia patients, prior to treatment, was compared to that
in a control group which was younger, and contained a lower
proportion of males. Olbrich (1947) however, could find no
difference in the peripheral leucocyte count of the elderly, and
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EFFECT OF SUCCESSIVE HYPERTHERMIA TREATMENTS ON THE TOTAL AND
DIFFERENTIAL CONCENTRATION OF PERIPHERAL BLOOD LEUCOCYTES
The lower graph shows the concentrations in a normal control
sampled over the same time period
hyperthermia treatments
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FIGURES A4b & A4c
EFFECT OF SUCCESSIVE HYPERTHERMIA TREATMENTS ON THE TOTAL AND
DIFFERENTIAL CONCENTRATION OF PERIPHERAL BLOOD LEUCOCYTES
subdivision of the control group, used in this study, into two
sub-populations, with significantly different mean ages (24.2 years,
and 40.5 years), did not produce a significant difference in the
leucocyte count between the two groups. Sex differences probably
do not account for these results, since they do not have a
significant effect on the total leucocyte count, except that the
count in women above 50 years of age is less than that in men
(Dacie & Lewis, 1975). It is known that leucocyte counts can be
affected by exercise (Wintrobe, 1961), climate and environment
(Woodliff et al, 1972), season and time of day (Dacie & Lewis
1975), pain and emotional disorders, and possibly, ingestion of
food (Wintrobe, 1961), although Holm and Palmblad (1976) found
that acute energy deprivation (involving 11 days starvation)
produced no significant changes in the lymphocyte or monocyte
concentrations. Furthermore, the validity of the results
obtained by comparing the patient and control groups, is reinforced
by reference to the published normal ranges. Whilst the controls
are within these ranges, the neutrophil and lymphocyte concentrations
in the hyperthermia patients tend to be at their limits. It is
therefore concluded that the increased peripheral leucocyte
concentration in hyperthermia patients, prior to treatment, is a
reflection of their poor clinical condition.
The leucocytosis in these patients is due to an increase in
the percentage, and concentration, of neutrophils. The reason for
this granulocytosis is not clear. It may be a response to a
secondary infection, or a reaction to the neoplasm (De Gruchy,
1964). Wintrobe (1961) has indicated that cancers which involve
the liver and gastro-intestinal tract, can produce a leucocytosis.
This explanation would seem applicable to these patients, the
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majority of whom had G.I. tumours, with liver metastases.
Lymphopenia in cancer patients has been reported previously
by Zacharski and Linman (1971) and Krant et al (1968), but was
not seen by Cochran et al (1976). In many cases, lymphopenia
g
was defined as a lymphocyte concentration below 1.5x10 (Riesco,
1970), or 1.0x10® (Amin & Lich, 1974) cells/ml peripheral blood.
On this basis, just over half (62.5%) of the hyperthermia patients
g
were lymphopenic at the 1.5x10 lymphocytes/ml level, and 18.8%
at the 1.0x10® lymphocytes/ml level - an incidence comparable to
the 16% reported by Zacharski and Linman (1971). However, the
degree of lymphopenia is somewhat masked by the high leucocyte
count in the patient group, which compensated for their low
percentage (20.4%) of 1ymphocytes.
The reason for this lymphopenia is not fully understood. It is
unlikely to be the result of previous chemotherapy and radiotherapy,
since these are known to produce an associated leucopenia.
Adrenalin is known to cause a two-phase increase in the leucocyte
count. During the second stage there is a granulocytosis and an
accompanying lymphopenia. It is possible that the increase in
adrenocortical activity, reported in pre-terminal cancer patients
(Werk, Sholiton & Marnell, 1963), may result in the abnormalities
in the differential leucocyte concentrations observed in these
patients. Alternative explanations, which do not account for the
granulocytosis, are those of depressed immunocompetence in these
subjects, resulting in the development of a tumour, or, the
presence of a substance which suppresses lymphocyte proliferation
(Papatestas et al, 1976).
In this study there was no clear relationship between the
pre-treatment lymphocyte concentration and the response to therapy,
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as judged by survival time following treatment. However, the
number of patients was too small, ari the follow-up too short to
exclude such a relationship.
The marked leucocytosis occurring during hyperthermia treat¬
ment has been described previously (Simon, 1935 ; Beisel, Goldman
& Joy , 1968 ; Cohen & Warren, 1935), and has been seen in cases
of heat stroke (Shibolet, Lancaster & Danon, 1976). The preceeding
leucopenia is not documented by these authors.
Variations in blood volume, during heating, are unlikely to
account for these fluctuations in the leucocyte concentration.
Fluid losses were minimised by intravenous infusions, and
measurement of haematocrit and haemoglobin concentrations indicated
no appreciable haemoconcentration or dilution (Pettigrew et al,
1974). In addition, falls in the numbers of one type of leucocyte
were often accompanied by increases in that of another.
It is not likely that anaesthesia is responsible for the
leucocytosis, since the previous studies, conducted on unanaesthet-
ised patients, produced similar results. Although slight increases
in leucocyte numbers have been described in volunteers undergoing
anaesthesia alone, it is generally accepted that the haematological
changes previously attributed to anaesthetics, are due to stress
(Cullen & Van Belle, 1975). Lecky et al (1974) reported similar
changes to those in hyperthermia patients (i.e. neutrophilia, but
no change in lymphocyte concentrations), in volunteers exposed to
N^O/O,, d-tubocurarin anaesthesia. They attributed these to an
increase in the levels of serum Cortisol which were indicative of
a stress response.
A number of different effects may be classified as stress
responses, but all involve a disruption in the balance of
catecholamine, ACTH and Cortisol production. Depending on the
nature of the disruption, the effect on the leucocyte concentration
can differ widely (Bruce & Wingard 1971). The type of hyperthermia
treatment used in this study is known to produce an initial fall in
Cortisol concentration (Ludgate et al, Unpublished observations),
followed by an increase during active heating. This is accompanied
by an earlier fall and rise in the ACTH concentration (Ludgate et al,
Unpublished observations). These changes could account for the
leucocytosis, which is initiated during the rise phases of both
ACTH and Cortisol. The leucopenia seen before active heating is
unlikely to be due to a change in the Cortisol concentration,
which is not thought to be affected by muscle relaxants, or pre¬
medications (Hammond et al, 1958). It is possible, however, that
these agents have a similar effect to that of barbiturates, which
are known to produce an immediate neutropenia, with a slight lympho¬
cytosis, similar to that seen in these patients.
The relationship between leucocyte concentration and the
level of stress, as measured by serum Cortisol concentrations, is
reinforced by the follow-up studies. These indicated that, whilst
initially elevated, both parameters returned to the pre-treatment
level within 3-4 days. Suryanarayan (1966) described a post-heating
leucopenia, consisting of neutropenia and lymphocytosis, lasting
for 15 days, in patients treated by hyperthermia and concomitant
chemotherapy. This has not been seen, either in this study, or in
that of Cohen and Warren (1935).
In summary, hyperthermia treatment produces a marked granulo¬
cytosis i n most patients. Lymphocyte concentrations are usually
unaffected. These changes may be due to a stress response,
involving increased serum Cortisol levels, rather than to anaesthesia.
Pre-treatment peripheral leucocyte concentrations return within
3-4 days, indicating ""hat hyperthermia does not produce the long-
term leucopenia associated with radiotherapy and chemotherapy.
Studies on the Granulocytosis occurring during Hyperthermia
Treatment The granulocytosis occurring during, or immediately
following, treatment, may be produced by the release of neutrophils
from capillary beds, due to heat-induced vasodilatation and a
hyperaemic circulation. Alternatively, hyperthermia may, directly
or indirectly, stimulate the production of granulocytes. In the
latter case there should be a marked shift in the age distribution
of the cells towards juvenile forms.
To find out which effect was predominant, the age distribution
of the neutrophils was determined by assessing the proportion of
peripheral blood granulocytes with 2, 3, and 4 or more nuclear
lobes, before and after treatment. Classification was based on
the system developed by Arneth (Wintrobe, 1961), in which
segmentation of the nucleus can be related to cell maturation
(Figure A 5). 400 neutrophils from stained, peripheral blood films
were classified for each time point.
With such a large influx of granulocytes into the peripheral
bloodstream, it was also of interest to determine whether there was
an associated increase in phagocytosis. If the neutrophilia was
due to the release of morphologically immature forms, it was
possible that these may, nonetheless, have some of the functions
of mature cells. Phagocytosis assays were carried out on granulo¬
cytes isolated from peripheral blood before and after treatment. A





NUCLEAR LOBE FORMS USED TO DETERMINE THE AGE-DISTRIBUTION OF
PERIPHERAL BLOOD GRANULOCYTES
Cytocentrifuge preparations, May-Grunwald/Giemsa stained
(Magnification x!045)
LOBES PER NUCLEUS
PATIENT 1 2 3 £4
K.S.
1ST TREATMENT 432 171 106 103
2ND TREATMENT 643 205 89 83
3RD TREATMENT 670 201 82 81
A. W.
1ST TREATMENT 307 133 97 128
2ND TREATMENT 347 234 121 38
I.W. 774 280 190 95
H. A. 941 148 334 158
D.G. 799 281 149 92
PRE-TREATMENT VALUE FOR ALL CATEGORIES = 100
TABLE A5
EFFECT OF HYPERTHERMIA TREATMENT ON THE CONCENTRATION OF
PERIPHERAL BLOOD GRANULOCYTES SHOWING A PARTICULAR
NUCLEAR LOBE FORM
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FIGURE A6
HYPERTHERMIA TREATMENT ON THE AGE-DISTRIBUTION OF PERIPHERAL BLOOD NEUTROPHILS
ing age of the cells is indicated by segmentation of the nucleus. See Fig.A5
Prior to hyperthermia, the majority of neutrophils were 2 or
3-lobed forms, however, at the end treatment, there was a marked
increase in the proportion of less manure (1 and 2 lobed forms) in
the peripheral blood (Figure A 6). The possibility of selective
destruction of the older forms during heating, was excluded by
determining the concentration of each of the age groups before,
and after heating. The results (Table A 5) indicate that the mature
granulocytes (4 lobed forms) were 1argely unaffected, or may even
increase in numbers, during hyperthermia.
The results of the phagocytosis studies (expressed as
concentrations of phagocytic neutrophi1s/ml peripheral blood) are
shown in Figure A 7.
Where there was an appreciable neutrophilia during hyperthermia,
there was an accompanying rise in the number of cells capable of
phagoc.ytosing latex particles (Patients: L.K., M.D., and M.W.),
indicating that the immature forms were functional in this respect.
In one patient (T.M.), who received radiotherapy between hyperthermia
treatments, leucopenia developed during the first four heating
sessions (Figure A 7), but there was a slight leucocytosis during
the fifth. This is reflected in the changes in the concentration
of phagocytic neutrophils, which fell during the first four
treatments, but rose during the fifth., In these, and similar
sessions in which there was no massive granulocytosis (so that
essentially the same granulocyte population was studied before and
after heating) the percentage of neutrophils capable of latex
phagocytosis did not change, indicating that the treatment did not
affect the process of phagocytosis.
This was confirmed in vitro, by carrying out the incubation


































OF HYPERTHERMIA TREATMENT ON THE CONCENTRATION OF ACTIVELY-PHAGOCYTIC NEUTROPHILS
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FIGURE A8
DIFFERENT INCUBATION TEMPERATURES AND LATEX CONCENTRATIONS
EFFICIENCY OF PHAGOCYTOSIS BY NEUTROPHIL GRANULOCYTES
See text for details
The results are shown in Figure A 8. At 37°C there was little
difference between the percentage of cells capable of phagocytosis
when a I.igh (0.4% v/v), or a low (0.2%v/v) concentration of
latex was used. At 42°C the total number of cells phagocytosing
latex at high concentrations was similar to that seen at 37°C,
and there is little difference in the 'efficiency' (as measured by
the number of particles ingested). However, at a low latex
concentration there was an increase in the proportion of neutro¬
phils ingesting fewer than 5 particles, at the expense of those
phagocytosing more than five particles.
Piscussion
The finding that the granulocytosis was primarily due to an
influx of immature neutrophils into the bloodstream is supported by
the work of Cohen and Warren (1935). Simon (1935) and Beisel et al
(1968) both reported a granulocytosis during heating in vivo, but
indicated that the neutrophilia was due to an increase in the number
of mature cells. It is likely that a combination of the tv/o
effects occurs during hyperthermia. Athens et al (1961) have
indicated that in the human, only 47% of granulocytes are in
circulation at any one time. The remainder form the so-called
marginal pool, which is in rapid equilibrium with the circulating
pool. The distribution of cells between these two pools can be
altered by exercise, injection of adrenalin etc., and it is
probable that hyperthermia also increases the size of the circulating
fraction. This may be combined with stimulation of neutrophil
O
production (which is normally 8.5x10 cells/kg body weight/day
(Dancey et al, 1976) ), either directly by heat, or indirectly,
possibly by release of tissue autolysates (Lawrence et al, 1950)
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from neoplastic, or normal tissue.
The results from the phagocytosis experiments indicate that
heat may depress the 'capturing efficiency' of the neutrophils,
whilst not affecting their ability to ingest latex. The fact that
this phenomenon is apparent at low particle densities could be of
relevance in vivo, where small amounts of tumour debris may be in
circulation after hyperthermia. In addition, bacteria and viruses
are less liable to be 'captured' by heated cells, which may leave
the patient open to infection. It is likely however, that this
effect is amply counteracted by the greatly increased numbers of
phagocytic cells, which are in circulation after treatment.
The reason for the depression of phagocytosis at 42°C is not
clear. Anaesthesia has been reported to inhibit phagocytosis, Nitro-
blue Tetrazolium reduction (Cullen, Hume & Chretien, 1975), and
neutrophil chemotaxis (Stanley et al, 1976). However, in the
former case, the inhibition was minimal, and it is likely that
many of the effects attributed to anaesthetics may have been due
to stress, and an associated elevation of serum steroid levels
(Duncan & Cullen, 1976); although Brote and Stendahl (1975) found
essentially normal phagocytic function after surgical trauma, but
some depression in burns patients. A direct effect of elevated
temperature on phagocytosis has been reported by Mandell (1975),
where temperatures above 40°C inhibited the ingestion of bacteria
by human neutrophils in vitro. It is therefore possible that
heat directly affects the cell, or, alternatively, may degrade the
opsonins required for phagocytosis. Douglas (1970) has stated that
neutrophils require complement to accomplish efficient phagocytosis,
and this study has indicated that complement concentrations are
depressed by hyperthermia treatment (See p.168 ). It is possible
therefore, that low levels of complement, whilst not inhibiting
at high latex densities, become critical when combined with a
decrease in the latex concentration.
It remains to be established whether this slight depression
in phagocytic ability of individual cells, when balanced against
the increase in the total number of cells capable of phagocytosis,
is of relevance in the clinical situation.
Effect of Hyperthermia Treatment on Granulocyte Morphology As part
of a later study (See p.130 ) the effect of hyperthermia treatment
in vivo, on granulocyte morphology was assessed by scanning electron
microscopy (See p.107 ). In order to compare similar cell
populations, granulocytes were isolated before, and after, a
treatment during which there was only a slight leucocytosis (Patient:
T.M. ; Treatment 5 - Figure A 7).
Prior to hyperthermia the majority of cells were amoeboid in
shape, with relatively few surface ridges, or villi (Figure A9).
In contrast, granulocytes separated from end-of-treatment blood
were spherical, and the surface was folded and villous (Figure A 10).
Piscusssion
These findings are in agreement with those of Lichtman et al
(1976), who noted a rounding-up of granulocytes kept in suspension
at 4°C, They also described changes in the cell surface, similar
to those reported in this study, and indicated that this may be
due to the folding, or rucking, of the surface membrane, when the
amoeboid processes are retracted. Their study correlated the
amoeboid form with granulocyte integrity, and normal functional
capacity, and this is partly supported by the work on hyperthermia
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Scanning Electron Micrograph of Peripheral Blood Granulocytes
prior to Hyperthermia Treatment (x 1,100)
Figure A9a
Scanning Electron Micrograph of Peripheral Blood Granulocytes
prior to Hyperthermia Treatment (x 3,600)
Figure A9b
Figure AlOa
Scanning Electron Micrograph of Peripheral Blood Granulocytes
at the end of Hyperthermia Treatment (x 1,100)
Figure AlOb
Scanning Electron Micrograph of Peripheral Blood Granulocytes
at the end of Hyperthermia Treatment (x 3,600)
patients. It is possible that the reduction in latex 'capturing
efficiency' at 42°C is due to the withdrawal of the cell processes
at this temperature, so that the chance of contact between the cell
and the latex particles is reduced.
In summary, although this finding of a change in granulocyte
morphology during hyperthermia treatment, is based on a single
observation, it may be of value in explaining the effect of
elevated temperatures on the 'capturing efficiency1 of these cells.
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PAPER B
THE EFFECTS OF WHOLE-BODY HYPERTHERMIA THERAPY ON THE
CONCENTRATION OF PERIPHERAL BLOOD T AND B LYMPHOCYTES
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The Effects of Whole-Body Hyperthermia Therapy on the
Concentration of Peripheral Blood T and B Lymphocytes
Introduction
Mammalian and avian lymphocytes can be grouped into various
subclasses, the more important of which include T and B cells.
T Lymphocytes T lymphocytes are responsible for cell-mediated immune
responses, and, as such, are potentially of great importance in the
host's defence against, and response to, malignant disease.
The percentage of human lymphocytes bearing T cell markers has
been reported to be between 1% (Bach et al, 1969) and 82% (Bentwich
et al, 1973), however much of this variation is due to technical
differences in the assay method (See p. 97 ). It is generally
accepted that the normal range is 50-80% (Mendes et al, 1973 ;
Steel, Evans & Smith, 1974a ; Robinson & Lertratanakul, 1975 ;
Holm et al, 1975), but it may be affected by age (Teasdale et al,
1976), strenuous exercise (Steel, Evans & Smith, 1974b) etc..
Depression of T lymphocyte levels has been reported in various
clinical conditions e.g. sarcoidosis (Cummiskey, McLaughlin & Keelan,
1976), lepromatous leprosy (Dwyer, Bullock & Fields, 1973), various
immunodeficiency diseases (Wybran et al, 1973), and in patients who
are immunosuppressed, following heart (Khalaf et al, 1976) or kidney,
transplants, or who are on haemodialysis (Sengar, Rashid & Harris,
1975).
There has also been considerable interest in measuring the relati
(%) and absolute numbers (concentration) of T cells in the blood of
patients with malignant disease. Much of this work has concentrated
on cancers of lymphoid cells and tissues (Bobrove et al, 1975 : Esber
et al, 1976), including the classification of the cell types involved
in various leukaemias (Mathe & Belpomme, 1974). A number of investi¬
gations have been carried out on patients with non-lymphoid tumours.
The results from some of the more recent studies are shown in Table B1.
Although technical variations strictly invalidate direct
comparisons between the results obtained by different workers (Holland,
Browne & Thornes, 1975), several trends are apparent:-
i) The relative and absolute numbers of T lymphocytes are
depressed in cancer patients, in comparison to normal
control subjects.
ii) In many cases, the degree of depression can be related to
the extent of disease, such that progression of the tumour
correlates with a decline in T cell numbers.
iii) In several cases, a correlation has been reported between
the T lymphocyte count and the prognosis, response to
treatment etc.
It is the combination of these observations which makes the
monitoring of T cell levels valuable in the assessment of the immuno-
competence of cancer patients. However this assay is purely
quantitative, and gives no indication of the functional integrity
of the cells. It is therefore of greater value when used in
association with a test of T cell activity, such as response to
Phytohaemagglutinin (See Paper C).
There have been several reports that assays which do not
detect the maximum number of T cells, give results which correlate
more closely with the patient's clinical status and prognosis
(Wybran & Fudenberg, 1973 ; Cochran et al, 1976 ; Herberman, 1976).
These tests are believed to detect a subpopulation of 'active' or
'early-rosetting' cells (Fudenberg, Wybran & Robbins, 1975). This
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WHILEABSOLUTECOUNT WASDEPRES EDBYVARYING DEGREES
TABLEB1Cont.
since the number of 'active' T cells has been found to correlate
with delayed cutaneous hypersensitivity to microbial antigens, in
the human (Felsberg, Edelman & Gilman, 1976 ; FelsbeK'g & Edelman,
1977).
It is likely, however, that the T lymphocyte population, in
both animals and humans, is composed of a number of sub-groups
(Kaplan & Uzgiris, 1976, Cantor et al, 1975), differing in both
function and activity (Sasaki et al, 1975). At present, the
significance of numerical changes in these groups is not understood
and the majority of studies have therefore concentrated upon
monitoring variations in the population, as a whole.
Methodology Human T lymphocytes are usually detected by their
ability to form non-immune rosettes with unsensitised sheep
erythrocytes (Coombs et al, 1970 ; Brain, Gordon & Willetts, 1970 ;
Lay et al, 1971). Evidence for the thymus-dependence of the rosette-
forming cells was based upon their:-
i) lack of surface immunoglobulin (Jondal, Holm & Wigzell,
1972)
ii) localisation in thymus-dependent areas of the tissues
(Silveira, Mendes & Toinai, 1972).
iii) possession of a thymus-dependent antigen - HTL - Human
Thymus-Lymphoid Tissue Antigen (Yata, Tsukioto & Tachibana,
1973).
The nature of the receptor involved in the binding of sheep
erythrocytes is not fully understood. Treatment of either lymphocytes,
or erythrocytes, with Neuraminidase results in an increase in the
number of rosettes formed (Galili & Schlesinger, 1974) ; probably by
the reduction of surface electronegativity, by the cleavage of Sialic
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Acid residues from lipid chains (Small, 1975 ; Sandi1ands et al, 1975).
Alternatively, the enzyme may unmask previously-hidden receptors, as
it is known to alter the antigenicity of cells (Sedlacek, Seiler &
Schwick, 1977). These experiments do not however indicate the nature
of the receptor. It is known that heating lymphocytes to 45°C for lh
removes the receptors, and that rosetting is restored by incubating
the cells in human serum (Mendes et al, 1975). This suggests that
the receptor is labile, but that it can be rebound to the cell.
This 'fluidity1, and the weak bonding between the red cells and
lymphocytes - consisting of only limited areas of membrane contact
(Tonietti et al, 1975) - have probably contributed to the large
variations in estimates of T cell numbers in normal subjects. The
technique for rosetting is simple (See p. 103 ), enumeration being
performed on wet preparations in a haemacytometer, although permanent
preparations can be used (Scafer et al, 1975), and various
automated counting techniques have been reported (Vandenbark, Burger
& Vetto, 1976 ; Teodorescu, Mayer & Dray, 1975). However, this
apparently straightforward test may be affected by numerous variables
e.g. method used to separate the lymphocytes (Holm et al, 1975), pre¬
incubation of the cells (Roszman, Brooks & Muse, 1977), source and
age of sheep erythrocytes (Steel et al, 1974a), centrifugation speed
and rough handling (Anthony et al, 1975), ratio of red cells to
lymphocytes (Chisholm & Tubergen, 1976), temperature of incubation
(Galili & Schlesinger, 1975), serum concentration (Steel et al,
1974a) etc. (Reviewed by Browne & Greaves, 1974 ; Mendes et al, 1973 ;
WHO Report, 1974). It is therefore important, when making serial
measurements, e.g. in monitoring the response to cancer therapy, to
adopt strictly standardised techniques, in order to minimise the
effect of these variables(WHO Report, 1974).
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Alternative methods for the detection of T lymphocytes have
been described (Browne & Greaves, 1974), but the simplicity and
rapidity of the rosetting technique, makes it the most popular
method. In addition, Small (1975) has stated that 'the surface
areas involved in rosette formation are also involved in other T
cell functions' and that 'the SRBC receptor may be of general
importance for T cell functions'.
The rosetting assay can also be of value in detecting various
subpopulations e.g. morula-form rosettes may be formed by activated
T cells i.e. T-blast cells (Huang et al, 1976 ; Yu, 1976).
Another marker for these cells is thought to be rosette formation
under 'sub-optimal' conditions, or with autologous erythrocytes
(Sheldon & Holborrow, 1975 ; Sandilands et al, 1975).
In conclusion, rosette formation with sheep erythrocytes
provides a useful marker for human T lymphocytes, and, under special
conditions, for their subpopulations. It can also give valuable
information on cellular immunocompetence, provided that carefully-
standardised conditions are used.
B Lymphocytes B cells mediate humoral immune reactions (See p.21)
and, as such, are probably of lesser importance in the response to
cancer.
Changes in the relative and absolute numbers of B cells have been
reported in response to heart transplants (Khalaf et al, 1976), and
in various immunodeficiency diseases (Seligmann, Preud'Homme & Brouet,
1973). Some studies have been carried out on patients with cancer
(especially lymphoma and melanoma). Results from some of the more
recent of these are shown in Table B2.
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in these patients, probably reflects the heterogeneity of the B
cell population (See below).
Methodology I lymphocytes can be identified by their exclusive
ability to form rosettes with unsensitised sheep erythrocytes. In
contrast, the recognised markers for B cells, namely, surface immuno¬
globulin and receptors for complement and the Fc portion of immuno¬
globulin, are shared by other leucocytes (Table B3).
Although T cells have been shown to possess surface immuno¬
globulin (S-Ig) under certain circumstances (Marchalonis, Atwell &
Cone, 1972), it is difficult to detect, and as a consequence, this
marker has been used to identify B lymphocytes, which are known to
produce and secrete immunoglobulin. However, it is now realised that
there are two distinct populations of S-Ig-bearing lymphocytes in
human peripheral blood - L cells and B cells. In the former group
the immunoglobulin is not membrane-incorporated, but is bound to
the cell surface by receptors (Lobo, Westervelt & Horwitz, 1975),
in addition, these cells possess high-affinity, trypsin-resistant
Fc receptors (Lobo & Horwitz, 1975), and therefore probably
constitute a separate cell population (Horwitz & Lobo, 1975).
Receptors for complement have been used to enumerate B
lymphocytes, by rosette formation with erythrocytes coated with
antibody and complement (WHO Report, 1974). These receptors are
shared by monocytes. Simultaneous detection of S-Ig and complement
receptors has resulted in the discovery of four subpopulations
(Winterleitner, Rotter & Knapp, 1977), and the conclusion that the
cells bearing S-Ig are not identical with those possessing
complement receptors. This is supported by the work of Holm et al,
















































DISTRIBUTIONOFSU FACEMA KERSNHUMAMONONU L ARLEUCO YTES
The use of the Fc receptor as a B cell marker is complicated
by the various results that have been obtained using different
detection techniques. The receptor defected by the binding of
aggregated-IgG may be distinct from that responsible for rosette
formation with erythrocytes coated with human antiserum (Buckley,
1976). Additionally, it has been found that B cell form rosettes
with rabbit anti-ox coated ox erythrocytes, but not with human red
cells sensitised with Ripley IgG (Lobo & Horwitz, 1976 ; Hallberg,
Gurner & Coombs, 1973), suggesting that different receptors may be
involved in the recognition of human and xenogeneic Fc portions.
Techniques have been described which may specifically detect
B lymphocytes. These include the binding of Epstein-Barr virus
(WHO Report, 1974), and rosette formation with unsensitised mouse
erythrocytes (Gupta, Good & Siegal, 1976), although the latter may
be a property of a subset of B cells (Bertoglio et al, 1977).
Methods have also been described for the simultaneous enumeration
of B and T cells (Robinson & Letratanakul, 1975 ; Brain et al,
1976).
The main problem in any study on B lymphocytes, therefore, is
the exact nature of the cell population involved. The simple
division of the human lymphocyte population into two subgroups is
now revealed as an over-simplification. The original markers for
B cells are possessed by a number of cell types, and it is not clear
to what extent each of these subclasses is involved in the mediation
of humoral immunity. The use of several markers may be advisable,
and has been described by several groups (Franchi et al, 1975 ;
Holm et al, 1975), but it may complicate the situation by detecting
the various subgroups (Winterleitner et al, 1977). An alternative
method has been documented by Eby et al (1975), which detects cells
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that are actively secreting immunoglobulin, by the formation of
haemolytic plaques (by the lysis of erythrocytes sensitised to human
immunoglobulin). This technique is not however a strictly
quantitative measure of B cells, since it cannot deuect those which
are not producing immunoglobulin at the time of assay.
At present, therefore, any enumeration of B lymphocyte numbers,
whilst of value in the assessment of general immunocompetence, is
of limited worth, since the exact nature and function of the cell
types which comprise this population, remains to be established.
The aim of this study was to determine the effect of whole-
body hyperthermia treatment on the numbers of peripheral blood T
and B lymphocytes, as detected by commonly-accepted markers.
-102-
Materials and Methods
T Lymphocyte Counts " 'lymphocytes were enumerated using the
spontaneous sheep eryth.ocyte rosette test. The method used was a
modification of that of Steel et al (1974a).
Isolated lymphocytes were suspended in F10H supplemented with
20% v/v heat inactivated foetal calf serum, at a concentration of
2-4x10^ viable cells/ml.
Sheep red blood cells (from a specified animal - originally
SCI, and later 764 - both of which gave comparable results) were
supplied in Alsever's solution and stored, pelleted, at 4°C for up
to 14 days. Immediately before use, 0.1ml of pelleted cells was
resuspended in 10ml PBS1A' and centrifuged at 800g for 5min. The
cell pellet was resuspended in 10ml PBS'A' to give a 1% suspension,
and used immediately.
Equal volumes (30-100).tl) of erythrocyte and lymphocyte
suspensions were mixed in round-bottomed glass (50x8mm), or plastic
(Titertek transfer vials) tubes. The cells were pelleted by
centrifugation at 200g for 5min, and incubated overnight at 4°C.
The majority of the supernatant medium was removed and replaced
by an equal volume of 0.1% eosin in saline. The cells were
resuspended by very gently rocking the tubes. A sample was removed
with a wide-bore Pasteur pipette, to a mirrored improved-Neubauer
haemacytometer, fitted with a thin coverslip. The cells were left
to settle for 3-4min, and examined using a x40 objective. Viable
lymphocytes with 3 or more adherent erythrocytes (Fig. Bl) were
classified as rosettes. The percentage of rosette-forming cells
in the preparation was calculated from a count of at least 200
lymphocytes.
Routinely, the counts obtained by different observers, or from
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SPONTANEOUS ROSETTE FORMATION BETWEEN HUMAN LYMPHOCYTES AND
UNSENSITISED SHEEP ERYTHROCYTES
M = Morula form of rosette H=Halo form U = Unrosetted lymphocyte
(Magnification x595)
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FIGURE B2
SPONTANEOUS ROSETTE FORMATION BETWEEN HUMAN LYMPHOCYTES AND
UNSENSITISED RHESUS MONKEY ERYTHROCYTES
R=Rosetted lymphocyte U=Unrosetted lymphocyte
(Magnification x595)
two lymphocyte preparations from the same blood sample, did not differ
by more than 5%. Replicate counts made by one observer, on triplicate
tubes, usually varied by less than 4%.
'Active' or 'Rapid-Rosetting' T Lymphocyte Counts 'Active' T
lymphocytes were enumerated using the same technique as for total T
lymphocytes, except that the cell pellets were resuspended
immediately after centrifugation at 2C0g. Reproducibility of the
technique was the same as for total T lymphocytes.
Rosette Formation with Rhesus Monkey Erythrocytes (See p.119 ) The
procedure followed was the same as that for total T rosetting with
sheep erythrocytes, except that the cell pellets were incubated over¬
night at room temperature. Rapid-rosetting with rhesus red cells was
exactly as for sheep cells. Criteria for classification of rosettes
(Fig. B2) were as given above.
Conditions under which Lymphocytes were Heated in vitro Unless stated
-.v.- ■.. 6 '
otherwise, lymphocytes were heated at a concentration of 4x10 /ml in
F10H supplemented with 20% v/v heat inactivated foetal calf serum.
Cells were washed once, in an equal volume of the same medium at room
• %
temperature, before use.
B Lymphocyte Counts The number ofB lymphocytes in a lymphocyte
preparation was calculated from the number of cells forming rosettes
with sheep erythrocytes which had been coated with antibody and
complement. This technique detects the complement receptor on B cells.
The method used was a modification of that described by Stjernsward
et al (1972).
Freshly-separated lymphocytes were suspended at a concentration
of 2-4x10^ viable cells/ml in F10H supplemented with 20% v/v heat-
inactivated foetal calf serum.
Shcap erythrocytes were collected and stored as for T lymphocyte
rosettirg. 0.1ml of pelleted cells was resuspended in 10ml PBS'A1 and
centrifuged at 800g for 5min. The cell pellet was resuspended in 4ml
of a 1/2,000 dilution of heat inactivated, rabbit anti-sheep red cell
serum (Batch K9804 was used throughout the study, and had been
titrated by erythroagglutination - the dilution used was double the
end-point concentration) in PBS'A1. The suspension was incubated at
37°C for 30min, and the cells pelleted at 800g for 5min, and washed
in 3x10ml PBS1A' (centrifugations at 800g for 5min). The cells were
then resuspended in 2ml PBS'A' and divided into two aliquots. One
sample (EA) was pelleted and stored at 4°C until required. 1ml of
a 1/80 dilution ( double the end-point for the lysis of antibody-
coated erythrocytes) of fresh human serum (obtained from the same
donor - Group A, Rh -i-ve, - throughout the study) in PBS'A1 was added
to the second tube, which was incubated at 37°C for 30min. The cells
(EAC) were then washed three times in PBS'A', and the cell pellet
resuspended in 5ml buffer. Before use, the antibody-coated red cells
(EA) were brought to room temperature, and 4ml PBS'A' added , to
give a final VI suspension.
For each test the following mixtures were prepared in round-
bottomed glass tubes (50x8mm) :-
50j-il lymphocyte suspension +
a) 50p.l V/o suspension of uncoated sheep red cells E Control
b) 50j-il 1% suspension sheep red cells coated with antibody
EA Control
c) 50j_il V/o suspension sheep red cells coated with antibody and
human complement EAC Test
Immediately after mixing the suspensions were centrifuged at 200g for
5min, and incubated in a 37°C water bath for 20min.
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The majority of the supernatant medium was removed and replaced
by an equal volume of 0.1% v/v eosin in saline. The cells were
resuspended by vigorous vortex mixing. A drop of the suspension was
placed in a mirrored haemacytometer, under a thin coverslip. The
cells were classified as rosettes using the same criteria as for
T cell rosetting. The E control repeatedly showed no rosettes, and
was eventually abandoned. The EA control occasionally showed 1-5%
rosettes.
The reproducibility was similar to that for T cell rosetting.
Scanning Electron Microscopy (See p.130 )
Mate rials
Solution A












Cells for examination by scanning electron microscopy (SEM),
were resuspended in tissue culture medium at a high concentration
e.g. greater than IxlO^/ml. Using a wide-bore Pasteur pipette,
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5-10 drops of the cell suspension were put into 10ml fixative at 37°C.
This suspension was incubated for Ih at 37°C, and then transferred
to a 4°C refri gerator, at least overnight, before further processing.
Supernatant fixative was removed, and the cells suspended in
10ml cacodylate wash, at room temperature, for 30min. The cells were
then pelleted by centrifugation at 800g for lOmin, and then trans¬
ferred successively through 30min incubations in cacodylate wash :
distilled water (1:1), distilled water, and 25%, 50%, 75%, 80%, 95%,
100% (two changes) v/v acetone in distilled water. The final cell
pellet was resuspended in approximately double its own volume of
100% acetone, layered onto glass coverslips, under absolute acetone,
and dried in a critical point drier. The coverslips were mounted
onto aluminium specimen stubs with Araldite Rapid, gold coated in
a sputter coater, and stored under vacuum in a dessicator.
Preparations were examined, and photographed, on a Cambridge
Stereoscan (Model: 180) scanning electron microscope.
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Results
T Lymphocyte Concentration prior to Hyperthermia The pre-treatment
concentration of peripheral blood T lymphocytes in 14 hyperthermia
patients (80^, Mean age 52.6 years, Range 23-75 years) was compared
with that in 31 normal controls (17(7, Mean age 31.0 years, Range 17-
55 years). Statistical analysis was performed using the Student's
t test. Although the mean level in patients was slightly lower
(1.16x10^ T cells/ml against 1.34x10^/ml for normals), the difference
was not statistically significant. There was also no significant
difference in the percentage of E-rosetting lymphocytes in the two
groups.
T Lymphocyte Concentration during and after Hyperthermia Treatment
The response of T lymphocytes to hyperthermia treatment was measured
in 14 patients (9(?, Mean age 52.6 years, Range 23-75 years)
(Tables B4 and B 5). Statistical analysis v/as performed on the
concentrations (before and after logarithmic transformation, to
correct for any possible skew distribution of the data), using the
Student's t test for paired samples, p values of less than 0.05
were considered significant.
Prior to treatment the T cell concentration varied widely
between patients, however, during heating, it fell significantly
(p«=0.01) in 78% of cases, to approximately 75% of the pre-treatment
level. (The figures presented in this section were obtained after
omitting patients H.A. and E.C. from the analysis - the reason for
this will be described later). This decrease was apparent in
both the original and 1og-transformed data. Within 24h of hyper¬
thermia, the mean T cell concentration had increased to 86% of the
















































































































































































































































































































































































EFFECTOFHYPERTHERMIATR ATMENTNCONC NT ATIONFLYMPHOCY ESEX RESS DAPERCENT GETP -TR MENTVALU *Statisticallysignif antbyStudent'stesopaired,log-transformed,v lu s.B/T=lo dran fu ion.
There was a further rise, in most patients, during the following
2-4 days, which resulted in a net increase in the concentration
over the pre-treatment value. Any such 'peak' was n: longer
apparent by 7-9 days after hyperthermia, when the concentration
had fallen to 87% of the pre-heating value.
Similar decreases in T cell concentration, during heating,
were seen in the smaller number of patients receiving second and
third treatments (Figure B3), however, they were only statistically
significant (p«;0.02) during the second treatment. The return to
pre-treatment values was again seen within 24h, but there was no
indication of a 3 day 'peak' in numbers.
While most patients followed this trend, there were some
marked exceptions. The T cell concentration rose during heating
in several patients (notably H.A. and E.C.). This was due to an
atypical increase in the concentration of peripheral blood
lymphocytes, rather than in the percentage of E-rosette forming
cells. Similar increases were seen during subsequent treatments
of these patients. The following day both H.A. and E.C. showed
falls in T cell numbers (which, in some cases,were very substantial)
often to below the pre-treatment level, with recovery within 7-9 days.
Due to their persistantly atypical responses, statistical analysis
was performed both omitting, and including, these patients. Their
inclusion masks the fall in T cell concentration during the second
and third treatment, but indicates that there may be some slight
lymphopenia persisting after hyperthermia. This is supported by
the data from the other patients, but is not statistically
significant.
Only one (E.C.) of the two omitted patients showed atypical
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FTGIIRF B3
EFFECT OF SUCCESSIVE HYPERTHERMIA TREATMENTS ON THE PERCENTAGE
AND CONCENTRATION OF PERIPHERAL BLOOD T LYMPHOCYTES
IN THREE PATIENTS
and absolute lymphocytosi s, during her first treatment. During the
second treatment, the lymphocytosis was associated with an increase
in the total leucocyte concentration. This patient died of a
pulmonary embolism four days after her second hyperthermia fraction,
and, on post mortem, there was evidence of massive tumour necrosis.
This was taken as indicative of a positive response to therapy. The
only other clinically responsive patient studied, using this assay,
was A.W.. In contrast to E.C., he displayed the 'typical' pattern
of T lymphopenia during hyperthermia, but it is interesting to note
that he had by far the highest pre-treatment T cell concentration,
although this was rapidly depressed by hyperthermia therapy (Table
B 4 ).
In most cases, a course of treatment did not substantially
affect the concentration of peripheral blood T lymphocytes, and
there was no apparent correlation between any changes, and the
response to treatment, or survival time.
Piscussion
In contrast to previous studies (Table B 1 ), there was no
evidence of depressed T cell numbers in these cancer patients,
prior to hyperthermia, in comparison with the normal control group.
This was probably not due to the difference in the mean ages of
these groups. Teasdale et al (1976) reported a fall in the
percentage of rosetting cells with increasing age, and as the patient
group in this study was significantly older than the controls,
this should, if anything, reduce the slight difference in T cell
numbers between the two groups. Alexopoulos and Babitis (1976)
also note a progressive decline in the T cell concentration with
increasing age, due to a reduction in lymphocyte numbers in
elderly subjects. Again this should further reduce the small
difference between the cancer patiencs and normal control group
in this study.
It is, however, notable that, whereas T cell concentrations
below 1.0xl0^/ml peripheral blood were seen in only 19% of normal
subjects, they occurred in 50% of the patients. Data available
for four of the seven T-lymphopenic patients, indicated that they
tended to have reduced survival times following treatment (three
survived a mean of 22 days, however, the fourth survived for over
200 days) in comparison to the remainder (data is available for
five patients, mean survival time 150 days, range 11-485 days).
It is possible that a longer study may reveal a more widespread
depression of T lymphocyte numbers in these subjects, similar to
that previously reported in cancer patients. However, since all of
the hyperthermia cases had received other forms of treatment, their
increased incidence of T lymphopenia may not be attributable to
cancer, but rather to the residual effects of previous therapy.
This is supported by studies which have shown that radiotherapy
produces a marked T lymphopenia (Stefani, Kerman & Abbate, 1976 ;
Raben et al, 1976 ; Anderson & Warner, 1976) which may last for up
to a year (Stjernsward et al, 1972). In this study, one patient
(T.M.) had had recent radiotherapy, and this may have been reflected
by his continued T lymphopenia throughout the investigation (Table
B4). It is likely that similar changes may occur following surgery,
chemotherapy, anaesthesia and medications, and few studies that
report T lymphopenia in cancer patients, have taken account of this.
In summary, the investigation on pre-hyperthermia cancer
patients, indicated that, as a group, they had normal relative and
absolute T cell numbers, but that there was an increased incidence
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of T lymphopenia. The reason for this is not clear. In addition,
those patients with decreased T lymphocyte counts tended to
have reduced survival times, in comparison with the remainder.
The fall in the peripheral T cell count during hyperthermia
is due largely to a decrease in the percentage of rosetting cells,
since the total lymphocyte concentration is unaffected by treatment
(See p. 82 ). A similar phenomenon has been reported
in healthy subjects subjected to temperatures of 38.8°C (Bork-
Wolwer et al, 1977). In contrast, Fabricius et al (1977) described
only slight changes in T cell numbers during Ih of 40°C hyper¬
thermia. Neither group found changes in the total lymphocyte
count, and Fabricius et al indicated that there was no change in
the peripheral leucocyte concentration, during and after heating.
In the only other study on cancer patients, DeHoratius et al
(1977) found no statistically significant changes in the proportion,
or total number, of T cells, following 2h at 42°C, in three patients.
Nonetheless, in the two treatments they studied in which cytotoxic
drugs were not given, the concentration of T cells fell to 53% and
63% of the pre-treatment. values. This was mainly due to a fall in
the total lymphocyte count, although the percentage of E-rosetting
cells also fell by 20% in one case. In the two treatments in which
chemotherapy was given, the T cell concentration rose, but there
were slight falls in the percentage of rosette forming cells.
However the small number of patients studied,makes this report
difficult to evaluate.
The results from this study, taken together with those from
other workers, suggest that T lymphocyte concentrations are depressed
by whole-body hyperthermia. This is probably not due to the effects
of anaesthesia, since the normal subjects treated by sub-41°C heating
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were unanaesthetised. It is possible that the changes may be due to
a stress reaction, similar to that affecting the total leucocyte
concentration (See p. 87 ). It is known, for example, that Cortisol
levels affect T cell function (Tavadia et al, 1975 ; Zeman et al,
1972), and Steel et al (1974) have reported that the ratio of T to
B lymphocytes is decreased following strenuous exercise. This may
be due to elevated steroid levels, and they concluded that the
majority of rapidly-mobilised cells were B lymphocytes. Their
data, however, indicated that the decrease in T cell numbers was
only relative, their concentration remaining largely unaffected.
In contrast, the results from the hyperthermia patients indicated
a decrease in both the percentage and concentration of T cells. In
addition, in the patients, the lymphocyte concentrations did not
change significantly during heating, whereas the drop in E-rosetting
cells, described by Steel, was accompanied by a marked lymphocytosis.
These observations would argue against a steroid-mediated depression
of T cell concentration. The stability of the total lymphocyte
concentration during hyperthermia also suggests that the changes
are not due simply to haemodi1ution. Whilst the medications given
during treatment may contribute to the fall, it was concluded that
the most likely cause was the increased body temperature.
Experiments involving heating in vitro, were carried out
to test this hypothesis (See p.116 ).
Concentration of 'Active' or 'Rapid-Rosetting' T Lymphocytes before
and after Hyperthermia Treatment The concentration of peripheral
blood 'rapid-rosetting1 T cells has been reported to correlate more
closely with clinical status, and prognosis, that that of total T
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lymphocyte concentration (Wybran & Fudenberg, 1973 ; Cochran et al,
1976). This assay was carried out on two patients (L.T. and T.M.)
towards the end of this study.
Prior to treatment, the percentage of rapid-rosetting cells
was 70.8% and 49,3% in T.M. and L.T. respectively. In a group of
five, unmatched, normal controls, the mean percentage (t 1 S.D.) was
41.7% (t 11.2).
T.M. was given radiotherapy between hyperthermia fractions,
and so the test was performed only at the beginning and end of
each heating session. During each of four fractions, the active T
cell concentration fell to 54-92% of the pre-treatment value. This
was associated with a fall in the percentage of rapidly-rosetting
cells to between 53% and 70% of the pre-treatment percentage. During
the full course of treatments, there was a progressive decline in
both the percentage, and concentration of these cells, probably
reflecting the effects of the radiotherapy. There was a sudden
marked increase in the percentage of rapidly-rosetting cells
between the fourth and fifth treatments, and examination of the
separated lymphocytes, showed a very high granulocyte contamination
(33%). This emphasises the need to determine the separation
purity for each test, as it appears that, in this assay, it is
easy to confuse immune adherence, prior to phagocytosis, with
rapid-rosette formation.
The second patient, (L.T.) showed falls in active T cell
concentration during both treatments, to 74% and 66% of the pre-
treatment values. This depression was still apparent the following
day, and was deepened by a blood transfusion, but within 5 days,
the concentration had increased to 151% of the pre-hyperthermia
level. This was due to an increase in both the total lymphocyte
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concentration, and the percentage of rosetting cells. Following the
second treatment, the resulting active-T lymphopenia was still
evident four days later. As these are recent findings, the clinical
response of the patients to treatment, has yet to be determined, and
so it is not possible to relate these results to prognosis.
Discussion
The fall in concentration of rapid-rosetting cells is at
variance with the findings of DeHoratius et al (1977), who
reported significant increases in both the percentage, and the
number of the cells during hyperthermia. They liken this increase
to that in cancer patients responding to treatment with transfer
factor (Levin, Byers & Fudenberg, 1975). They do not, however,
indicate the purity of their end-of-treatment lymphocyte suspensions.
This is a most important parameter in this assay, since these
cell populations tend to contain higher proportions of granulocytes,
which may be erroneously classified as rapid-rosette-forming cells.
In the absence of literature on the effects of radiotherapy,
anaesthesia etc. on rapid-rosetting lymphocytes, it was felt that
the changes seen in these patients, since they were similar to
those occurring in the total T cell population, were probably
primarily the result of the increased body temperature. This
was examined in a series of experiments in vitro.
Effect of Heating Blood in vitro on the Percentage of T Lymphocytes
The effect of heating whole blood in vitro at 42°C on the percentage
of E-rosette-forming lymphocytes is shown in Figure B4 . In every
case, the percentage was depressed by heating at 42°C, but unaffected,
or slightly increased, in blood kept at 37°C. The effect of the
same heatdose,on different blood samples, varied widely, but the
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EFFECT OF HEATING WHOLE BLOOD IN VITRO ON THE
E-ROSETTE FORMING CAPACITY OF THE CONSTITUENT
LYMPHOCYTES
Lymphocytes were separated from heated blood and
rosetted overnight at 4°C. See text for details.
magnitude of the decrease was, in general, related to the duration
of heating.
Blood heated at 39°C, or at 40OC> for 2|h, showed an intermediate
depression of the percentage of E-rosetting cells. The viability
of lymphocytes from heated blood was routinely greater than 95%, by
dye exclusion.
To determine to what extent the fall in T lymphocyte concentr¬
ations seen in vivo, was due to raised body temperature, rather
than to medications etc., an in vitro/in vivo experiment was set up.
Blood was taken from a patient (K.S.) immediately before
treatment, defibrinated, and split into three aliquots. One sample
was used at once to determine pre-hyperthermia T cell concentration.
The remaining samples were sealed in plastic tubes, one of which
was incubated in a water bath at 37°C, and the other was inserted
into the patient's rectum. The blood in this tube was exposed to
the elevated body temperature, but not to the drugs etc., used
during treatment. At the end of hyperthermia, an end-of-treatment
blood sample was taken, and used to determine the post-treatment
T cell concentration. The percentage of resetting cells in the
rectal, and control tubes was also measured.
Prior to treatment 50.8% of lymphocytes formed E-rosettes,
this fell to 31.5% during hyperthermia treatment. Pre-treatment
blood kept at 37°C contained 55.7% resetting cells, but blood from
the rectal tube contained only 25.4% T lymphocytes. The viability
of all the separated cell suspensions was greater than 95%.
Effect of Heating Isolated Lymphocytes in vitro on the Percentage of
T cells The effect of heating a suspension of normal lymphocytes
in vitro at 42°C (See p.104 ) on the percentage of E-rosetting
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EFFECT OF HEATING LYMPHOCYTE SUSPENSIONS IN VITRO
ON THEIR E-ROSETTE FORMING CAPACITY
Heated lymphocytes were washed once and rosetted
overnight at 4°C. See text for details.
cells is shown in Figure B5 . Heating at 42°C resulted in a
marked decrease in rosetting lymphocytes (in the absence of any
fall in cell viability, as detected by dye exclusion^, whilst
there was no change in the control suspensions, incubated at
37°C. The depression was directly related to the heat dose, and
was similar in magnitude for lymphocytes from various donors. It
could not be produced by incubating cells for 2-|h at 37°C in medium
which had previously been heated at 42°C.
Typical results, from a more detailed study of shorter-term
incubations at 42°C, are shown in Figure B6. The decrease in the
percentage of E-rosetting cells was still apparent, however, in
general, the percentage did not fall below 30% during IBOmin at
42°C. There was also evidence of cycling of the percentage about
this value. It is unlikely that this is an artefact due to
technical variations in setting up the tests, as all the conditions
were rigorously standardised, and there is no evidence of
cycling in the control suspension incubated at 37°C. The phenomenon
was more marked in some lymphocyte suspensions than in others.
These results all point to the heat sensitivity of the T
cell, which was more apparent when isolated lymphocytes were
heated in medium + serum, rather than in whole blood. Cells
heated in suspension, for 2|h at 42°C, and then incubated in
autochthonous serum for Ih at 37°C, showed no increase in rosetting
capacity. Lymphocytes incubated for 15min in medium + foetal calf
serum, at 37°C or 4°C, following heating at 42°C for 15-150min,
showed some evidence of recovery of rosetting ability, as indicated
by a 0.5-15.5% increase in the percentage of rosette-forming cells.
However, this recovery was not always observed, and in some cases,
post-42°C incubation resulted in a fall (ranging from 0.5-7.0%) in
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EFFECTOFPRE-HEATINGISOLATEDLYMPHOCYTESINVITROONTH IRABILITFO MSPONTANEOUSR S TTESW SHEEPORR ESUSMONK YE YTHROCYTE
Pointsshownaremeanftriplicatsa ples.Thst ndarddeviationss wnartypicalofhof rp i ts. Lymphocyteswerpre-incubatedathtemperat resshownandros t dove n ght.St xtfd t ils
the percentage of E-rosetting cells. Where recovery was apparent,
its magnitude could net be related to the heat dose which the cells
had received.
There was some indication that heating isolated lymphocytes
in suspension in autochthonous serum, rather than medium, had a
less deleterious effect, as indicated by an increased percentage of
rosetting cells e.g. lymphocytes heated in autochthonous serum for
2|h at 42°C contained 53% rosette-forming cells, whereas the same
lymphocytes, heated in medium + foetal calf serum, contained only
33% rosetting cells - the suspension kept at 37°C contained 69%
rosetting cells.
Rosetting between human lymphocytes and rhesus monkey
erythrocytes (EM-rosette formation) has been reported to be a
T cell phenomenon (Lohrmann & Novikovs, 1974). In contrast to
the E-rosette assay, it is believed to be unaffected by the
temperature of incubation during rosetting (Lohrmann & Novikovs,
1974 ; Gali1i & Schlesinger, 1975). This system was investigated to
determine whether it was affected by pre-heating of the lymphocyte
suspension.
The percentage of cell forming EM rosettes (33.3%~67.5%) was
consistently below that forming E-rosettes. However, in marked
contrast to the results with sheep erythrocytes, EM rosette-formation
was not affected by the pre-incubation of the lymphocytes at either
42°C, or 37°C (Figure B6). There was some evidence of cyclic
variation of the percentage of rosetting cells around the control
value.
In parallel experiments, the percentage of E-rosetting cells
in a lymphocyte suspension, decreased during heating at 42°C, until
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it reached a level similar to the percentage forming EM rosettes.
The E and EM rosetting populations then cycled synchronously
(Figure B 6 ).
In an attempt to identify the EM-rosetting lymphocytes, purified
T and 'B1 cell populations were used. These were produced by
centrifuging a suspension of lymphocytes, which had been rosetted
with sheep erythrocytes for 3-4h at 4°C, on a Ficoll-Hypaque
gradient. The denser, rosetted T lymphocytes were collected as the
cell pellet, and the adherent sheep erythrocytes lysed with Tris-
buffered Ammonium Chloride. The unrosetted 'B1 lymphocytes were
retained at the Ficoll-Hypaque interface and were removed and
washed in medium, before use. This purification process produced
populations containing 1.75-14.50% E-rosetting (B enriched) and
80.5-81.2% E-rosetting (T enriched) cells. The number of EM-rosetting
lymphocytes, however, was similar in both populations e.g. 58.5% in
a 'B'-ertriched fraction (containing 1.75% E-rosetting lymphocytes)
and 56.5% in a T-enriched fraction (containing 80.5% E-rosetting
lymphocytes). This indicated that EM rosette formation was not
restricted to either T or B lymphocytes.
Effect of Heating Isolated Lymphocytes in vitro on the Percentage of
Rapid-Rosetting T cells The effect of heating whole-blood in vitro
on the proportion of rapid-rosetting lymphocytes, was not determined.
Heating isolated lymphocyte suspensions had a similar effect to
that described for total E-rosetting, namely, a substantial depress¬
ion , within 2h at 42°C. The effect was more severe than that
seen with E-rosetting, in that fewer than 10% of lymphocytes formed
rapid-rosettes after heating for 2h. Pre-incubation of the
lymphocytes at 37°C, for up to 2|h, has no effect on rapid rosette
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formation (Figure B7).
Parallel experiments in which rapid and E-rosetting tests were
carried out on the same heated lymphocyte suspension, confirmed the
increased heat sensitivity of the rapid-rosetting cells e.g. after
2h at 42°C the E-rosetting population fell to 76% of the pre-heating
value, whereas the rapid-rosetting population had declined to 32%.
If heated (15-150min at 42°C) lymphocytes were incubated for
15min at 37°C or 4°C, in medium + foetal calf serum, there was a
variable effect on their rosetting ability. This ranged from a
15% increase in the percentage of rosetting cells, to a 16% decline.
No clear trend to these changes could be discerned.
Rapid-rosetting with rhesus monkey erythrocytes was examined
in two experiments. In both cases, the proportion of rosetting
cells was not affected bv the pre-incubation of the lymphocytes
at either 37°C or 42°C. Experiments involving parallel rapid -
rosetting with sheep and monkey erythrocytes, using the same lympho¬
cyte suspension, produced similar results to those tests with
overnight rosette formation (as shown in Figure B6), i.e.
a decline in the proportion of rapid-rosetting cells to a level
similar to that forming rapid-EM rosettes (="20%). There was also
evidence of cycling around this value.
Piscussion
These results indicate that T lymphocytes are sensitive to
temperatures of 42°C in vitro, as indicated by their decreased ability
to form rosettes with unsensitised sheep erythrocytes. Since this
marker may be an indicator of T cell function (Small, 1975), it is
likely that heat also depresses T cell mediated cytolysis, and
indeed, this has been reported by Harris (1976).
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The temperature sensitivity of the incubation procedure during
rosette formation has been noted previously, but reports on the
effect of pre-heating the lymphocytes, are less common. Coombs et al
(1970), and Mendes et al (1975) found that heating normal lympho¬
cytes for Ih at 45°C, had little effect on their viability (as
assessed by dye exclusion), but abolished E-rosette formation.
Neither study included a control suspension kept at 37°C. Roszman,
Brooks and Muse (1977) reported that pre-treatment of the lymphocytes
by incubation at 37°C for 30min, in medium (t foetal calf serum)
significantly decreased their rosetting ability. However, longer
incubations resulted in a return to normal levels.
In this study, pre-incubation of lymphocytes at 37°C consist¬
ently had no effect on the percentage of E-rosette, or rapid-
rosette, -forming cells. The results are generally in agreement
with those of Coombs et al and Mendes et al, although abolition
of rosetting was not seen, even after heating lymphocytes in whole-
blood at 42°C for 4h.
There is some indication that the thermosensitivity of the
cells could be increased by using conditions which progressive'ly
departed from those pertaining during hyperthermia in vivo.
Heating of the 'same' blood sample in vivo and in vitro, in the
rectal tube experiment, showed that isolation from the peripheral
circulation, during hyperthermia treatment, resulted in a larger
fall in the T cell percentage, than that seen in vivo. In
addition, heating isolated lymphocytes in suspension, depressed
rosetting capacity more than heating cells in whole blood. This
suggests that lymphocytes in blood are either 'buffered' against,
or can recover from, thermal effects. The results from this study
favour the former explanation, since heating at 42°C had less effect
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on lymphocytes in autochthonous serum, than in medium + foetal
calf serum. Also, pre-heated cells showed no recovery of rosettinj
capacity following incubation in autochthonous serum at 37°C, although
there was some slight increase in rosette formation, after incubation
in medium + foetal calf serum, at 37°C and at 4°C, suggesting that
the damage is not completely irreversible. This shows some
similarity to the results obtained by Roszman et al, who found
that the decrease in rosetting capacity produced by pre-incubating
lymphocytes at 37°C, in medium + foetal calf serum, was not seen if
human autologous, or autochthonous, serum was added to the medium.
The nature of the cyclic variation in the proportion of
rosetting cells, during heating, is not understood. Conditions
were chosen which minimised technical variation during replicate
assays, however, these cannot be totally excluded. It is possible
that the increases in rosetting represent resynthesis, or recovery,
of E receptors following thermally-induced deformation, but it is
difficult to explain why this should occur while the cells are still
at elevated temperatures. If the variations are due to receptor
resynthesis, it is possible that the process can occur at 42°C,
but becomes increasingly inhibited during prolonged exposure.
Any theory on receptor resynthesis must be balanced by the
observation that the process was not apparent when cells were
incubated in medium at 37°C or 4°C for 15min, after heat exposure,
Mendes et al have reported a return of rosetting capacity in
heated (lh at 45°C) lymphocytes incubated in human serum, and have
postulated that E receptors are readsorbed onto the cell surface.
If this is the case then the dilution of cells, during the post
heating incubation (resulting from the addition of the cell suspension
to an equal volume of medium at the appropriate temperature) in
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these experiments, may have resulted in a reduction in the concen¬
tration of shed receptors, and an associated reduction in the effic¬
iency of readsorption. This would no+ explain the lack of recovery
of rosetting capacity seen after heated (2§h at 42°C)cells were incubated
in autochthonous serum (Ih at 37°C), although it is conceivable
that the effects of this size of heat dose, are irreversible.
There is no real evidence from Mendes' work that the receptors
are shed from the cell surface during heating, it is possible that
they are deformed by the heat, so that rosette formation is no
longer possible, and that the recovery is due to the reversal of
this process, rather than to the readsorption of complete receptors.
This could explain the lack of recovery seen in these experiments,
where the conditions may not have been suitable for the receptors
to recover within the 15min allowed. It is also likely that
the severity of receptor deformation is related to the heat dose,
so that the lack of recovery, seen when heated lymphocytes were
incubated in autochthonous serum for Ih, may have been due to
irreversible damage to the surface receptors, during 2|h heating.
Although the results indicate that the effects of heat on
E-rosetting and rapid-rosetting cells, are broadly similar, it
would appear that the latter are more thermosensitive, in that
the decrease in their rosetting capacity was greater (usually to less
than 10% rosetting cells). Assuming that rapid-rosette formation
detects a subpopulation of T cells, then it is possible to explain
much of the decrease in E-rosette formation, during heating, to a
selective effect on the rapid-rosetting fraction. If this is
indeed the case, it may be of clinical importance, since changes in
the concentration of these cells are believed to be of value in
predicting prognosis etc.
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The tests involving rosette formation with rhesus monkey
erythrocytes, are difficult to interpret. The results indicate that
this phenomenon is not an exclusive nrrker for T cells, but possibly
detects another lymphocyte subpopulation. This is at variance with
the findings of Lohrmann and Novikovs, who indicated that the EM
receptor was present in an accessible form only on T cells. However
they did demonstrate EM-rosette formation with Vibrio cholerae
neuraminidase-treated human B lymphocytes. Pellegrino, Ferrone and
Theofilopoulos (1975) found that rosette formation between human
lymphocytes and erythrocytes from a different species of monkey
(the Japanese ape, Macaca speciosa) was a marker for B cells.
These studies may be open to a different interpretation, as
indicated by this study. Certainly some EM-rosetting cells are
T lymphocytes by the criterion of E-rosette formation, and will
therefore have thermostable EM-receptors; but it is not clear
whether these same cells are those responsible for the apparently
thermoresistant tail of the E-rosetting population. The fact that
the E--rosetting population declines during heating, to a pro¬
portion similar to that forming heat-stable EM rosettes, indicates
that the same cells may be involved, and that rosette formation
with rhesus monkey red cells may be an indication of thermo¬
resi stance.
In summary, heating whole blood, or isolated lymphocytes,
in vitro, results in a decline in the proportion of T cells, as
detected by both E-rosette and rapid-rosette formation. The effect
is more severe on lymphocyte suspensions, indicating some thermo-
protection by whole blood. Rapid-rosette-forming T cells have
greater heat sensitivity than the E-rosetting population as a
whole, suggesting that the T lymphocyte population may be composed
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of various subpopulations, differing in their thermal tolerance.
This ir reinforced by the heat stability of EM-rosette-forming
lymphocytes. These cells are neither exclusively T or B lymphocytes,
by conventionally-accepted markers, and may represent a thermo-
resistart third population, whose clinical significance remains
to be established.
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B Lymphocyte Concentration prior to Hyperthermia B cell concen¬
trations in 7 patients (3 d1, Mean age 55.0 years, Age range 35-
75 years), prior to hyperthermia treatment, were compared with
those of 10 normal controls (2c?, Mean age 32.2 years, Range 20-
55 years).
The mean concentration of B lymphocytes in the patients was
5
2.97x10 cells/ml peripheral blood (S.D., 2.97) and the mean per¬
centage of EAC-rosetting cells was 19.8 (S.D., 12.5). In the control
5
group, the mean concentration was 3.33x10 cells/ml (11.61), and the
mean percentage was 17.0 (±5.99).
None of these differences was statistically significant by
the Student's t test.
B Lymphocyte Concentration during and after Hyperthermia Treatment
B lymphocyte concentrations in the peripheral blood, v/ere monitored
in the same 7 patients, during and after treatment. The results
are shorn in Tables B6 and B 7. Statistical analysis was
performed as for the data on T cell concentrations.
During hyperthermia the concentration of B cells increased in
the majority of patients. Although this increase was often
substantial, it was only statistically significant (p«=0.02 -log. data)
the second treatment. In general, there was a return to the pre-
treatment level within 24h, with some indication of an undershoot
after the third treatment. The concentration remained essentially
unchanged (with respect to the pre-hyperthermia level) 3-9 days
following heating. This pattern was repeated during subsequent
treatments (Figure B8)
Effect of Heating Blood in vitro on the Percentage of B Lymphocytes
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EFFECT OF SUCCESSIVE HYPERTHERMIA TREATMENTS ON THE PERCENTAGE
AND CONCENTRATION OF PERIPHERAL BLOOD B LYMPHOCYTES
IN TWO PATIENTS
on their EAC-rosetting capacity was examined. In two cases there
was no significant ch nge in the percentage of rosetting cells after
2|h heating at 42°C. In the remining two experiments, the same
heating conditions, resulted in the reduction of the percentage of
rosette-forming cells by one half.
Piscussion
Although the study on the pre-hyperthermia B cell concentration
was small, the findings are in general agreement with those of
Heier et al (1977). This showed no significant difference in B
cell numbers between cancer patients and normals, but indicated that
the range of the concentrations was wider in the patient group.
The results obtained during treatment, indicate that hyperthermia
therapy produces a substantial B lymphocytosis, similar to that
seen in sub-40°C heating, in normal subjects (Bork-Wolwer et al,
1977). DeHoratius et al (1977), did not observe an elevation of
B cell concentration, although all of their patients showed an
increase in the percentage of EAC-rosetting cells, during 2h of
42°C hyperthermia.
It is possible that the increase seen in hyperthermia patients
is similar to the exercise-induced increase, reported by Steel
et al (1974), which occurred during an associated lymphocytosis.
In most of the patients, however, there was no increase in the
concentration of peripheral blood lymphocytes during hyperthermia,
and the changes seen would have to be at the expense of the T
lymphocyte population, as reported by Bork-Wolwer.
It is felt that a more likely explanantion of these changes,
is variation in the purity of the lymphocyte separation. The per¬
centage of EAC-rosetting cells, in most patients, was low prior to
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treatment, and could be greatly increased by the mistaken inclusion
of a few non-B cell ro,ettes. This was very likely to occur at.the
end of treatment, because the neutrophilia makes it difficult to
separate a >97% pure lymphocyte population. The contaminating
polymorphs and monocytes have complement receptors, and will
therefore, form rosettes with EAC cells, thus falsely increasing
the B cell percentage, and hence the concentration. In addition,
in some cases, erythrocytes coated with antibody alone, also formed
rosettes, indicating the presence of cells with Fc receptors, and
also complicating the B cell count.
The results from the experiments in which whole blood was heated
in vitro, were also confusing, but probably indicate a slight
depression of B cell rosetting by heat. In an attempt to overcome
the problems with this assay, an immunofluorescence technique, for
detecting surface immunoglobulin, was used. This procedure
proved to be too lengthy, however, for use on samples from the
hyperthermia patients, and was therefore discontinued.
In summary, the concentration of B lymphocytes is increased
by hyperthermia treatment, and returns to the pre-heating level
the foil lowing day. It is not certain, however, that this increase
is real, since the assays used, could be heavily biased by the
presence of a small number of contaminating monocytes or
neutrophils.
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Effect of Heating in vitro on Lymphocyte Morphology The effect of
heat in vitro on the surface morphology of lymphocytes was assessed
by scanning electron microscopy.
Cells were heatea at 42°C for 2|-h, either in whole blood, or
as an isolated suspension in tissue culture medium. Lymphocytes
heated in blood were separated using the standard technique, and
processed for SEM examination, as described in the Methods (See p.107).
Heated lymphocyte suspensions were centrifuged at room temperature
(800g for 5min) and resuspended in less than 1ml of the supernatant
medium, prior to fixation at 37°C. Control lymphocytes were
obtained from unheated blood samples, or suspensions kept at 37°C.
Lymphocytes from control preparations were uniformly spherical
in shape, with a mean diameter of 4.4pm. The surface of most cells
was covered with short, blunt microvilli, the number of which varied
widely from cell to cell (Figure B9).
Following heating, either in blood, or in suspension, there
were rio marked changes in the size or appearance of the lymphocytes.
There was an indication that heated cells were somewhat less micro¬
villous, the surface membrane appearing 'rucked' or folded (Figure BIO).
In spite of this, some highly-microvillous forms were still seen in
the heated suspensions.
Piscussion
Temperature-induced changes in leucocyte morphology, as studied
by SEM, have been reported previously (Lichtman et al, 1976). However,
in most cases, they have been reported to occur at temperatures outside
the 30-42°C range. The results from this study are in agreement with
those of Lin, Wallach and Tsai (1973), who found that there were few
changes in lymphocyte surface morphology between 37°C and 44°C. Above
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FIGURE B9
SCANNING ELECTRON MICROGRAPH OF PERIPHERAL BLOOD
LYMPHOCYTES INCUBATED IN VITRO FOR 2Jh AT 37°C
(Magnification x7,300)
FIGURE BIO
SCANNING ELECTRON MICROGRAPH OF PERIPHERAL BLOOD
LYMPHOCYTES INCUBATED IN VITRO FOR 2|h AT 42°C
(Magnification x8,700)
44°C, the alterations which they observed showed a similar trend to
those produced by heating isolated cells at 42°C for 2§h, namely, a
decrease in the number of microvilli. This occurred .ery rapidly
(within 2min) at 47°C, and was much more severe than that seen in this
study. These changes were attributed to alterations in the membrane
proteins, and may reflect a change in the activity of the cells.
Polliack et al (1976) noted an increase in the number of surface
villi on mouse thymic lymphocytes, which had been activated by
incubation with Concanavalin A; a decrease in their number may
therefore indicate a reduction in the functional integrity of
lymphocytes. However Polliack reported that non-microvillous forms
predominated in the circulation, and that these were probably T-
lymphocytes, in contrast, in this study, the majority of unheated
lymphocytes possessed surface villi. This is in agreement with the
work of Firket and Schaaf-LaFontaine (1976), who believed that the
position of the cells in the blood or tissues, during the hours
prior to fixation, considerably influenced their surface morphology,
which could not therefore be used to distinguish between T and B-
lymphocytes. In this study, the same cell population was examined
before and after heating, and so the changes cannot be explained on
this basis. It is known that the method of fixation and preparation
can affect the appearance of the cell surface, and although this may
be partly responsible for the changes seen here, it is felt that there
was some small direct effect of heat on lymphocyte morphology in this
study. A reduction in the numbers of surface villi has been described
during lymphocyte culture, but it is less severe if PHA is added to
the culture medium (Firket & Schaaf-LaFontaine, 1976). The tendency
for lymphocytes to have fewer surface structures after heating at 42°C
for 2|h, may therefore be related to the reduction in their capacity
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to form E rosettes (See pi20) and to respond to PHA (See p. 154)
PAPER C
THE EFFECTS OF WHOLE-BODY HYPERTHERMIA THERAPY ON THE
LYMPHOCYTE RESPONSE TO PHYTOHAEMAGGLUTININ
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The Effects of Whole-Body Hyperthermia Therapy on the
Lymphocyte Response to Phytohaemagglutioi n
Introducti on
Contact between a T lymphocyte and an antigen, tc which it has
become specifically-sensitised, results in the transformation of the
cell into a proliferating lymphoblast. This transformation process
is associated with morphological changes, resulting in a large cell
with basophilic and pyroninophilic cytoplasm, virtually no rough
endoplasmic reticulum, abundant free ribosomes and prominant
nucleoli. Mitotic figures are often seen, and there is active
incorporation of DNA precursors. The cells are highly motile,
moving from the lymph into the peripheral bloodstream, and then into
the tissues, however, there is no evidence that they are attracted
to the target antigen (Roitt, 1974 ; Currie, 1974).
Lymphoblasts are the main effectors of cell-mediated immune
responses. They are able to lyse target cells bearing the antigen
to which they are sensitised. This has been demonstrated by tests
in vitro, in which tumour cells were killed by lymphocytes from
patients bearing cancers of the same histogenesis. It is believed
that the effector cells had become sensitised to the tumour-
associated antigen(s) in vivo, however there is, at present, no
clear evidence for tumour cell killing occurring in vivo, possibly
due to the abrogation of cytotoxicity by serum blocking factors,
e.g. antigen-antibody complexes, an effect which has been described
in vitro.
Due largely to methodological problems, and doubts concerning
the relevance of tumour cell cytotoxicity tests to the situation
in vivo, other methods have been developed to assay T lymphocyte
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activity. The commonest of these is the phytohaemagglutinin
transformation test.
Phytohaemagglutinir. is the generic name for the aqueous extracts
of the seeds of certain plant species, especially the bean Phaseolus
vulgaris. Its powerful erythrocyte-agglutinating properties made
it useful in the separation of leucocytes from whole blood (Li &
Osgood, 1949), however, in 1960 Nowell found that it induced mitosis
of lymphocytes in culture (Fig. CI). The gross morphological and
biochemical changes that it produced e.g. induction of increased
DNA synthesis (Cooper, Barkhan & Hale, 1961) were suggestive of
the action of an antigen upon a previously-sensitised cell (Elves,
Roath & Israels, 1963). It was proposed that PHA acted through the
normal immunological pathways of lymphocyte stimulation, but by¬
passed the early antigen-recognition stages (Coulson & Chalmers,
1964).
In 1966 Mills showed that the transformation of lymphocytes
by an antigen in vitro could be correlated with the delayed hyper¬
sensitivity reaction to that antigen in vivo. This suggested that
the reaction, in vitro, of a patient's lymphocytes to a non-specific
mitogen, such as PHA, may be indicative of the subject's cellular
immunocompetence. This has proved to be the case (Oppenheim, 1968).
The value of PHA tests in the assessment of cellular immune
status was reinforced when it was demonstrated that the mitogen
acted primarily upon the T lymphocyte population (Janossy & Greaves,
1971 & 1972). These observations were supported by the finding
of a diminished, or absent, PHA response in patients with congenic
thymic aplasia - DiGeorge's syndrome (Lischner, Punnet & DiGeorge,
1967). It now seems that this may be an over-simplification.




CYTOCENTRIFUGE PREPARATION OF HUMAN LYMPHOBLASTS
Blast cells were produced by incubating peripheral
blood lymphocytes with PHA for three days in vitro
U = Untransformed lymphocyte L = Lymphoblast
M= Lymphoblast in mitosis
May-Grunwald/Giemsa stained (Magnification: xl,100)
cultures of normal peripheral blood lymphocytes, bore surface immuno¬
globulin. They demonstrated that th1'*- was not a membrane component
of T cells, and was not passively adsorbed fromB lymphocytes during
the culture period. They concluded that human B cells were also able
to respond to PHA in conventional cultures. This was later confirmed
by Chess, MacDermott and Schlossman (1974), who found that more
than 90% of B lymphoblasts bore surface immunoglobulin, whereas blasts
derived from T cells were devoid of immunoglobulin. The action of
PHA is therefore not wholly restricted to T lymphocytes (although
it is possible that contaminating T cells may be responsible for
the responses noted in purified B lymphocyte populations (Han & Dadey,
1977)).
The situation has been further complicated by the observations
of Potter and Moore (1975) which indicated that pure T cell populations
responded less well to PHA than those containing a proportion of B
lymphocytes, or non-lymphoid cells. The degree of contamination
could have a critical effect upon the results (Potter & Moore, 1977).
In addition, Yachnin (1972) has shown that blastogenesis may be
affected by the presence of autologous erythrocytes, and platelets,
in the culture. These findings, combined with numerous different
techniques, and technical problems, make the critical evaluation
of this test rather difficult. Nevertheless it remains the
commonest method of monitoring cellular immunocompetence.
PHA tests have been used to study the influence of ageing
(Weksler & Hutterotes, 1974), renal failure (Hosking, Fitgerald
& Simons, 1971 ; Oppenheim, Blaese & Waldmann, 1970) etc. upon
the immune system, and to investigate various immunodeficiency
states. Perhaps the most extensive application however, has been
in the study of the effects of malignant disease upon immuno-
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competence. There is a large amount of literature on this subject,
but some of the more recent results are summarised in Table CI.
Differences in technique, make these studies difficult to
compare, but there are several general conclusions which can be drawn:-
i) The PHA response of fractionated peripheral blood
lymphocytes is usually depressed in cancer patients, in
comparison with both normal controls and patients with
benign disease.
ii) This impairment appears to be due to some defect in the
lymphocyte, but is often associated with serum blocking
factors.
iii) These blocking factors may also inhibit the response of
normal lymphocytes to PHA.
iv) In many cases a correlation has been found between the
response to PHA and the patient's clinical status,
prognosis, response to therapy etc..
In spite of the encouraging relationship between the lymphocyte
response in vitro and clinical status, the results from PHA tests do
^ *
not allow the distinction between cause and effect. In an animal
system, it has been found that the PHA response of rat peripheral
blood lymphocytes was progressively diminished by the growth of a
tumour, probably due to a factor produced by the cancer and released
into the serum, which then bound to the lymphocytes (Schumm &
Billmire, 1976 ; Schumm, Billmire & Morris, 1976). A similar
phenomenon has been described in a mouse system (Gillette & Boone,
1975). However, any increase in the response of a patient's
lymphocytes, following hyperthermia therapy, may indicate, either,
direct action of the treatment on cell responsiveness, removal of
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patient's general healLh, following reduction of the tumour burden.
In addition, it is not possible to tell whether the low response in
cancer patients is associated with, or secondary to, the establishment
of their disease. However, it is the correlation with clinical
status, and the lack of a suitable alternative assay, that has
sustained the use of PHA transformation tests in the assessment of
cellular immunocompetence in cancer patients.
Methodology There are a number of methods of studying lymphocyte
response to PHA.. Probably the simplest technique is to add the
mitogen directly to defibrinated, or anti-coagulated, whole blood.
Blast transformation can then be assessed, after first lysing the
erythrocytes in the cultures, by a differential count of transformed
and untransformed cells, in a stained smear (Roberts & Jones-Williams,
1974). Alternatively, the cultures can be pulsed with radioactively-
labelled RNA or DNA precursors (Hall & Gordon, 1976 ; Eskola et al,
1975). The uptake of the precursor is measured by radioactive
counting of either cell fragments (resulting from the hypotonic
lysis techniques used in automatic cell harvesters), or,
solubilised DNA (extracted from the cells by precipitation with
Tri chloraceti c acid). The advantage of the whole blood method
lies mainly in the ease and rapidity with which the cultures can be
established. It requires very small volumes of blood, e.g. 2ml
(Buimovici-Klein et al, 1976), a factor that can be of great
importance in the clinical situation (Pauly, 1976). However, the
serum of cancer patients often contains factors which may block the
response, these will be present in whole blood cultures, making it
difficult to determine whether an impaired response is due to a
cellular, rather than humoral, defect.
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Buimovici-Klein et al (1976), using a modification of the method
developed by Park and Good (1972), have attempted to overcome this
problem by replacing autochthonous serum by human AB plasma. It is
likely that more extensive washing procedures are requi red to remove
both serum-associated blocking factors, and/or the immunosuppressive
effects of anaesthesia, noted by Espanol, Todd and Soothill (1974).
Kjaer (1976) has found that washing leucocytes lead to an
increase in their migration index, and that this could also be
achieved by using Ficoll Hypaque-separated cells, suggesting that
the separation procedure may remove blocking factors, and give a
clearer indication of lymphocyte responsiveness. The use of
separated cells also allows the investigator to control the number
of potentially-responsive cells in the culture, whereas their
concentration in whole blood may vary during the period of repeated
sampling, and this may affect the accuracy of the results (Hall &
Gordon, 1976). In addition, the elimination of erythrocytes from
the cultures, obviates the problems of erythroagglutination by PHA,
and of red cell lysis during prolonged culture. The former can cause
problems when automatic cell harvesters are used, and the latter
is likely to result in the release of unwanted factors into the
culture medium. Due to these complications, the majority of
workers have used either unpurified (Lehane & Lane, 1974), or
purified leucocyte populations.
The purification process usually involves the removal of
granulocytes, e.g. by isopyknic centrifugation of the blood on a
Ficol1-Hypaque gradient (Boyum, 1968), and/or phagocytic mononuclear
cells, by incubation with carbonyl iron (Catalonaet al, 1975).
Glass-adherent cells have also been removed by some workers (Webel,
Briggs & Ritts, 1975). In most cases transformation is assessed
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by the uptake of the radioactively-labelled DNA precursor - Tritiated
14
Thymidine, although ° Thymidine can also be used (Wanebo et al,
1976). Uptake can be quantitated by autoradiography (Whittaker,
Rees & Clark, 1971) or scintillation counting, following either
DNA precipitation (with (Potter and Moore, 1975), or, without
solubilisation (Bader et al, 1976)) or automatic cell harvesting
(Simmler et al, 1976). Blastogenesis can also be measured by flow
cytofluorometry (Braunstein et al, 1976 ; Darzynkiewicz et al, 1976),
and visual (Simo-Camps et al, 1976) or automated counting (Stewart &
Ingram, 1967 ; Stewart, Cramer & Steward, 1975).
Due to these variations in technique, and the results which
they produce, the need for the standardisation of conditions has been
emphasised (Yamamura, 1973 ; Fitzgerald, 1971). In addition,
the requirement for large volumes of blood (usually 15-20ml), for
most of the methods, has lead to the development of micro-assays,
for use in repeated testing (Webel, Briggs & Ritts, 1975 ; Pees &
Pappas , 1975 ; Pen'nale et al, 1974). The reduction in cell numbers
has probably been taken to its limit in the method developed by
Steel and Creasey (1976), in which the cultures contains as few as
4 4
1x10 lymphocytes, although lOOjal volumes containing 2.5x10 cells
were routinely used.
The aim of this study was to determine the effects of whole-
body hyperthermia treatment on the response of the patient's




Three different assay systems we-e used to measure the PHA
response of lymphocytes.
Materi al s
Pooled Normal Human Serum Serum was isolated from the peripheral
blood of 10 healthy, untransfused, young males (5 Group 0,
4 Group A and 1 Group B or AB). It was decomplemented by heating
at 56°C for 30min, centrifuged, and Seitz filtered, before
storage at -25°C.
Culture Medium Prepared immediately before use.
Ham's F10H 7.50ml
L-Glutamine, 3% v/v, aqueous 0.05ml
HEPES solution, 500mM 0.20ml
Pooled Normal Human Serum 2.00ml
14
Isotope For isolated lymphocyte cultures: 2- C thymidine,
(specific activity 50pCi/mmol) diluted to 5pCi/ml in F10H,
and stored at -20°C until required.
3
For whole blood cultures: (Methyl- H) thymidine, (specific
activity 2Ci/mmol), diluted to 12.5p.Ci/ml in F10H, and
stored at 4°C until required.
Phybohaemagglutinin The same batch of Reagent Grade PHA
(K0763, Wellcome Reagents Ltd.) was used throughout the study.
Methods
i) Using Isolated Lymphocytes Isolated lymphocytes were
suspended in freshly-prepared culture medium, at a concentration of
5
5x10 viable cells/ml. 50pl cell suspension was added to an equal
volume of double the required concentration of PHA, diluted in
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culture me di urn, in a Dreyer agglutination tube. Control tubes
contained no PHA. All the tests were performed in triplicate, or
quadruplicate. The tubes were sealed with silicone rubber bungs,
and incubated in racks in a 37°C incubator for 3, 4, and 5 days.
14
17h before the termination of incubation, 0.1 jaCi 2- C thymidine
(20pl) was added to each tube.
Thymidine uptake was terminated either by transferring the tubes
to a 4°C refrigerator, or by harvesting the cell immediately. Cells
were harvested onto glass fibre mats using a Skatron Automatic Cell
Harvester (the principle behind automatic cell harvesters is shown
in Fig C2). The mats were thoroughly washed with water, to remove
any unbound isotope, and dried overnight at 37°C. Each pad was then
transferred to a glass scintillation vial, to which was added 10ml
scintillator. The vials were counted for lOmin each, using the
14iHC window of a liquid scintillation spectrophotometer. Results
are expressed as 1'og-jQ radioactive counts/min.
i i) Modified Method for Isolated Lymphocytes (modified from
Steel and Creasey (1976)). 50pl samples of lymphocyte suspension,
5
at a concentration of 5x10 viable cells/ml in culture medium,
were seeded into the flat-bottomed wells of a microtiter plate
containing triplicate, serial dilutions of double the required
concentration of PHA in culture medium. Cells were added to the
lowest concentrations of PHA first, to avoid the accidental transfer
of mitogen. The block of test wells was surrounded by a double
row of wells, each of which contained 1 OOjllI distilled water, to
help to maintain a stable environment within the plate (See p.145)
The lids of the plates were sealed in place with Lasso tape, and the
cells incubated at 37°C in a fan-assisted incubator (See p.145)
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FIGURE C2a
SIDE VIEW OF THE 'AUTOMASH' AUTOMATIC CELL HARVESTER
PRINCIPLE OF THE AUTOMATIC CELL HARVESTER
FIGURE C2b
DIAGRAMATIC SECTION THROUGH AN AUTOMATIC CELL HARVESTER
Radioactive]ly-labelled cells are collected onto filter pads which
are dried, placed in scintillator, and counted in a liquid
scinti11ation spectrophotometer
1 4
for either 3 or 4 days. 0.1 jaCi 2- C thymidine (20jul) was added
to each well (starting again at the control cultures) 24h before the
end of incubation. The cells were harvested and counted as for
Method i.
iii) Whole Blood Method 25p.l samples of well-mixed whole blood
were added to lOOp.1 dilutions of PHA in F10H, to give a final
volume of 125jal at the required PHA concentration. Blood was added
by reverse-pi petting, as this was found to give more reproducible
volumes. The plates were sealed and incubated as for Method ii.
3
24h before the end of incubation, 0.25pCi (Methyl- H) thymidine
(20ju.l) was added to each well. The cells were harvested and counted
as for Method i.
Heating of Lymphocyte Suspensions in vitro Lymphocyte suspensions
were heated in vitro under the same conditions shown on p.104.
Measurement of RNA synthesis Cultures were established using
Method (ii). 2-^C uridine was diluted as indicated for 2-^C
thymidine (See p. 141). 1 day cultures had O.lptCi isotope added
immediately after establishment. Cultures harvested after 2-4days
had isotope added 24h before the end of incubation. All cultures
were harvested as indicated for Method (ii).
Presentation of Results Results are shown as the logarithm^ of
radioactive counts per minute plotted against:
i) the treatment time scale, for Method (i)
ii) the PHA concentration, for Methods (ii) and (iii).
Results
Effect of Hyperthermia Treatment on the Response of Peripheral Blood
Blood Lymphocytes to PHA as studied using Method (i) - (incubation in
glass tubes) This technique was used to study lymphocyte transformation
in 6 patients (A.B., E.C., W.M., H.A., P.N. and A.S., 4cPs, Mean age
46.5 years, Range 35-51 years). Blood was taken immediately before and
after each treatment session, the following day, and on alternate
days, until the next treatment, or until the patient was discharged.
The results from individual patients are shown, since the range of
responsiveness to PHA was so large that it was not practicable to take
the mean values.
In general, during heating, there was a fall in the response to
a single concentration of PHA (1%). The following day the response
increased, to return to, or exceed the pre-treatment level. This trend
was sustained, so that by 3-5 days after hyperthermia, lymphocyte
blastogenesis was markedly increased, often to more than double the pre-
treatment level (Figures C3 and C4). Over the following 3-4 days there
was a fall in lymphocyte responsiveness, so that within 7 days of
treatment there was a return to the level seen prior to hyperthermia.
This general pattern was common to all the patients studied, and was
seen after each treatment (Figure C4). It was not due to variations
in the PHA culture conditions, as was shown by including lymphocytes
from a normal control studied over the same period (Figure C3). Cells
cultured for periods ranging from 2-5 days all showed the 3-5 day
peak in lymphocyte activity, with the maximum response usually occurring
following a 3 day incubation with PHA. The use of autochthonous serum
had little effect on the general pattern of lymphocyte activity, but
the responses were always lower than those with pooled normal serum,
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FIGURE C3a
EFFECT OF A SINGLE HYPERTHERMIA TREATMENT ON THE PHA RESPONSE OF PERIPHERAL BLOOD LYMPHOCYTES
The broken line shows the response of lymphocytes from a normal control tested simultaneously
Cultures were set up using Method (i). PHA concentration: 1% ; Incubation time: 3 days
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FIGURES C3b ft C3c
EFFECT OF A SINGLE HYPERTHERMIA TREATMENT ON THE
PHA RESPONSE OF PERIPHERAL BLOOD LYMPHOCYTES
Cultures were set up using Method (i)
PHA concentration: 1 % ; Incubation time: As shown
Points shown are mean of quadruplicate samples
Standard deviations are shown for the 4-day points
DAYS
EFFECTOFSUCCESSIVEHYPERTHERMIATREATMENTON Cultureswes tpusingMethod(i).PHA SerumCo tisolconcentrationsweremeasuredo
IEC4 THEP ARESPONSEOFPE IPHERALBLOODLYM H CYT S concentration:V:;Incubationtime:3days thebloodusfortheseparationoflymphocytes
indicating the possible presence of a blocking factor(s) in the
patients' serum. Results from one patient (A.B.) (not shown) indicated
that the degree of blocking was not altered during the week following
hyperthermia. This factor(s) in the patients' serum also inhibited the
PHA response of lymphocytes from a normal control.
Changes in the concentration of plasma Cortisol have been reported
to affect the response of lymphocytes to PHA (Tavadia et al, 1975).
In the hyperthermia patients there was no statistically significant
correlation between the serum Cortisol concentration and the PHA response,
although the peak in response was usually associated with a slight fall
(usually less than 0.2p.mol/l) in the Cortisol concentration (Figure C4).
It was felt that the standard deviation on triplicate, or quad¬
ruplicate, cultures was rather large (usually greater than 10% of the
mean), using this technique. In addition, the method required large
numbers of tubes, which made PHA dose/response testing impracticable.
The tubes themselves were not uniform, in that the bottoms varied
widely in shape, resulting in different cell densities during incub¬
ation. In an attempt to solve these difficulties, Method (ii) was
introduced.
i
Effect of Hyperthermia Treatment on the Response of Peripheral Blood
Lymphocytes to PHA as studied using Method (ii) - (incubation in
Mi crotiter piates)
Methodology This technique produced smaller standard deviations
(usually less than 7% of the mean) than Method (i), but was extremely
difficult to establish. The use of sealed microtiter plates resulted
in condensation forming on the inside of the lids. During prolonged
incubation this became so bad that the medium in some wells became
concentrated due to the evaporation of water, and cells in others were
lysed by droplets of condensation falling into the culture. Tests
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eventually showed that this was due to the use of a static convection
incubator, and although condensation could be considerably reduced by
stacking the plates, or by wrapping them in aluminium foil, it could
be eliminated only by using a fan incubator. Even so, during incub¬
ation, the medium in the outer row of wells became more concentrated,
resulting in a gradient of PHA response across the plate. This was
prevented by surrounding each block of test wells by a double row of
buffering wells containing distilled water. Using these conditions
it was possible to obtain, from each plate, good dose/response curves
with small standard deviations. At this stage, the test was used to
study the responses of the hyperthermia patients.
During the intervals between hyperthermia treatments, the range
of responsiveness in normal controls, and the influence of a number of
variables on the test system were examined.
A standard dose/response curve (Figure C5) was constructed from
the dose/response curves of 17 normal individuals obtained after a 4
day incubation with PHA. The result is shown as the mean of the
responses at each concentration t 1 standard deviation. Although the
number of controls was small, there was no correlation between the age
or sex, and the magnitude of the PHA response, however, the range of
the results was so wide that the time course of the PHA response was
examined. In the standard system the maximum response generally
occurred with a 4-5 day incubation with PHA, however, increasing the
density of the cells in culture (by tilting the plate, or changing the
well shape) resulted in an earlier peak (day 3-4).
PHA tests established using different lymphocyte separations
from the same blood sample, occasionally showed wide variation.
However, this was also shown when identical plates were set up using
the same batch of cells. Examination of the kinetics of the response
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FIGURE C5
STANDARD PHA DOSE/RESPONSE CURVE FOR 17 NORMAL CONTROL SUBJECTS
The dose/response curve was established from 17 dose/response
curves set up for normal individuals, using Method (ii).
Points shown for each PHA concentration are the average
of 17 mean values t 1 S.D.. See text for details.
indicated that these differences were due to variation in the time
course for the stimulation in parallel cultures, such that lymphocytes
in both plates reached a similar peak of response, but did so at
different times. By harvesting the cultures at one time point a false
impression of the reproducibility of the tests could be obtained.
The situation was complicated by the results from an experiment
in which PHA tests on a single normal control were set up at regular
intervals over a 3 week period (the maximum time of hospitalisation
for a hyperthermia patient). These indicated that response measured
at a single time point (4 days) could remain stable (in this case
5,000 cpm) over this period. However, the same individual sampled at
various intervals over 2 years, had shown responses ranging from
below 2,000cpm to above 10,000cpm, although the average response was
around 5,000cpm. Repeated samples, taken every day, showed little
variation. Therefore, the results from any plate are probably
influenced by:-
i) the microenvironment within the plate, which affects the
time course of the PHA response, and,
ii) the spontaneous variation in the activity of the cells
themselves.
These factors have been borne in mind in interpreting the results
from the hyperthermia patients, and the experiments on heat in vitro.
Significance has only been attached to either gross changes in PHA
response, or to those which showed a consistent pattern.
Response of Lymphocytes to PHA prior to Hyperthermia Treatment Prior
to hyperthermia the dose/response curves of all the patients studied
were within the normal range.
Response of Lymphocytes to PHA following Hyperthermia Treatment This
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method was used to study lymphocyte transformation in 5 patients
(L.K., M.M., K.S., T.M. and L.T., 3(?s, Mean age 58.6 years, Range 35-73
years).
During heating there was a decrease in response in 4 patients
(for example L.K. - Figure C6), and an increase in the remaining one
(M.M. - Figure C7). The changes were often slight, and were evident
at all concentrations of PHA. Responses in autochthonous serum
were depressed in comparison to those in pooled normal serum
(Figure C7), as with Method (i). A satisfactory follow-up was only
possible with 2 patients (M.M. and L.T.). M.M. showed a steadily
increasing response during the period following hyperthermia (Figure C7)
Results from this patient indicated a slight increase in serum blocking
accompanied the post-heating elevation of lymphocyte transformation.
Results from L.T, obtained using autochthonous serum in the cultures,
showed low levels of lymphocyte activity throughout the study, but
were indicative of a post-treatment increase in responsiveness.
To determine to what extent the changes in lymphocyte activity
were due to raised body temperature, rather than drugs etc., an
in vitro/in vivo experiment was set up.
Blood was taken from a patient (K.S.) immediately before
treatment, defibrinated, and split into three aliquots. One sample
was used at once to set up a PHA test. The remaining samples were
sealed into plastic tubes, one of which was incubated in a water bath
at 37°C, and the other was inserted into the patient's rectum. The
blood in this tube was exposed to the elevated body temperature, but
not to the drugs etc. used during treatment. At the end of hyperthermia
an end-of-treatment blood sample was taken, and used for establishing
PHA cultures, alongside those from the blood incubated in the tubes.
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FIGURE C8
EFFECT OF IN VITRO/IN VIVO HYPERTHERMIA ON THE
RESPONSE OF LYMPHOCYTES TO PHYTOHAEMAGGLUTININ
See text for details
37°C showed similar PHA responsiveness to those from unheated pre-
treatment blood. During hyperthermia in vivo there was a fall in PHA
response, which was also apparent, but to a greater extent, in the
lymphocytes isolated from the blood, in the rectal tube.
Piscussion
Method (i) The range of PHA response in normal controls was not
measured using this method, and so the pre-hyperthermia levels of
lymphocyte activity cannot be related to any standard. This was because
the technique was established using blood samples from hyperthermia
patients, and was subsequently modified into Method (ii) before use
on control samples.
The fall in response seen during hyperthermia treatment may be
due to a number of factors e.g. anaesthetics and drugs. Depression of
PHA-induced lymphocyte transformation has been attributed to anaesthesia
(Espanol, Todd & Soothill, 1974), but studies on normal volunteers
(Lecky et al, 1974), and healthy surgical patients (Kanto, Vapaavuori
and Viljanen, 1974), and in vitro (Saito et al, 1975 ; Bruce, 1976)
have failed to show any effect by anaesthesia alone. It is now
i
believed that the fall may result from trauma during surgical
procedures (Cullen & Van Belle, 1975 ; Riddle & Berenbaum, 1967 ;
Kent & Geist, 1975) and may be related to rises in the concentration
of piasma cortisol.
The large rise in serum Cortisol concentrations during hyperthermia
treatment, may be partially responsible for the depression of PHA
response in the patients, however increased Cortisol levels have been
found to be associated with both enhanced (Tavadia et al, 1975) and
depressed (Zeman et al, 1972) lymphocyte transformation. Berenbaum,
Cope and Bundick (1976) have found that a suppressive effect of
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incubating lymphocytes with Cortisol in vitro was removed, or even
reversed, by washing the cells prior to culture with PHA, but that
this was not the case in vivo. They indicate that the depression seen
in patients post-operatively cannot be readily explained solely by
increases in the blood Cortisol concentration, and suggest that prosta¬
glandins may also be involved. The study on hyperthermia patients
suggest only a very tenuous association between lymphocyte transformation
and Cortisol concentrations, and it is felt that the magnitude of the
change in the PHA response, during heating, is not sufficient to
indicate any single major suppressive factor, but rather points to
a combination of influences. It may possibly due to the fall in the
percentage of T lymphocytes which occurs during treatment, although
this would not explain the peak in reponse seen after 3-4 days, when
the percentage of these cells is usually similar to that seen prior to
hyperthermia. These results agree with those of Potter and Moore
(1977) which suggested that there was not a simple, direct relationship
between the PHA response and the number of T lymphocytes in the culture.
The rise in response occurring the day after hyperthermia, probably
reflect the release from the suppressive effects of the treatment. The
significance of the peak occurring at 3-5 days is not understood. It
is unlikely that it is due to the small fall in Cortisol concentration
which occurs at this time. Spontaneous lymphocyte activity (i.e.
thymidine uptake in the absence of PHA) showed some increase during
this period, but, since the radioactive counts from these cultures were
so close to the background level, it is difficult to assess the
relative importance of this change. It is possible that the increase
is an overshoot of the recovery phase after treatment, similar to that
seen following successful chemotherapy (Cheema & Hersh, 1971),
however, it may represent a stimulation of lymphocyte activity, either
-150-
by changes in the immunogenicity of the heated tumour, or by the
release of antigenic tumour debris into the bloodstream. If so, these
changes must occur irrespective of the clinical response to hyperthermia,
since this peak was seen in both responsive, and non-responsive patients.
The return to pre-treatment levels of lymphocyte activity would
indicate the physical removal (e.g. by phagocytosis) or blocking
(e.g. by serum factors) of any antigenic stimulus, or alternatively,
a recovery from the post-treatment overshoot. The indications are that
there are no great changes in the degree of serum blocking during the
post-treatment period, and the phagocytosis studies (see p.88)
indicated that any tumour debris would be rapidly removed from the
bloodstream soon after hyperthermia. It is believed that macrophages
are involved in the presentation of antigen to lymphoid cells (Unanue,
1972), and so it is possible that phagocytosed tumour debris might
first be processed to a more immunogenic form, resulting in the
delayed increase in lymphocyte activity; and it is then removed from
the system within a week of hyperthermia treatment. This explanantion
is purely hypothetical, since tumour debris was not seen in either the
blood, or the cytoplasm of polymorphs, following hyperthermia. However,
it is possible that the antigen may be shed in a sub-microscopic, or
soluble form.
There are only two other studies on the effects of whole-body
hyperthermia on the PHA response in humans. Lymphocyte activity was
increased in normal subjects following In of heating at 40°C
(Fabricius et al, 1977). In their study on cancer patients,
DeHoratius et al (1977) found no change in the PHA response in two
patients. In a third, lymphocyte activity increased markedly during
one treatment, but decreased during a subsequent session. As with the
previous study, there was no post-heating follow-up.
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Method (ii) The results obtained from hyperthermia patients, by the
use of Method (ii), were comparable to those from Method (i), in that
the changes during heating were usually small, and tended towards a
fall in responsiveness. A satisfactory post-heating follow-up was
only possible for two of the five patients. The results from one
of these showed the 3 day increase in PHA response seen in the
previous patients; and the results from the second indicated a similar
pattern. No difference between the effects at various PHA concentrations
could be discerned, although the number of patients was too small to
evaluate the worth of sub-optimal doses of PHA in predicting clinical
prognosis (See Introduction, Table CI). Most responses were within the
normal range throughout treatment, except in the case of the patient
receiving radiotherapy (T.M.), where they were depressed during the
whole period of the investigation.
The results from the experiment in which blood was heated in a
rectal tube indicated that heat alone was affecting the PHA responsive¬
ness of lymphocytes, arid to a greater extent than when combined with
drugs etc., during hyperthermia in vivo.
Further data to confirm this finding were obtained by heating
lymphocytes, either in whole blood, or as a separated suspension,
in vitro.
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The Effects of Heat in vitro on the Response of Lymphocytes to PHA
The effect of heating Whole Blood in vitro The effect of heating blood
in vitro on the PHA responsiveness of lymphocytes subsequently isolated
from the blood, is shown in Figures C9a and b.
Heating at 42°C for periods up to 4h, resulted in a depression of
PHA response in two cases. Incubation at 37°C had either no effect,
or produced only a slight depression (Figure C9b). In two experiments,
temperatures of 42°C resulted in an unchanged, or slightly increased,
response. The effect of heating blood from hyperthermia patients
in vitro, was studied in two subjects (M.M. and L.K.) in six
experiments. The results indicated that a temperature of 42°C could
either enhance (Figure ClOb-blood taken prior to hyperthermia treat¬
ment) or depress (Figure ClOa-blood taken at the end of hyperthermia
treatment) the PHA response of different blood samples from the same
patient, possibly indicating a change in the thermal tolerance of the
cells during the course of treatment. However, the results obtained
by heating the pre-hyperthermia treatment blood in vitro, were
similar, in most cases, to those produced by the hyperthermia treat¬
ment itself, e.g. an increase in PHA response seen in M.M., following
heating in vitro (Figure ClOb), was seen during hyperthermia in vivo
(Figure C7).
The effects of heat in vitro were usually similar at all
concentrations of PHA, and in the case of cancer patients, were not
affected by the use of pooled normal, or autochthonous serum in the
cultures. In general, the degree of serum blocking was not affected
by heating in vitro, although changes were occasionally seen (Figure
CI Ob).
It was possible that lymphocytes from blood incubated at 42°C were
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Since lymphocyte separation usually took 2-3h, there was the possibility
that cells were recovering from the effects of heat during this period.
To eliminate the delay between heating the blood and establishing
the cultures, whole blood PHA tests were used. In these experiments,
whole blood was put into culture with PHA within 5min of heating in
vitro. The results from cultures established from 33 samples, taken
at 15min intervals over 2-|h periods, in three experiments, consistently
showed no significant difference between the PHA response of blood kept
at 37°C or 42°C (Figure CI 1). There was considerable variation
between aliquots taken every 15min from the same blood sample, but the
fluctuations were similar in both tests and controls, and were probably
due to differences in the response kinetics between the different
micro titer plates (See p. 145 ). It was difficult to assess the effect
of the incubation process on lymphocyte transformation, because of
these fluctuations, however the general trend was towards a fall in PHA
response over a 2|h period at either 37°C or 42°C.
The Effect of heating Isolated Lymphocytes in vitro Lymphocytes,
isolated by the standard method, and heated at 42°C for 2|-4h, showed
virtually no response to PHA, although they were initially viable by
dye exclusion. Control suspensions incubated at 37°C displayed a
normal, or more frequently, a slightly depressed response, in comparison
to cells from unheated blood. Over a 2|h period at 42°C the pH of
the medium in which the cells were heated, fell by less than 0.1, to
pH 7.10.
The inhibition seen at 42°C could not be reversed by incubating
the heated normal lymphocytes in autochthonous serum for lh at 37°C.
Cells heated at 42°C i_n autochthonous serum tended to show slightly
increased responses, compared to those incubated in tissue culture
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EFFECT OF HEATING IN VITRO ON THE PHA RESPONSE OF WHOLE BLOOD
A sample of defibrinated normal blood was divided into two aliquots and incubated at the
temperatures shown. Samples were taken at the times indicated, and used to set up PHA
dose/response curves, using Method (iii).
Points shown are the mean of triplicate samples - 1 S.D.
lower than that of control lymphocytes maintained at 37°C in serum.
In the latter case, incubation in serum at 37°C always resulted in >.
slightly higher responses than incubation in medium supplemented with
foetal calf serum.
These results were confirmed by examination of May-Grunwald/Giemsa-
stained cytocentrifuge preparations of PHA cultures of heated cells.
Blast transformation was not seen in cultures of cells that had been
pre-incubated in medium at 42°C, whereas a few colonies of lymphoblasts
were observed in the cultures established from lymphocytes that had
been incubated in autochthonous serum at 42°C. In standard cultures
of unheated cells, the majority of cells in the preparation were lympho¬
blasts .
In an attempt to determine whether the thermal damage to isolated
lymphocytes was evident immediately after heating, or became manifest
during the subsequent incubation with PHA, the cultures were pulsed with
14
C-Uridine (See p. 143 ) to measure RNA synthesis. Since production
of RNA precedes that of DNA, it was hoped that the uptake of the pre¬
cursor by control lymphocytes, would be large enough, during short
incubations (1-3 days), to determine at what point the damage to heated
cells occurred.
This proved to be the case. The results are shown in Figure CI2.
They indicate that there is a marked inhibition of RNA synthesis within
24h of 42°C treatment (24h is the pulse time of the isotope). Although
uridine uptake was higher in heated cells incubated with PHA for 48 and
72h, the increases were not significant, compared to those seen in the
control lymphocyte suspension, pre-incubated at 37°C.
Discussion



















EFFECT OF HEATING ISOLATED LYMPHOCYTES IN VITRO ON THEIR PHA-INDUCED RNA SYNTHESIS
Isolated normal lymphocytes were heated under the conditions shown, and used to
set up PHA dose/response curves, using Method (i i i). Cultures were pulsed with
14
O.lpCi C-Uridine 24h before harvesting.
Points shown are the mean of triplicate samples.
vitro indicate that the effect becomes more severe the further one
departs from the conditions in vivo. Parallel experiments in which
blood was heated in vitro and in vivo suggested that the results were
related, in that changes in the response, although they were often small,
were usually in the same direction e.g. increased or decreased in both
cases. However it is not clear to what extent the alterations produced
by heating the blood in vitro were due to increased temperature, rather
than to changes in the oxygen content of the medium, pH etc. all of
which are known to affect the thermosensitivity of tumour cells. The
one parameter that was monitored, pH, showed little change during the
standard 2§h incubation period, when isolated cells were heated in medium.
The experiments in which whole blood was cultured with PHA are
difficult to interpret because of the variation in response between
replicate plates. In every case there was no significant difference
between the results from blood pre-heated at 42°C or 37°C. This may
indicate that cells are protected from, or can recover from, thermal
effects, provided that they are kept in whole blood. The depression
of responsiveness seen after hyperthermia in vivo, may be due to
changes in serum steroid concentrations etc., which will not occur
during heating in vitro. The hypothesis of thermoprotection may
explain the other results, in that there was usually a difference in
the PHA responsiveness of lymphocytes isolated from heated and control
blood samples, although the difference varied in magnitude and direction
depending upon the sample. This may be due to different thermo-
sensitivities of the blood samples, combined with recovery from heat
damage during the lymphocyte separation procedure. In contrast, the PHA
response of isolated lymphocytes was virtually abrogated by pre-heating
the cells at 42°C in medium, but was slightly less affected by heating
the cells in serum. This also suggests that the components in whole
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blood may be thermoprotective, although serum alone cannot prevent
heat damage to lymphocytes, nor can it reverse the damage once it has
occurred, since incubation of heated cells in serum did not reconstitute
their PHA responsiveness. It would appear that the damage produced by
2|h incubation at 42°C is irreversible, since the cells also showed
no recovery during the 3-5 day incubation with PHA. This was confirmed
by the uridine uptake studies, which indicated that PHA-stimulated RNA
synthesis by heated lymphocytes, was rapidly, severely, and
irreversibly depressed.
As is the case with hyperthermic damage to tumour cells, the
mechanism of this depression is not fully understood. The results
from this study indicate that 2Jh heating at 42°C (300C°M) is sufficient
to virtually abolish RNA and DMA synthesis in lymphocyte suspensions,
resulting in the 'death' of the cells within a few days. It is
difficult to define cell death for lymphocytes. The cells which did
not respond to PHA stimulation were more than 95% viable by eosin
exclusion, when set up in culture. It is known that dye exclusion is
not a good criterion for viabiility in heat-treated cells (Harris,
1966), but the other commonly used criteria - isotope uptake and
release, and colony formation - are affected by heating in vitro, or
are unsuitable for use with lymphocytes. A morphological technique
(Schrek, 1964 and 1966) was examined, but was unsuccessful. It is
therefore possible that the heated lymphocytes were essentially dead
when set up in culture.
In summary, heat applied either in vivo, during hyperthermia treat¬
ment, or in vitro, resulted in a depression of lymphocyte activity, as
measured by blastogenic response to PHA. In vivo the depression was
slight, and normal, or slightly increased responsiveness was seen the
day after treatment. There was a marked peak in lymphocyte activity
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within a further 2-3 days, followed by a return to the pre-treatment
level within a week. This pattern of response was not directly related
to the serum Cortisol concentration, but may be associated with changes
in the level of some other corticosteroid. Pre-heating at 42°C in vitro
had no significant effect on the PHA response of whole blood, and
lymphocytes separated from heated blood showed variable responses. An
irreversible, almost complete inhibition of both uridine and thymidine
uptake could be produced by heating isolated lymphocytes in tissue
culture medium at 42°C for 2|h. These differences may be due to either
thermoprotection of lymphocytes by the other components in whole nlood
(for which there is some evidence from experiments in vitro), or to
changes in the factors affecting the heat sensitivity of the cells.
This study emphasises the need for a more reliable criterion of the
viability of heated lymphocytes, and indicates that the results of
studies in vitro are not directly applicable to the situation in vivo.
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The Effects of Whole-Body Hyperthermia Therapy on the
Concentration of Serum Immunoglobulins and Complement
Introduction
Although it is believed that the immune response to neoplastic
disease is largely eel 1-mediated, there is evidence that the humoral
system is involved. Anti-tumour antibodies have been found in the
serum of patients with various types of cancer, e.g. malignant
melanoma, osteogenic sarcoma and leukaemias (See p. 29 ). Their
purpose is not fully understood, although humoral cytotoxicity
against the appropriate tumour type, has been demonstrated in the
serum of some cancer patients.
Work by Finney, Byers and Wilson (1960) indicated that the
cancer patient is able to mount a humoral response to his own
tumour. They noted a rise in'the circulating anti tumour antibody
titre, following the intra-muscular injection of autochthonous
tumour cells, homogenised in Freund's adjuvant. Other studies have
shown that, in contrast to many indices of cellular immunocompetence,
humoral antibody synthesis is not greatly impaired in malignant
/
disease (Southam, 1968). For example, Krant et al (1968) found that
patients with bronchogenic cancer, had normal primary and secondary
humoral responses, when immunised with plague and diphtheria vaccines
respectively. In contrast, Lytton, Hughes and Fulthorpe (1967)
found that cancer patients showed an impaired response to primary
immunisation with tetanus toxoid, and this occurred irrespective of
age, or general condition of the patient. In addition, the degree
of impairment could be related to the survival time. Similar studies
this time on the primary humoral response, were conducted by Lee,
Rowley and Mackay (1970). They found that patients with active, non-
lymphomatous cancers displayed an impaired antibody-producing
response to immunisation with monomeric flagellin from Salmonella
adelaide, in comparison to sick, non-cancer, control subjects. The
degree of impairment could be related to the survival time. Those
patients 'cured' by surgery and/or radiotherapy showed a return to
near-normal levels of antibody response. This suggests that
monitoring of humoral immunity may provide some useful indication
of the patient's response to therapy.
Hobbs (1970) has stated that 'serum immunoglobulin patterns
offer a crude window through which to view some immunological events,
but can be useful in certain contexts'. Nonetheless, because of
their ease of quantitation, serum immunoglobulin concentrations are
widely used as an indication of general humoral immunocompetence in
cancer patients. The results from some of these studies are
summarised in Table Dl.
Many of the contradictory results may be explained by the
nature of the control population with which the patients were
compared. Roberts used patients with benign disease, whereas
Dostalova's control group was disease-free. In addition, a number
of other factors are known to affect immunoglobulin levels, e.g.
age (Teasdale, Newcombe and Hughes, 1976), sex (Rhodes et al, 1969)
and environment (Cohen et al, 1961), and must be taken into account
when interpreting these studies.
Several general conclusions can be drawn however:-
i) IgM concentrations are not greatly affected by malignant
disease.
ii) IgG levels tend to be increased.
iii) IgA concentrations are often elevated, especially in those
tumours affecting organs with mucous membranes.
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REFERENCE TUMOUR TYPE IgG IgA IgM COMMENTS
KRANT et al
(1968)
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TABLE D1
REVIEW OF PREVIOUS STUDIES ON SERUM IMMUNOGLOBULIN CONCENTRATIONS IN CANCER PATIENTS
This may reflect local antigenic stimulation of the IgA-
secreting cells associated with these areas.
In some cases it has been shown that the levels of serum
immunoglobulin can be related to the stage of disease, and prognosis.
Meyer, Mackler and Beck (1973), found that women with increased IgA
concentrations, prior to mastectomy and radiotherapy, had an
improved prognosis. Roberts, Bathgate and Stevenson (1975) however
indicated that immunoglobulin levels were not affected by mastectomy
or hormone therapy, and showed no correlation with prognosis. A
similar conclusion was reached by Cochran et al (1975) and Krant et al^
(1968), whereas Dostalova et al (1976) found that the level of IgG
correlated with the stage of disease. Munzarova et al (1977) showed
that patients with advanced breast cancer had significantly increased
IgA, in comparison to those with localised tumours, although the
levels were elevated at all stages of the disease. Krant et al (1968)
also suggested that moderate elevation of IgA, in longer surviving
patients with bronchogenic cancer, merited further investigation.
Although not measured as part of this study, IgE may have an
important role in tumour immunity. The serum concentrations of IgE
are within the normal range in cancer patients, but there is evidence
from both animals and man (Bartholomaeus & Keast, 1972 ; Grace & Kondo
1958) for the existence of tumour-specific IgE (or IgE-like)
antibodies in cancer-bearing hosts. There may also be a relationship
between IgE levels and T cell function. For a more detailed review,
the reader is referred to the article by Rosenbaum and Dwyer (1977).
In summary, the results from measurements of serum immunoglobulin
concentrations are often contradictory, and their full value, as both
a monitor of humoral immunocompetence, and a guide to clinical
prognosis, remains to be established.
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There are very few studies on the concentration of serum
complement components in cancer patients. In a survey of 200 cases
of malignant disease, Verhaegen et al, (1976) found significantly
higher levels of the CH'50, C'3, C14 and C'lq components, in
comparison to 90 healthy control subjects. Similar increases,
especially of C'8 and C'9, were reported in 15 out of 21 patients
with squamous carcinoma of the lung, by McKenzie, Col sky and Hetrick
(1967). Southam (1967), however, found that levels of the second
component were normal in cancer patients. Cochran et al (1976) have
described various abnormalities of the complement system in 52% of
the cancer patients that they examined. These included elevated
concentrations of the various components - but they could find no
significant difference between the levels in patients with primary,
as opposed to metastatic, disease. Verhaegen et al (1976), in
contrast, found a stage-linked increase in complement concentrations
such that patients in remission has almost normal levels, whereas
those with advancing disease showed progressively higher concentrations,
until the terminal phases of their illness. Treatment by chemotherapy
or radiotherapy resulted in the lowering of the levels, suggesting
that serial measurements could provide information on the state
of the disease. Lehane and Lane (1974) also found that advanced
cancer patients had increased C'3 concentrations, which could be
related to the future response to chemotherapy.
In summary, many patients with malignant disease have increased
concentrations of serum complement. This may be a response to the
elevated demand for complement, due to an increase in the levels of
antigen-antibody complexes, formed between soluble tumour antigen
and serum antibodies. There is also some indication that the
concentration of complement, measured as the C'3 component, may
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be related to the clinical status of the cancer patient.
The aim of this investigation was to determine the effects of
whole-body hyperthermia therapy on the concentrations of serum IgG,
IgA, IgM and C'3, with a view to correlating any observed changes
with the clinical response to therapy.
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Materials and Method
Measurement of the concentration of serum immunoglobulins
(IgG, IgA, IgM) and complement (as C'3) was carried out by the
Central Microbiology Laboratories, Western General Hospital,
Edinburgh, using the radial immunodiffusion technique (Mancini,
Carbonara and Heremans, 1965).
Materi al s
Radial immunodiffusion plates for IgG, IgA, IgM and complement
as C'3 (B1C/B1A) estimations, control and reference sera were all
obtained from the Oxford Diffu-Gen Division of Searle Dignostic,
High Wycombe.
Method
Serum samples for immunoglobulin and complement estimations
were stored at -25°C until tested. They were then thawed and 5p.l
samples pipetted into the appropriate wells on the immunodiffusion
plate. Standard and control sera were run for each test. The plates
were incubated at room temperature for 18h after the addition of the
final sample.
The diameter of the precipitin ring was measured using a
Hoechst diverging-line scale, as this was found to give the most
consistent results. A standard curve was plotted on 2-cycle semi-
logarithmic graph paper, using the values obtained from the
reference sera. The concentration of immunoglobulin, or complement,




Serum Immunoglobulin and Complement Concentrations prior to
Hyperthermia Prior to hyperthermia treatment, the concentration of
serum IgA, IgG, IgM and complement (C'3), was measured in 8 patients
(Table D 2).
Before therapy, 7 of the 8 patients had IgG concentrations
within the normal range, whereas IgA levels were markedly elevated
in 4 cases. The majority of patients had essentially normal
concentrations of IgM, with the notable exception of the two cases
of leiomyosarcoma (W.M. and E.C.), who had slightly depressed levels.
Complement (C13) concentrations were increased in 62% of the
patients, but within the normal range in the remainder.
Serum Immunoglobulin and Complement Concentrations during and
after Hyperthermia Treatment Serum immunoglobulin and complement
concentrations were monitored in the same 8 patients, over their
course of treatment.; Statistical analysis was performed, using the
Student's t test for paired samples, p values of less than 0.05
were considered significant.
The effects of the first hyperthermia treatment are summarised
in Table D2. Measurements on individual patients often showed large
changes in the concentrations of the various immunoglobulin classes,
and, although these were not statistically significant, and did not
show any clear trend, there was a tendency for IgM levels to increase,
following hyperthermia. It is unlikely that the changes which
occurred during treatment, were due to haemoconcentration, or dilution,
since an increase in one class of immunoglobulin was sometimes
accompanied by a fall in concentration of another class.
Similar changes in immunoglobulin levels were seen following the
PATIENT
TEST KS RM AW AB WM EC AS HA MEAN + 1 S.D.
IgG
PRE 1150 890 1580 1425 1450 580 1300 950 1166 339
END 782 800 1580 1550 1100 700 1150 950 1077 339
POST 1 1150 1250 1580 1425 980 660 1250 820 1139 306
POST 2 1200 890 1580 1550 700 600 1250 1100 1109 362
NORMAL RANGE - 700 - 1900 mg/dl
IgA
PRE 515 320 310 600 590 215 570 400 440 148
END 440 230 310 600 360 320 600 400 408 134
POST 1 515 450 410 450 425 290 540 400 435 76
POST 2 470 320 410 480 360 320 780 390 441 150
NORMAL RANGE - 90 - 450 mg/dl
IgM
PRE 62 45 192 210 38 52 115 107 103 67
END 62 40 170 210 52 75 180 120 114 66
POST 1 115 87 192 200 47 68 92 120 115 55
POST 2 80 87 285 170 45 63 92 130 130 78
NORMAL RANGE : -<$ s 45 - 180, $s 55 - 220 mg/dl
C' 3
PRE 135 130 157 104 180 95 92 190 135 38
END 157 100 130 113 145 N/D 97 160 129 26
POST 1 145 86 130 104 140 95 100 117 115 22
POST 2 140 86 130 100 N/D 94 137 125 116 22
NORMAL RANGE 55 - 120 mg/dl (d1 >9)
TABLE D2
EFFECT OF THE FIRST HYPERTHERMIA TREATMENT ON THE CONCENTRATION OF
SERUM IMMUNOGLOBULINS (IgG, IgA & IgM) AND COMPLEMENT (C'3)
All values are in mg/dl N/D = Not done
Post 1 samples were taken the day following treatment
Post 2 samples were taken 3-4 days following treatment
PATIENT:K.S. FIGUREDla
EFFECTOFHYPERTH RMIATREATM NTSNHCONCEN RATIONSERUMIMMUN GLOBULINS&CO PL M N( (3)
PATIENT:R.M. FIGUREPIh
EFFECTOFHYPERTHERMIATREATM NNHC NC N RATIONS UIMMUNOGLOBULI&MPLE NT( '3)
second and subsequent treatments (Figures Dla and Dlb), and again,
no clear trend could be discerned.
There was no significant change in the concentration of C'3
during hyperthermia, however, the levels fell to 88% of the pre-
treatment value the following day (p-eO.l). The depression was
transitory, with a return to the pre-hyperthermia level within a
further 2 or 3 days. This pattern was usually repeated during
subsequent treatments,(Figures Dla and Dlb).
Piscussion
The pattern of an isolated increase in serum IgA concentrations,
prior to treatment, has been noted previously in cancer patients
(Hughes, 1971),. All the hyperthermia patients in whom this was
detected, had gastro-intestinal malignancies. The association
between G.I. disease and elevated IgA concentrations may be
explained by the origin of this class of immunoglobulin. It is
synthesised, as a 7S monomer, by the laminae propriae which underlie
the mucous membranes throughout the G.I. tract. This monomer is
stabilised, and protected from proteolysis, by combination with
a secretory piece, which is produced by the epithelial cells. The
pool of 7S IgA can enter the bloodstream, either by the lymphatics,
or, directly, via the portal veins (Hobbs, 1970), and thus, diseases
which involve an antigenic stimulation of the G.I. tract e.g. Crohn's
disease and cancer (either directly, or via secondary infection) may
result, not only in increased concentrations of IgA in mucous
secretions, but also in the serum.
The finding of elevated C'3 concentrations in hyperthermia
patients, prior to treatment, is in agreement with the study by
Verhaegen et al (1976), who reported significantly higher levels in
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cancer patients. This increase was linked to the stage of disease,
in that the highest values were found in cases of metastatic cancer.
They also indicated that the concentrations fell pre~terminally. It
is interesting to note that the 3 hyperthermia patients with essent¬
ially normal levels of C'3, had a mean survival time of only 15 days
(Range 9-25 days), following the final treatment, in contrast to the
184 days (Range 71-485 days) for the remaining patients; indicating
that they were indeed in the pre-terminal stages of their disease.
Following hyperthermia, DeHoratius et al (1977) also found that
there were no persistant changes in immunoglobulin concentrations.
In contrast, Mendez et al (1959) reported a fall in gamma globulin
levels in healthy subjects, after 2h 39°C~40°C hyperthermia. They
did not, however, distinguish between the subclasses. In general,
therefore, it would appear that whole-body hyperthermia treatment
has no marked effect on the concentrations of serum IgG, IgA or
IgM, although it may be necessary to carry out a longer-term follow-
up to confirm this.
There was also no significant change in the concentration of C'3
during heating, however the levels fell to 88% of the pre-treatment
value within 24h. A similar decrease in serum C'3 was noted by
DeHoratius et al, in 2 patients receiving whole-body hyperthermia
alone, and a third,given concomitant chemotherapy. This could be
correlated with a decline in total haemolytic complement activity in
two of the cases. Failure to detect a significant fall in the
complement components C3PA and CH50, involved in the alternative
pathway, indicated that the classical pathway was primarily affected
by heat treatment. It is not clear whether the fall,seen in both
studies, is due to partial thermal degradation of complement (which
can be inactivated by heating to 55°C), or, to the selective
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consumption of the various components, possibly by an increase in the
numbers of tumour antigen-antibody complexes, which may be formed
following hyperthermia.
These changes in complement concentrations may prove to be of
considerable interest. Schutte et al (1975) have indicated that
the components may act as acute phase reactants, the levels of which
could be related to various immune parameters, the extent of disease,
and tumour stage in cancer patients (Chretien, 1977 - Personal
Communication). If this proves to be the case, a fall in C'3
concentration following hyperthermia, may be indicative of an
enhanced immune status, and/or tumour destruction. It is notable
that in the 3 pre-terminal patients, the C'3 levels were not depressed
24h after treatment, which could indicate that the treatment was
without effect. One of these cases (E.C.) received a second hyper¬
thermia session, during which the concentration of complement fell
by 25%. This patient died 4 days later, and, upon post mortem, there
was evidence of massive tumour necrosis. It should be noted, however,
that a non-cancer patient (P.N.), treated with three sessions of
hyperthermia, showed a fall in C'3 within 24h of one of the sessions
(although the concentration actually increased during hyperthermia),
which may suggest that, in the absence of a tumour, there is a direct
effect of heat on complement..
In summary therefore, whilst the number of patients studied was
small, there was some indication that concentrations of serum C'3 may




THE EFFECTS OF WHOLE-BODY HYPERTHERMIA THERAPY ON
ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
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The Effects of Whole-Body Hyperthermia Therapy on
Antibody-Dependent Cellular Cytotoxicity
Introduction
Since its discovery in 1965 by Moller, the cytotoxic effect of
non-sensitised effector cells upon target cells coated with specific
antibody, has been under intensive investigation. This has largely
centred around the nature of the lytic mechanism, and the identity
of the effector cell. It is now accepted that the latter is
determined by the type of target cell used in the assay (Nelson
et al, 1976), and that more than one class of leucocyte can display
antibody-dependent cellular cytotoxic activity.
Due to these technical and methodological difficulties, reports
on clinical applications of the ADCC test are rather rare. The
majority have concentrated upon investigations in patients with
immune disorders, e.g. Hashimoto's thyroiditis (Calder et al, 1973),
systemic lupus erythematosus (Scheinberg & Cathcart, 1976) and
immunodeficiency diseases (Rachelefsky et al, 1975). Depressed
cytotoxicity has been reported in kidney transplant patients
(DuPont et al, 1977) and infectious asthmatics (Flaherty et al,
1977).
One of the earliest studies in cases of malignant disease,
was carried out by Blaese, Rosenberg and Wunderlich (1973), who
found that the ability of lymphoid cells to lyse HL-A-coated
lymphocytes, was not impaired in patients with cancer, in
comparison to a single normal control subject. Similar results were
obtained by Peter, Knoop and Kalden (1976), in a study of 14
melanoma patients, and 13 healthy controls. They found that
cytotoxicity in the cancer patients was slightly lower, but that
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this depression was not statistically significant. However both of
these investigations were carried out on relatively small numbers
of patients, and a larger study (44 patients with various tumours),
conducted by Ting and Terasaki (1974), found that ADCC was signific¬
antly lower in patients with cancer, than in normal and 'sick'
controls. They also showed that this could not be correlated with
reduced antibody production in these subjects, but was due to a
deficiency of K cells (See p. 160 ) in cancer patients. In addition,
the degree of impairment could not be related to the stage of
disease, or age.
Similar impaired responses have been described in patients
with acute myeloid leukaemia, by Hersey et al (1973). They proposed
that this failure could be due to serum blocking factors, e.g.
antigen-antibody complexes, or K cell depletion, assuming that these
patients produce antibodies to autologous myelocytes. Nonetheless,
they suggested that the assay may be of use in charting the
response to immunotherapy, especially in giving early warning of
relapse.
The belief that K cell activity can be blocked by serum factors,
has received some support recently. Matthews and Whitehead (1976)
found that sera from 39% of breast cancer patients (and 8% of healthy
controls) inhibited lysis. Partial characterisation of the blocking
factor(s) suggested that it was not an IgG-containing complex.
Serum inhibition has also been reported in animal systems (Matthews
et al, 1975), where it was found to be independent of the stage of
tumour growth. In contrast, Calder, Irvine and Ghaffer (1975) found
that spleen cells from tumour-bearing mice were actually more active
in a K cell system, than those from control animals. They also noted
that normal lymph node cells had virtually no ADCC activity, whereas
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cells from nodes draining the tumour were active, suggesting that
K cells may be present in the tumour mass. A similar situation may
exist in the human, since O'Toole (1977) has found that lymphocytes
from lymph nodes are inactive in a K cell assay. As yet, there
are no comparable studies on cancer patients.
In summary, studies on antibody-dependent cellular cytotoxicity
in cancer patients are still in their early stages. There are
indications that, in the human, K cell activity is essentially normal
or slightly depressed, probably by immune complexes in the serum.
These blocking factors may be affected by therapeutic procedures
(Vose and Moudgil, 1976). In the animal, the presence of a tumour
can lead to increased ADCC, either due to elevated K cell numbers
and/'or activity, although blocking factors may be present.
The purpose of this investigation was to determine the effect of
hyperthermia in vivo on the K cell activity of the patient, and to




Mediurn The medium used in all the assays was sodium
bicarbonate-buffered Eagles Basal Medium, supplemented with
10% v/v heat inactivated, foetal calf serum, (+T% v/v non¬
essential amino acids, for tests using KB cells).
Target Cells The cells used as targets in these tests were
grown in serially subcultured monolayers (See p. 69 )
They were:-
i) H.Ep.2 Established from a human epidermoid carcinoma
of the larynx (Moore, Sabachewsky & Toolan, 1955).
Used between passages 3.75 and 420
ii) KB Established from a human epidermoid carcinoma of
the mouth (Eagle, 1955). Used between passages 386
and 412.
Unless stated otherwise, the cells used in all the tests were
obtained from confluent monolayers.
Antiserum Antisera to both cell lines was prepared using
the same protocol (given below). Two mature New Zealand White
rabbits were used for each line. (The H.Ep.2 antiserum was
prepared and titrated by Dr. M.A. Scragg, Teaching and Research
Centre, Western General Hospital, University of Edinburgh).
Production and Titration of Antiserum. Prior, to the injection
of ceils, 12ml blood was collected from each animal by venepuncture
of the marginal ear vein. The serum was separated (See p.175 ),
membrane filtered, and stored at -20°C.
Day 0 Tumour cells were harvested from two Roux flasks, using
standard procedure (See p. 69 ) and washed in 2x20ml PBS * A'. The
cell pellet was resuspended in 1ml PBS1A' counted, and the
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concentration adjusted with PBS'A' to 4x10 viable cells/ml. 0.5ml
of this suspension was emulsified with an equal volume of Complete
Freund's Adjuvant, by repeated aspiration through a 21 guage needle.
The emulsion was stored overnight at 4°C, re-emulsified, and injected
intra-muscularly into the right hind leg of the rabbit.
Day 11 1ml suspension, containing 1x10^ washed tumour cells,
emulsified in an equal volume of Complete Adjuvant, was injected i.m.
into the left hind leg of the same animal.
Day 23 Approximately 12ml blood was obtained from each animal by
venepuncture of the marginal ear vein. The blood was collected in
a sterile glass universal container, and allowed to clot for lh
at 37°C. The clot was ringed and left to retract at 4°C over¬
night. The serum was removed to a glass centrifuge tube and spun at
4,000g for 20min. The supernatant fraction was removed, membrane
filtered, heat inactivated at 56°C for 30min, and stored at -20°C.
Normal and immune rabbit serum was titrated against the
appropriate cell line to determine the concentration of antibody.
The method used was complement-dependent lysis of radioactively-
labelled target cells.
Cells of the appropriate cell line were harvested from a confluent
monolayer, and 1x10^ viable cells, suspended in tissue culture medium,
51
were incubated with lOOpiCi Cr (sodium chromate) in a total volume
of 1ml, for Ih at 37°C. Extracellular label was removed by washing
the cells in 6x10ml medium (centrifugations at 800g for 5min). The
final cell pellet was resuspended in 3ml medium and the concentration
of viable cells determined by dye exclusion. The labelling procedure
did not affect the viability of the cells, which usually remained
greater than 97%. Immediately before use, the concentration was
5




PRINCIPLE OF THE AUTOMATIC SUPERNATANT HARVESTER
Microtiter plate and harvesting frame positioned beneath press.
Press activated, radioactive supernatant taken up by absorbing
elements.
Press released and harvesting frame raised. Cells are retained






















Fresh guinea pig serum was used as the source of complement.
Guinea pig blood was collected by cardiac puncture and allowed to
clot. The clot was ringed and left to retract for approximately Ih.
The serum was removed and centrifuged at 4,000g for 20min. The
supernatant fraction was removed, diluted 1 part in 3 in medium,
and used immediately.
Freshly-thawed normal and immune serum were diluted in medium
to give final concentrations of 33%, 3.3% and 0.33% v/v.
The plan of the test is shown in Table El. Each row of the
table represents the contents of one U-bottomed well in a micro-
titer plate. All the tests and controls were performed in triplicate.
The suspensions and dilutions were seeded, in the order shown, into
the wells of a plate standing in a plastic lunch box, through which
was passed an humidified 95%/5% Ai r/CO^ mixture. The completed plate
was then placed in a second lunch box, containing sterile swabs
moistened with distilled water, to maintain the humidity of the
atmosphere during incubation. This box was gassed and the lid sealed
in place with Lasso tape. It was incubated for 20h at 37°C.
At the end of incubation the supernatants were collected from
each well, using a Titertek Supernatant Harvester (the principle
of which is shown in Fig. El). The absorption elements, containing
the supernatants, were transferred to plastic counting vials, which
were counted on a Wallac gamma sample counter for 2min, using the
51
'Cr window. The following labelling controls were also included,
in triplicate:-
Total Radioactive Count 50p.l samples of the target cell
suspension.
150|j.l samples of the following suspensions were seeded into the
wells of a microtiter plate, at the start of incubation, and
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NORMAL SERUM IMMUNE SERUM
TEST CELLS MED. COMP. 33% v/v 3.3% v/v 0.33% v/v 33% v/v 3.3% v/v 0.33% v/v
CONTROL ONE i/ n/V - — — - - — -
CONTROL TWO N/ \/ v/ — — — - — —
CONTROL THREE v/ N/ — \/ — — - - -
\/ N/ - - \/ - - — -
sj \/ - - — \/ — — -
s/ \/ — - — — v/ — -
\/ N/ — — - — — \/ -
i/ V - - — — — — s/
v/ - \/ N/ — - - — -
V — \/ — sj — - — —
TEST \/
— N/ — — N/ — — —
V — V — — — l/ — —
N/ - \/ — - — — \/ —
\/ — s/ — — — — —
TABLE El
EXPERIMENTAL DESIGN FOR THE TITRATION OF RABBIT ANTI-KB SERUM BY COMPLEMENT-DEPENDENT LYSIS
See text for full explanation of table and titration experiments
Key:- Cells = 51Cr-labelled KB cells at 3xl05/ml
Med. = Eagles Growth Medium
Comp. = Fresh guinea pig serum diluted 1/3 in medium
Serum = Normal or immune serum diluted in medium as shown
J = 50^1 : - = No addition
TEST - COMPLEMENT + COMPLEMENT 1 SPECIFIC RELEASE
NORMAL SERUM
10"1 FINAL 1353.0 1302.0 -0.97
DILN.
10~2 FINAL 1180.7 1261.3 1.48
DILN.
10"3 FINAL 1111.0 1284.0 3.14
DILN.
IMMUNE SERUM
10"1 FINAL 2409.0 6522.7 97.50
DILN.
10"2 FINAL 1137.5 1532.3 7.19
DILN.
10"3 FINAL 1144.3 1317.3 3.16
DILN.
CONTROLS TOTAL RADIOACTIVE COUNT 8074.7
TOTAL RELEASABLE LABEL 6628.0
TABLE E2
RESULTS FROM THE TITRATION OF KB ANTISERUM BY COMPLEMENT-DEPENDENT LYSIS
Figures shown in columns 2 and 3 are radioactive counts / 2min
and the mean of triplicate samples.
Percent specific release was calculated as shown in the Methods section
See text for details.
harvested immediately:-
Supernatant Count 50pl target cell suspension + 1 OOjo.1 medium.
Total Releasable Label 50j_il target cell suspension, heated for
30min at 60°C, + 100p.l medium.
Isotope release, due to the presence of antibody, was calculated as:-
% Specific Release = C - B -jqq
A - B
Where:- A = Total Releasable Label count
B = Count from (Target cells + Test Serum + Medium)
C = Count from (Target cells + Test Serum + Complement)
Results from a typical experiment are shown in Table E2, and
indicate that the end-point for this serum lies at a concentration
-2 -3
between 10 and 10 . Serum was used in ADCC tests at a concentration
tenfold below the end-point.
Method for ADCC Tests
Three slightly different assay systems were used, all of which
gave comparable results.
51
i) Target cells were labelled with Cr (sodium chromate) as for
the complement dependent lysis experiments (See p.175 ), and were
5
adjusted to a concentration of 3x10 viable cells/ml in tissue culture
medium, immediately before use. The cell suspension was kept gassed
throughout, to prevent fluctuations in pH.
Lymphocytes and/or polymorphonuclear cells were separated from
peripheral blood using the standard techniques (See p. 65 and 67 ).
The cells were counted and resuspended in medium at the required
concentration.
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Freshly-thawed normal and immune rabbit sera were diluted to
triple the final required concentration in medium.
The test was carried out in 2ml flat-bottomed tubes (Sterilin)
standing in a rack, in a gassed, humidified plastic lunch box. All
the tubes were initially seeded with lOOpil target cell suspension.
Control tubes then received 100^x1 of the dilution of normal serum,
IOOjj.1 of diluted immune serum was added to the test tubes. lOOpil
of the appropriate effector cell concentration was then added to
both tests and controls. Blank tubes, containing target cells, serum
and medium only, were set up to determine the rate of leaching of
51
Cr from the labelled cells. All the tubes were set up in triplicate,
The lid of the lunch box was sealed with Lasso tape and the box
incubated at 37°C. After 20h 300jal PBS'A' was added to each tube.
The cells were pelleted by centrifugation at 800g for 7min, and
IOOjj.1 of the supernatant transferred to plastic, gamma counting vials.
All the samples, including the labelling controls, were counted for
51
5min each, using the Cr channel on an automatic gamma counter.
Labelling controls were set up at the start of the incubation
period, using the following flow cnart:-
300j_l1 Target Cell Suspn. + 600jil Medium
1
900|_tl Suspn.
200p.l Suspn. 300jil Suspn. 300pil Suspn.
+ Heated 30min +
200p.l Medium @ 60°C 300jal Medium
I + I
3x1 QOp.! samples 300p.l Medium C'fugd. 7min @
for Total Radio- | 800g
active Count C'fugd. 7min
@ 800g
} 3x100p.l S.N. for






All the radioactive counts are expressed, in the results, as
the mean of the triplicate. For each experiment the following
values were calculated:-
i) Cell Bound Count = Total Radioactive Count - Supernatant Count
ii) % Total Releasable Label =
Total Releasable Label Count - Supernatant Count -jqq
Cell Bound Count
iii) j Specific Release =
Test Count - Control Count ,nr.xlOO
Total Releasable Label Count - Control Count
where:-
Test Count = Count from Target ceils + Effector ceils + immune
serum
Control Count = Count from Target cells + Effector cells + normal
serum
ii) Target cells, effector cells and serum dilutions were prepared
as for Method i. The volume of each addition was reduced to 50j.il,
thereby cutting the cell requirement by one half. The tests were
carried out in the V-bottomed wells of a microtiter plate, which was
incubated, without a lid, in a gassed, humidified lunch box. 20h
later, 50pil samples of the supernatant were carefully withdrawn from
each well, and transferred to a gamma counting vial. Samples were
counted as for Method i.
Labelling controls were performed in triplicate.
Total Radioactive Count = 50ql Target Cell Suspension
Supernatant Count = 50pil sample of supernatant from:
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50jal Target Cell Suspension, diluted 1/3 in medium and
centrifuged at 800g for 7min.
Total Keleasable Label Count = 50jll1 sample of supernatant
from 50p.l Target Cell Suspension, heated at 60°C for 30min,
diluted 1/3 in medium, and centrifuged at 800g for 7min.
Results were calculated as for Method i.
iii) Method iii was a modification of Method ii, which allowed the
supernatants to be collected using an automatic harvester. Cells
were incubated in round-bottomed wells of a microtiter plate for 20h.
The supernatants were sampled using a Titertek Automatic Supernatant
Harvester. The absorption elements, containing the collected
supernatants, were placed in gamma counting vials, and counted as
for Method i.
Labelling controls were set up as described in the section on
the titration of antisera (See p.176)
Results were calculated as for Methods i and ii.
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Results
In the assay system used in this study, lymphocytes were found
to be the primary effector cells. The low levels of cytotoxicity
(usually less than 20% specific release) produced by a granulocyte
population, could be largely explained by contamination of the cell
suspension by small numbers of lymphoid cells. Lymphocytes from
normal controls routinely produced 80%-90% cytotoxicity during 20h
incubation with the target cells.
Antibody-Dependent Cellular Cytotoxicity before and after Hyperthermia
Treatment The antibody-dependent cytotoxic effect of lymphoid
cells, on the H.Ep.2 cell line, was studied in 5 patients (D.G., J.C.,
M.P., M.M. and I.W.). The results are shown in Figures E 2 and E 3.
Prior to treatment, 3 patients showed levels of cytotoxicity
comparable to those in normal subjects (i.e. greater than 80% specific
release). Cytotoxicity was markedly depressed (less than 25% specific
release) in one patient (J.C.), and slightly lower (64%) in the
remaining case (M.P.).
During the first hyperthermia treatment, 2 patients (J.C. and
M.P.) showed an increase in K cell activity to 160% and 120% of the
pre-treatment values, respectively. In contrast, in a third patient,
cytotoxicity fell to 80% of the pre-treatment level, following hyper¬
thermia. All of these changes represent alterations in the percent
specific release values, of between 13% and 17%, which were not
statistically significant. Within 24h of treatment, the specific
release in one patient (M.P.), returned to within 4% of the
pre-hyperthermia value.
Two patients (I.W. and M.M.) were studied during their second
treatment. In both cases there was a slight fall in K cell activity
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EFFECT OF SINGLE HYPERTHERMIA TREATMENTS ON THE K CELL ACTIVITY OF
LYMPHOCYTES AGAINST H.Ep.2 TUMOUR CELLS IN VITRO
FIGUREE3
EFFECTOFSUCC SSIVEHYPERTHERMIATR ATMENTSONKLLA IVI YFLYMPHOCYTESAGAI TH. p.2UMOURC LL
(to 95% and 86% of the pre-treatment level, respectively). Pre-
hyperthermia levels of cytotoxicity were shown by lymphoid cells
from blood taken 4h (Patient I.W., Figure E3) and 7 days (Patient
M.M., Figure E 2) after treatment.
The effects of a third treatment were studied in patients
D.6. and I.W.. Although the results indicated that there was a
marked fall in cytotoxicity during hyperthermia, the results are
not definitive, since one of the patients (I.W.) was given cytotoxic
drugs during heating, and it was not possible to obtain sufficient
cells from the second, to allow directly comparable ratios of
effector cells : target cells to be used before and after hyper¬
thermia.
It was possible to conduct a limited follow-up on patient
I.W.. This indicated that cytotoxicity remained depressed
(Figure E3) the day after treatment, and was virtually unchanged
3 days later, in spite of a blood transfusion of 1| units of
packed cells, between the tests.
The effects of a course of hyperthermia treatments on antibody-
dependent cytotoxicity, in a single patient are shown in Figure E3.
Each treatment produced a small fall in H.Ep.2 cell killing.
Following the first hyperthermia fraction (158C°M), cytotoxicity
fell to 80% of the pre-treatment value, and remained depressed for
6 days. The second fraction (204C°M) had virtually no effect on K
cell activity, however, within a weeek, there was an increase in
cytotoxicity (represented by an increase of over 30% in the percent
specific release), to above the pre-treatment value. A third
treatment (202C°M), with concomitant gastric heating and chemotherapy
(5 Fluorouracil and Vincristine), resulted in the largest decrease !
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in cytotoxicity (from 92.5% to 52.5% specific release), which was still
evident the following day, and 3 days later. Although each treatment
produced a fall in K cell activity of varying magnitude, and
apparently unrelated to the size of the fraction, it is notable that
the specific release values fell, in each case, to between 60% and 65%.
Effect of Heating Lymphoid Effector Cells in vitro on their K Cell
Activity Three experiments were conducted to determine the effects
of heat in vitro on ADCC by lymphoid cells. In all cases, the control
effector cells were unheated.
In two experiments, heating the lymphocytes in whole blood at
42°C for 2|h, resulted in a fall in the specific release to 59.8%
and 29.1% of the value seen in unheated cells, at a 25:1 and 50:1
effector:target cell ratio, respectively.
Heating isolated lymphocytes for 2^-h at 42°C (at a concentration
of 7x10® cells/ml in Eagles Basal Medium + 20% v/v Foetal Calf Serum),
resulted in a fall in cytotoxicity to 33.9% of that produced by
unheated cells, at a 50:1 effector:target cell ratio. The viability
of the lymphocytes was not affected by the heating procedure.
Piscussion
The results from patients, suggest that ADCC is only marginally
affected by hyperthermia treatment, but, on balance, tends to be
depressed. A depression of cytotoxicity has been reported in surgical
patients post-operatively (Vose & Moudgil, 1976), and in anaesthetised
animals (Vose & Kimber, 1977), where it was attributed to the use of
the anaesthetic agents, rather than to stress. This would not, however,
explain the small increases in K cell activity seen in some of the
hyperthermia patients. In those cases where an increase was seen (J.C.
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and M.P.) it was small, and the pre-treatment level of cytotoxicity
was below that usually found in normals. In the patients with normal
pre-hyperthermia K cell activity, it is not clear why the cytotoxicity
concistently remained above 60-70%. It may be related to the size of
the heat fraction that these subjects received, although this varied
from patient to patient, or might indicate the presence of thermo-
resistant cells. This is not, however, supported by the results
involving heating in vitro, which indicated that ADCC could be markedly
inhibited by heating the effector cells in whole blood, or as a
suspension in tissue culture medium.
These results are in agreement with those reported by
DeHoratius et al (1977), who found a non-significant decline in
lymphoid eel 1-mediated ADCC, and a significant fall in polymorph-
mediated ADCC against erythrocyte targets, following hyperthermia
therapy for 2h at 42°C. The results from the iri vitro study were
supported by those of Romano and Shore (1977), who found that heating
a suspension of mononuclear cells at 46°C for lOmin, abolished its
ability to kill antibody-coated, herpes virus-infected cells. They
indicated that this inactivation could be reversed by incubating the
ceils for 24h at 37°C, and that the recovery was dependent on RNA and
protein synthesis (Shore et al, 1977). If this is indeed the case,
then recovery should not occur with the heating conditions which were
used in this study (2|h at 42°C), since these have been shown to
abolish RNA synthesis in T lymphocytes (see p. 155 ), which have now
been shown to be capable of K cell activity (Saal et al 1977a and
1977b). There was some indication of rapid recovery of ADCC, after
hyperthermia treatment, in three of the patients studied, but the
changes are too small to be definite.
The mechanism by which cytotoxicity was depressed by heating the
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effector cells in vitro, has not been studied. Shore et al (1977) have
proposed that the inhibition of ADCC by elevated temperatures, is
mediated by heat-labile proteins at, or near, the effector cell
surface, and that these may be enzymes or cytoskeletal structures.
In summary, hyperthermia therapy usually resulted in a slight
fall in antibody-dependent cellular cytotoxicity mediated by lymphoid
cells, against tumour cell targets. The depression was largest
during a treatment in which cytotoxic drugs were given. Heating of
the effector cells, in whole blood, or as isolated cells, in vitro,
produced a substantial inhibition of their cytotoxic potential,
greater than that seen in vivo.
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GENERAL SUMMARY AND CONCLUSIONS
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General Summary and Conclusions
A number of tests have been used to determine the effects of
whole-body hyperthermia therapy, and heat in vitro, on immunocompetent
eel Is.
The results from advanced cancer patients indicate that this form
of treatment produced an initial stress-mediated leucocytosis, resulting
from an increase in the concentration of actively-phagocytic peripheral
blood neutrophils. This was accompanied by a T-lymphopenia and B-
lymphocytosis, but no significant changes in the total lymphocyte
concentration. There was also a tendency for antibody-dependent cellular
cytotoxicity, and PHA-induced lymphocyte transformation, to be slightly
depressed during heating.
Within 16-18h of treatment, the T-lymphopenia became more severe,
and the concentration of serum complement (as C'3) was also depressed.
Most parameters returned to their pre-treatment values within 3-5 days,
at which time there was an increase in T lymphocyte activity, as
measured by response to PHA; this declined to the pre-hyperthermia
level, within a week of treatment. A course of hyperthermia treatments
had no significant overall effect on the parameters studied.
These results indicate that cancer patients may be temporarily
immunosuppressed, for periods up to 3 days, following whole-body
hyperthermia treatment. This could be of clinical importance, especially
during the hours immediately after therapy. It is possible that, with
inadequate heating, still-viable tumour cells may be seeded into a
hyperaemi c circulation at this time. In the absence of a full immune
response these may become established as metastases, and this may
explain the increased incidence of tumour dissemination, in animal
models, following generalised hyperthermia (Dickson & Muckle, 1972).
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Depression of general immunocompetence has also been described
in tumour-bearing rabbits treated by generalised, as opposed to local
hyperthermia (Dickson & Shah, 1977). This would suggest that elevation
of body temperatures depresses the activity of immunocompetent cells,
and this is supported by the results from the experiments, in this
study, in which lymphocytes and granulocytes were heated in vitro.
During local tumour hyperthermia very few immunocompetent cells will
be subjected to increased temperatures, and so there is not likely to
be any marked inhibition of the patient's immune status. In addition,
antigenic material may be shed from the heated tumour into the blood¬
stream, and elicit a renewed immune response, explaining the
potentiation of immunity by local heating described by Dickson and
Shah (1977) and Szmigielski et al (1977a). Although changes in
antigenicity of the tumour are also likely to occur during whole-
body treatment, the antigenic stimulus would be acting on a depressed
immune response.
It is possible that the depression of lymphoid cell function may
be partially counteracted by the increase in the concentration of
active!y-phagocytic neutrophils which occurs towards the end of treat¬
ment, and persists the following day. Although these cells were found
to be inactive in the ADCC assay system that was used in this study,
they may be capable of tumour cell killing in vivo.
It is interesting to note that the pattern of general immunological
responses following hyperthermia treatment, is similar to that
reported by Minion et al (1976) after the intravenous administration of
Corynebacterium parvum, which is believed to stimulate general, and
thereby tumour-directed, immunity. This would suggest either that
i) C. parvum does not potentiate immunity
ii) The potentiation by C. parvum is not detected by these assays
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iii) The changes are associated with the fever produced by
C. parvum.
It is felt that this latter explanation is the most likely, since
Minton indicated that most of the patients experienced fevers, ranging
from 37.8°C - 40.0°C, following the administration of C. parvum.
The experiments in which heat was applied in vitro, indicate that
elevated temperatures markedy depress the indices of general immuno-
competence, that were monitored in vivo. This inhibition became more
severe as the conditions progressively departed from those in vivo.
It is possible, therefore, that this increase in thermosensitivity is
due to changes in the factors affecting the heat tolerance of cells
e.g. pH, oxygen tension etc.. A purely heat-mediated depression of
immunological function is probably also involved, and has been
reported by other workers (Shore et al, 1977).
This study is limited by two factors. Firstly, as with all
in vitro assays, there is always uncertainty as to how closely the
results correlate with measurements of tumour-directed immunity in
vivo, and with clinical prognosis. No correlation has been found in
this small group of patients, in which there were few clear-cut
responses to therapy. The finding that the changes in the parameters
have been common to most patients, indicates that they may be inherent
in this form of treatment.
Secondly, it is not known how the immunogenicity of a tumour is
affected by hyperthermia treatment. Elevated temperatures have been
shown to affect cell membranes etc., and it is likely that the
antigenicity of the cancer cell (and perhaps that of normal cells) may
change during a course of heat treatments (Mondovi et al, 1972).
Antigenic, necrotic tumour tissue may also be released into the blood¬
stream during hyperthermia. The tests used in this study, do not
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take account of this, e.g. a fall in the T lymphocyte concentration,
following treatment, may be associated with the sequestration of
sensitised T cells by a more-immunogenic tumour, rather than with direct
depression of the cells by heat.
The effect of hyperthermia treatment on the immune status of
the cancer patient is therefore the resultant of the effect on the
immunocompetent cells, and on the immunogenicity of the tumour. The
indications, from previous work, are that the latter is increased by
elevated temperatures, whilst immune function tends to be depressed,
as shown by this study. Although the change in tumour antigenicity
may eventually become masked by serum factors etc., it is possible that
it persists longer than the general immunodepression (i.e. 2-3 days)
which could mean that the overall effect of whole-body hyperthermia
treatment, may, in fact, be benificial, as regards the tumour-directed
immune response.
In any clinical study it is difficult to evaluate the influence
of factors ancillary to the treatment under investigation (e.g. drugs,
anaesthetics etc.), on the immune status of the patient. Since these
procedures are, at present, inherent'irf most clinical hyperthermia
treatments, it will be necessary to develop a good animal model in
order to isolate the effects of heat on the immunocompetence of the
tumour-bearing host. This has presented many problems, since the
temperatures used in clinical treatments are poorly tolerated by
laboratory animals, because of their different thermoregulatory
mechanisms. In spite of this, animal models have been described, and
used, in preliminary studies on immunocompetence (Williams & Gait,
1977).
Future work should be directed towards monitoring tumour-
directed immunity in these systems, since they permit the use of
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procedures which are not ethical in the clinical situation, e.g.
tumour transplantation. The use of syngeneic systems also allows more
rigid control experiments to be performed, which should aid in
distinguishing between the effects of heat and anaesthetics, drugs etc..
Results from these investigations could then be applied to the study
of tumour-directed immunity in patients undergoing whole-body
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A. P. Gee, R. T. Pettigkew, A. N. Smith
and A. E. Williams, Teaching and Research
Centre, and Departments of Anaesthetics and
Clinical Surgery, Western General Hospital,
Edinburgh.
The general immune status of i> patients
with advanced gastrointestinal or genito¬
urinary cancer has been monitored prior to,
during and following whole body hyper¬
thermia. During treatment the absolute
number ofT cells in peripheral blood increased
in patients with responsive tumours (f>) and
decreased significantly in the remainder (.'I).
In both groups T cell activity, as measured
by response to PHA, decreased at the end of
heating but increased the following day,
reaching a peak within a further 3 days and j
returning to the pre-treament level within a
week. Changes also occurred in numbers of
circulating B cells and in scrum immuno¬
globulin and complement levels, but these did
not show any clear trend. Although work is
still at an early stage, these results indicate
that hyperthermia therapy may induce a
small but favourable change in the responsive
patient's immune status at a critical time.
British Journal of Cancer 31_, 313 (1976)
PRELIMINARY STUDIES ON THE EFFECT OF WHOLE-BODY
HYPERTHERMIA ON THE IMMUNE RESPONSE OF CANCER
PATIENTS AND EXPERIMENTAL ANIMALS
By A. E. Williams, Jean H. Gait, A. P. Gee,
R. T. Pettigrew and A. N. Smith
Teaching anil Research Centre and Departments ofAnaesthetics
anil Clinical Surgery, University of Edinburgh, Western
General Hospital, Edinburgh
The cfl'cct of whole-body hyperthermia (41-42 cleg.) on the
genera! immunocompctence of patients with advanced
malignancy and of normal rats is being studied. In both
humans and rats, hyperthermia causes a lymphocytopenia
followed by a granulocytosis with a return to control values
within four days. However, patients with tumours respond¬
ing to hyperthermia show an increase in absolute numbers
of circulating T cells. The lymphocyte response to PHA is
depressed after hyperthermia in both rats and humans. At
three days, the response of human lymphocytes is above pre-
treatment levels, but is still partially depressed in rat
lymphocytes!. In anaesthetized control rats, a less severe and
shorter lasting lymphocytopenia is produced. PHA respon¬
siveness is not depressed. During the granulocytosis in
patients there is an increase in the number of actively
phagocytosing cells. Antibody-dependent cytotoxicity of
both lymphocytes and granulocytes is severely depressed by
heating in vivo or in vitro.
The results of thin pilot study suggest that the possible
effects of hyperthermia on the immune response should be
considered when assessing the clinical application of this
mode of therapy.
British Journal of Radiology £9, 808 (1976)
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The Effects of Whole-Body Hyperthermia Therapy on the General
Immunocompetence of the Advanced Cancer Patient
A. P. Gee, A. E. Williams, R. T. Pettigrew and A. N. Smith
Departments of Teaching and Research, Anaesthetics and
Clinical Surgery, University of Edinburgh, Western General
Hospital, Edinburgh, Scotland, U.K.
Introduction
The immune system can modulate the course of cancer in animals
and man (1,2). Many workers have suggested that the anti-tumour
effects of hyperthermia are mediated by an immune response (3,4,5).
Heat may stimulate cells of the lymphoreticular system and/or
change the immunogenicity of the tumour, however little experimental
evidence exists.
The aim of our work was to determine whether whole-body
hyperthermia used by Pettigrew (6) in terminal cancer, affected the
patient's immunocompetence. Several in vitro assays were used to
monitor the general immune status before, during and after
treatment. 19 patients with various advanced cancers (mainly gastro¬
intestinal) have so far been studied. In addition, the effect of
heating in vitro on the function of isolated lymphocytes has been
studied.
Whole-Body Hyperthermia
The duration of hyperthermia treatments varied slightly
depending on the fraction given and the patient, but one session
usually involved heating at 41.8°C for 2-4hr.
Total and Differential Peripheral Blood Leucocyte Counts During
heating there was an initial leucopenia, followed by a substantial
leucocytosis, resulting in a mean increase in the white cell count
of 24% during the first treatment and over 60% during subsequent
treatments. This was due primarily to an increase in the numbers
of immature neutrophils in the peripheral blood. These cells could
phagocytose latex particles; hence the concentration of actively-
phagocytic cells may more than double following heating, resulting
in an increased capacity to remove tumour debris that may result
from hyperthermia treatment
The concentration of lymphoid cells decreased by ca. 25%
during the first treatment and remained depressed during the
following 24hr. Within 3-4 days the concentration had returned
to the pre-treatment value. In the smaller group of patients
receiving a second treatment, the mean mononuclear cell count
increased slightly during heating, but then decreased to ca.
85% of the pre-heating value at 24hr., and then remained low
at 3-4 days after treatment. This longer term depression
occurred after a third treatment.
The changes during heating are characteristic of a stress
response and have been noted in induced fever therapies (7,8).
Over a full course of hyperthermia sessions the total and
differential leucocyte count was not significantly alteredo
Concentration of Peripheral Blood T and B Lymphocytes The concentration
of T and B lymphocytes was determined by E (9) and EAC (10) rosetting




In the majority of patients, during heating, there was a
significant fall in the T cell concentration to ca. 70% of the
pre-treatment level, followed by a slow recovery over the following
3-4 days This pattern was repeated during the second and third
treatments. In three patients the pattern was completely reversed.
T cell concentrations increased during heating and subsequently
declined sharply and remained depressed 3-4 days later. These
patients displayed other abnormal clinical and immunological
responses to hyperthermia.
B lymphocytes changed rather erratically in response to
treatment. The percentage of EAC-rosetting cells tended to increase
by ca. 50% in most patients, however no clear trend could be seen.
Serum Immunoglobulin and Complement Levels Concentration of serum
immunoglobulins (IgG, IgA and IgM) and complement (as C'3) were
measured by radial immunodiffusion (12). All three subclasses
showed large variations during and after hyperthermia (Range 48-193%
of the pre-heating value), but no general patterns were apparent.
A small, but significant, decrease in the concentration of C'3
occurred the day after treatment; however, normal values had been
regained by 3-4 days post-treatment.
Response of Lymphocytes to Phytohaemagglutinin (PHA) Phytohaem-
agglutinin acts mainly upon T lymphocytes (13) and hence the blasto-
genic response to PHA may be used to assess T cell activity. A modi¬
fication of Steel and Creasey's method was used (14).
In virtually all the patients there was a slight decrease in
the PHA response during heating. Within 24hr. the values had
returned to, or exceeded, the pre-treatment level, and subsequently
increased to a marked peak within a further 2-3 days. (2-3 fold
the pre-heating level). This was followed by a decline to the
pre-hyperthermia value within a week of treatment. This pattern
of response followed each heating session (Fig.l), and occurred
whether autochthonous or pooled normal serum was used in the
cultures. Lymphocyte responses were lower if the patient's own
serum was used, indicating a possible blocking factor(s)* The extent
of blocking was not significantly altered by hyperthermia treatment.
The clinical significance of this pattern of PHA responsiveness is
not clear but could not be related to plasma Cortisol levels, which
affect lymphocyte activity (15). The peak in response may however
be partially due to release from the suppressive efffects of the
anaesthesia and/or drugs used during hyperthermia treatment.
Antibody-Dependent Cellular Cytotoxicity The cytotoxic effect of
peripheral blood lymphocytes on a 51Chromium-label led human tumour
cell line (H.Ep.2), in the presence of anti-H.Ep.2 antiserum, was
measured at the beginning and end of hyperthermia.
During heating there was usually a slight decrease in cyto¬
toxicity (to about 80-95% of the pre-heating level) followed by
recovery before the next treatment. In one case where cytotoxic
drugs were given during heating, the suppression was more marked
(30% decrease in cytotoxicity).
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Effects of Heating in vitro
"Concentration ofHotal' and 'Active' Lymphocytes in a Suspension
T cells in a suspension of lymphocytes heated at 42°C for up to 3hr.
were monitored using three methods:-
i) Rosetting with sheep erythrocytes for 18hr. at 4 C - total
T cells (9)
ii) Rosetting with sheep erythrocytes for 5min. at 20 C -
'active' T cells (16) 0
iii) Rosetting with rhesus monkey erythrocytes for 18hr. at 20 C
EM rosettes (17)
'Active' T cells were studied because their concentration in the
peripheral blood has been reported to correlate more closely with the
clinical status and prognosis of the cancer patient (18). EM rosettes
are of interest because the incubation temperature used during rosette
formation is less critical than with sheep erythrocyte rosetting
tests (17).
During heating the number of total and active T cells decreased
but a control suspension kept at 37°C was unaffected. Although the
trend was a decrease in T cells, the proportion of rosetting cells
varied cyclically during incubation at 42°C. In addition, if the
cells that had been heated at 42°C were subsequently incubated at
37 C or 4°C for 15min., the number of rosetting cells increased.
These findings suggest that, although erythrocyte receptors on T
cells are destroyed by heating at 42°C, they can be resynthesised.
In contrast to the results with sheep erythrocytes, the
proportion of lymphocytes rosetting with monkey erythrocytes (although
smaller 20-40%) was little affected by heating at 42°C. In parallel
experiments the percentage of total T cells in the suspension
decreased during heating, until it reached a level similar to the
percentage rosetting with monkey erythrocytes. The total and EM-
rosetting populations then cycled synchronously (Fig.2). These
results indicate that there may be two types of erythrocyte receptor
on T cells:-
i) Thermolabile - detected by 'active' T cell rosetting but
also as a subpopulation during total T cell rosetting.
ii) Thermoresistant - detected by EM rosetting but again
present as a subpopulation during total T cell rosetting.
As it is believed that 'active' T cell numbers correlate more closely
with clinical parameters, the possible thermosensitivity of this cell
type could be of concern to the clinician using hyperthermia treatment.
Lymphocyte Response to PHA Isolated lymphocytes heated at 42°C for
2J-4hr. failed to respond to PHA, although initially viable by dye
exclusion. PHA-stimulated RNA synthesis was also virtually abolished
by pre-heating the cell suspension. Lymphocytes heated in whole blood
were less susceptible. Preliminary results from whole-blood cultures
showed no significant difference between the PHA response of blood
incubated at 42 C and that kept at 37°C, for periods up to 2|hr..
Antibody-Dependent Cellular Cytotoxicity Heating of the lymphoid
effector cell population, either in whole blood, or as an isolated,
suspension, for 2-2|hr., resulted in a substantial reduction in its
cytotoxic potential to about 40% of the pre-heating value. This




Whcle-body hyperthermia treatment appears to cause a slight,
short-lived, general immunosuppression, particularly of cellular
immune responses. Most parameters return to their pre-treatment
levels within 3-4 days, although T lymphocyte activity reaches a
marked peak at this time. Heat applied in vitro produces a more
severe depression of immune function.
These results contrast with similar studies on chemotherapy
and radiotherapy (19,20), which produce marked, long-term immuno¬
suppression. However, the temporary depression of immunity result¬
ing from hyperthermia treatment may be of critical importance. It
is possible that, with inadequate heating, viable tumour cells
may be seeded into a hyperemic circulation, and, in the absence of
a normal immune response, become established as metastases (21).
This initial study has concentrated on indices of general
immunocompetence, and may not necessarily relate directly to
tumour-directed immunity. Also possible changes in the immuno-
genicity of the tumour, resulting from hyperthermia treatment, have
not been investigated. These parameters, which are of primary
interest to the tumour immunologist, are currently under study
using an animal model (22).
In: Proceedings of the Second International Symposium on Cancer
Therapy by Hyperthermia and Radiation. In Press. Urban &
Schwarzenberg, Munich, 1977.
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